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The expression of two phenotypically-contrasting LDL 
receptor mutations was characterized in cultured fibroblasts 
from the genetically-homozygous Afrikaner subjects, FH1a and 
lb, and FH3a and 3b, respectively. Surface receptor 
expression and functional activity were studied by ligand 
( 125 I-LDL) and monoclonal antibody ( 125 I-IgG-C7) binding, 
and c35s]-methionine pulse-chase experiments were used to 
analyze biosynthesis, processing and degradation of IgG-C7-
immunoprecipitable mutant receptors. 
Cells from the "receptor-negative" subjects, FH3a and 3b 
exhibited reduced, but significant (40-60% of normal) LDL 
receptor synthesis rates. Newly-synthesized precursors 
were processed slowly (t~ 1.5 hours versus normal t~ of 
approximately 15 minutes) to mature receptors which reached 
the cell~surface, but were rapidly degraded thereafter with 
a half-life of approximately 1.7 hours (normal value 12.6 
hours) thus representing a new type of LDL receptor defect. 
Lysosomotropic weak 
partially inhibited 
bases such as ammonium 
rapid degradation of the 
chloride 
mutant 
receptors, suggesting the involvement of proteolysis in 
acidic compartments such as lysosomes.or endosomes. 
Fibroblasts from FH1a and lb exhibited normal synthesis 
rates of LDL receptor precursors that were processed at a 
severely reduced rate (t~ approximately 5 hours) to 
functionally heterogeneous mature surface receptors. One-
third of the receptors (20% of normal levels) bound l25I-LDL 
with normal affinity at 4°C and 37°C, whereas the majority 
were able to recognize only 125I-IgG-C7~ and apparently 
showed defective internalisation and subsequent degradation 
of the bound IgG-C7 at 37°C. The existence of the two 
receptor populations was further supported by selective 
intracellular trapping and degradation of only the active, 
ii 
LDL-binding population, in the presence of ammonium chloride 
and LOL. The abnormal form predominated even in newly-
synthesized receptors and reached a maximum of 50-70% of 
normal levels after 48 hours of upregulation. Upregulation 
kinetics and degradation rates (t~ = 10-11 hours) of both 
functionally-active and abnormal receptor populations were 
similar to normal. A progressive increase in apparent 
molecular weight of the slowly-processed precursor receptors 
suggested a possible role for abnormal glycosylation in the 
formation of both "normal" and abnormal conformations of the 
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INTRODUCTION 
Cholesterol is an essential component of the cell membrane 
and is the precursor for steroid hormone and bile acid 
synthesis (1). To provide for these functions, cholesterol 
is transported in the esterified form in plasma 
lipoproteins, and delivered to cells via lipoprotein 
receptors by the process of receptor-mediated endocytosis. 
If plasma cholesterol levels are elevated, this can lead to 
the formation of atherosclerotic plaques in the arteries, 
and eventually heart attacks and strokes. The 
concentration of cholesterol in the bloodstream must 
therefore be kept low. An important factor in regulating 
plasma cholesterol 
(LDL) receptors. 
is the level of low-density lipoprotein 
The LDL receptor is a cell-surface protein which plays a 
central role in cholesterol homeostasis (1). This receptor 
binds LDL~ the most abundant cholesterol transport 
lipoprotein, and carries it into the cell, thus clearing 
cholesterol from the plasma and initiating several 
regulatory processes within the cell (1). Study of the LDL 
receptor pathway has led to (i) the concept of receptor-
mediated endocytosis (2,3,4), the process by which 
macromolecules enter cells after binding to receptors in 
coated pits, (ii) the elucidation of the mechanism by which 
the LDL receptor mediates feedback control of cholesterol 
synthesis (1,5), and how cholesterol levels in turn mediate 
transcriptional control of LDL receptor expression (6-9), 
and (iii) understanding of the genetic disease, familial 
hyperchol~sterolaemia, caused by mutations which disrupt the 
normal structure and function of the LDL receptor 
(1,3,10,11). For these, and other fundamental concepts 
emerging from their elegant studies of the LDL receptor and 
cholesterol homeostasis, Brown and Goldstein were awarded 
the Nobel Prize in Physiology or Medicine in 1985. 
4 
1.1 Familial hypercholesterolaemia and the low-density 
lipoprotein receptor - Historical perspective (1,10) 
"The physiological, biochemical and genetic characterization 
of the LDL pathway in both normal and FH cells has had a 
profound impact on our understanding of sterol metabolism, 
hypercholesterolemia, atherosclerosis and endoc·ytosis" 
(Krieger et~· ref. 12). 
Familial hypercholesterolaemia (FH) was first described in 
1938 by Carl Muller as an inborn error of metabolism, 
inherited as a dominant trait, which led to elevated blood 
cholesterol, xanthomata and myocardial infarctions in young 
people ( 10) • Gofman et al. later showed that the 
hypercholesterolaemia resulted from a selective elevation of 
low density lipoprotein (LDL) particles (13). Kachadurian 
(14) clarified the clinical features of heterozygous and 
more severe homozygous FH. Fredrickson, Levy and co-
workers demonstrated abnormally slow. catabolism of both the 
apoprotein and cholesterol components of LDL in FH patients 
( 15) • 
Brown and Goldstein began their classic studies in 1972 in 
an attempt to understand FH (1). They postulated that the 
elevated blood cholesterol observed in the disease was due 
to a failure of end-product repression of cholesterol 
synthesis. In their model system of cultured human skin 
fibroblasts, they showed that HMG-CoA reductase (a rate-
limiting enzyme in cholesterol biosynthesis) was subject to 
negative regulation 
specificity of the 
by LDL-cholesterol 
regulation (only 




cholesterol) and the concentration of LDL required (less 
than 10-8 M) suggested the involvement of a high affinity 
receptor mechanism. In fibroblasts from homozygous FH 
subjects, no suppression of cholesterol synthesis by LDL was 
observed, and the cells exhibited HMG-CoA reductase 
activities 50 to 100 times greater than normal (16). These 
observations showed that the genetic defect was expressed in 
cell culture. However, when ethanolic cholesterol was 
" 
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added directly to the FH cells, suppression of HMG-CoA 
reductase activity took place at the same rate and to the 
same extent as in normal cells. Thus, the defect in the 
cells appeared to be in the ability to extract cholesterol 
from lipoproteins such as LDL, possibly by high-affinity 
binding to a specific receptor. The existence of the LDL 
receptor was confirmed by 125 I-labelled LDL binding studies 
(16). Normal fibroblasts showed high-affinity binding of 
125!-LDL, followed by internalisation and degradation in the 
lysosomes, liberating free cholesterol from cholesterol 
esters, thus leading to suppression of HMG-CoA reductase 
activity. 
were shown 
In contrast, fibroblasts from FH homozygotes 
to lack high-affinity receptors. This 
deficiency in LDL receptors in these subjects would thus 
lead to reduced clearance of LDL from the plasma, explaining 
the elevation of LDL levels in FH. FH was thus shown to be 
caused by inherited defects in the LDL receptor. 
The ability to measure LDL receptor activity in cultured 
cells was followed by methods to solubilize and purify the 
receptor in homogeneous form (17) and the development of 
antibodies directed against the protein (18). These 
advances led to a detailed understanding of the biosynthesis 
and intracellular itinerary of the LDL receptor, and of the 
disruption of these aspects in FH (18,19,20). In 1983, 
Russell et al. cloned a partial cDNA of the bovine LDL-
receptor (6) and this was used by Yamamoto et al. in 1984 to 
isolate a full-length cDNA for the human LDL receptor (21). 
Subsequent work has led to the elucidation of the structure 
of the normal receptor gene (22) and the definition of 
mutations in the gene at the molecular level (10). In this 
way, the structural basis for the multiple biochemical 
classes of LDL receptor mutations in FH has been elucidated. 
1.2 Structure-function relationships in the LDL receptor 
1.2.1 LDL receptor protein 
The extreme N-terminus of the LDL receptor consists of a 
hydrophobic signal sequence of 21 amino acids which 
6 
presumably mediates insertion of the nascent polypeptide 
into the endoplasmic reticulum (3). Excluding the signal 
sequence, the LDL receptor protein contains 839 amino acids 
and is composed of five functional domains (see Figure 1.1). 
1.2.1.1 Ligand binding domain 
The ligand binding domain was shown to be on the external 
surface of the membrane by anti-peptide antibody binding 
studies (3). This domain consists of 292 amino acids, made 
up of 7 repeats of approximately 40 amino acids each. Each 
repeat contains 6 cysteine residues, regularly spaced at 
intervals of 4 to 7 amino acids. All the cysteines are 
involved in disulphide bonds, creating a tightly cross-
linked structure of extreme stability (3). At the carboxyl 
terminal of each repeat is a cluster of negatively-charged 
amino acids believed to be importan~ for binding to positive 
charges on the ligands for the receptor. Since the centre 
of each repeat is relatively hydrophobic, it is likely that 
many of the disulphide-bonded cysteines are buried in 
hydrophobic pockets, flanked by polar residues, thus 
allowing the negatively-charged residues to be exposed at 
the surface of the binding domain (11) [See figure 1.1). 
All of these features are highly conserved between the human 
and rabbit receptors, particularly the exact spacing of the 
cysteine residues and the groups of negatively-charged amino 
acids (23). Only the 16 N-terminal amino acids of this 
domain in the bovine receptor are known (3) and show strong 
sequence homology with the human and rabbit receptors, 
including the positions of the first two cysteine residues. 
The protein ligands which bind to the LDL receptor are 
apolipoprotein(apo) E (found on particles of B-VLDL, HDLc, 
VLDL, IDL) and apolipoprotein(apo) B-100 (found on B-VLDL, 
VLDL, IDL, and LDL particles). The LDL receptor binds 
lipoproteins containing multiple .copies of ape E with higher 
affinity than LDL, which contains a single copy of ape B-
100, but the receptor has a higher maximum binding capacity 
for LDL particles (24). The ligand ape E contains 299 
7 
amino acids, and has a cluster of positively-charged 
residues between amino acids 140 to 160, believed to occupy 
one face of a single a-helix. It has been shown with 
mutant and proteolyzed forms of apo E, and with monoclonal 
antibodies to different regions of the molecule, that this 
cluster represents the binding site of ape E for the LDL 
receptor (24). Apo Bis produced in 2 forms: ape B-100 is 
produced by the liver, and apo B-48 by the intestine. Apo 
B-48 is produced from the same gene as apo B-100 by a post-
transcriptional, tissue-specific modification to introduce a 
stop codon at residue 2153 (25), thus producing a shortened 
protein product representing the amino-terminal 2152 amino 
acids of apo B-100. Apo B-100 binds to the LDL receptor, 
whereas ape B-48 does not, suggesting that the binding site 
is situated in the carboxyl end of apo B-100. The cDNA for 
apo B-100 has been cloned (26,27) and the amino acid 
sequence (4536 amino acids) derived. Evidence for the 
carboxyl terminus as the site of the binding domain has been 
obtained from inhibition of binding by antibodies to this 
region, and striking homology between 2 basic amino acid 
sequences in this region (amino acids 3147 to 3157 and 3357 
to 3367) and the receptor binding domain of apo E (24). 
The numerous disulphide bonds in the binding domain of the 
LDL receptor create a very stable. structure. This is 
presumably important in the acidic endosome, where the 
negatively-charged residues of the receptor become 
protonated, lose their charges and thus release the 
positively-charged ligand, accompanied by conformational 
changes in the receptor. The receptor does not become 
irreversibly denatured by this titration of the carboxyl 
groups because of structural stabilization of· the binding 
domain by the disulphide cross-linking (3). Esser et.!!.• 
(28) have used oligonucleotide-directed mutagenesis to alter 
the cysteine-rich repeats in the binding domain of 
expressible cDNA for the human LDL receptor. By expression 
of the mutated receptors in transfected monkey COS cells, 
the effect ·of the various mutations on the ability of the 
8 
receptor to bind LDL (apo B-100) or D-VLDL (apo B-100 plus 
multiple copies of apo E) could be measured. For example, 
the modification of the acidic binding sequence Ser-Asp-Glu 
to Ser-Tyr-Glu in repeat 5 caused a dramatic loss of binding 
to both D-VLDL and LDL. The same modification in repeat 6 
decreased LDL binding by 50% but had no effect on D-VLDL 
binding, whereas this modification in the first re~eat had 
no effect on binding of either LDL or D-VLDL (See Table 
1. 1). The results support the finding of van Oriel et al. 
(29) that the first repeat binds monoclonal antibodies and 
ca 2 +, but is not required for ligand binding. Repeats 2 
and 3 and repeats 6 and 7 were found to be required for 
maximal LDL, but not D-VLDL, binding. Repeat 5 was shown 
to be required for binding of both ligands. The results 
support a model where the various repeats play an additive 
role in ligand binding, but are not functionally equivalent. 
Assuming that the first repeat has no functional role, and 
since a linker region of ide~tical length (8 amino acids), 
but divergent sequence, has been found between repeats 4 and 
5 in the human, rabbit and hamster receptor, the possibility 
of 2-fold symmetry of repeats 2 to 7 around the linker 
sequence has been proposed (28). 
1.2.1.2 EGF-precursor homologous domain 
The second domain of the LDL receptor consists of about 400 
amino acids, of which 35% are homologous to a portion of the 
extracellular domain of the precursor for epidermal growth 
factor (EGF) (30). The sequence of this domain includes 
two sites used for N-linked glycosylation (21) (See figure 
1 • 1 ) • This region of the LDL receptor contains 3 cysteine-
rich repeats, A, Band C, known as "growth factor repeats", 
that are present in many cell surface and secreted proteins, 
including clotting factors, complement proteins and membrane 
receptors ( 2 2) • These cysteine-rich repeats have a 
different evolutionary origin from the 7 binding repeats 
(22), and, since they lack clusters of negative charges, are 
unlikely to participate directly in ligand binding. 
I Protein domains j Homology NH2 jExonsj 
Signal sequence (21 aa) (%) D 1 -1 - 2 8 ,V\ /:';,)"")\:::J I 2 - 3 3 
Ligand binding 75% 4 4 
8 I Domain (292aa) 5 -6 5 -H2N/ \c0 JID A / 7 6 \ fE: 7 - 8 
Cysteine-rich ~ I ~ -
9 i EGF Precursor 10 
repeat Homology Domain 84% - 11 
(400aa) - 12 -
N-linked rl ~c J . - 13 oligosaccharide C 14 o-} 0-linked Sugar 15 I.O - Domain (58aa) 40% 
0-linked j 
oligosaccharide } Transmembrane 68% ~= 16 Domain (22aa) 
17 
Cytoplasmic 
D-Domain (SOaa) 86% 18 
COOH COOH 
1-lntronsj 
!}gure_1 ._1 Model for protein domains and exon organization of the LDL receptor 
Adapted from references 1, 22 and 28. See sections 1.2.1 and 1.2.3 for detailed 
description. The percentage homology between the human and rabbit LDL receptors 
in each domain (23) is indicated. 
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However, repeats A and B indirectly assist in the binding of 
LDL, since deletion of these two r~peats, or the entire EGF-
precursor homologous domain caused a dramatic l~ss in 
binding of LDL, but not ~-VLDL at the cell surface (31). 
Esser et al. (28) showed that repeat A was required for LDL 
but not ~-VLDL binding, but repeat B was not required for 
ligand binding (See Table 1.1). Since deletion of the 
repeats did not abolish the ability of the receptor to bind 
LDL on ligand blots (31) it was suggested that the repeats 
played a role in allowing LDL to gain access to the binding 
domain on the cell surface. 
The growth factor repeats in the region of EGF-precursor 
homology appear to play an important role in release of 
bound ligand via acid-dependent conformational change in the 
endosome. When this entire domain, or only repeats A and 
B, were deleted from the protein, the receptor did not 
release its ligand at acid pH, did not recycle efficiently 
and was therefore rapidly degraded after ligand binding an~ 
internalisation (31). The importance of this region in the 
LDL receptor function is indicated by the high degree of 
conservation between the human, rabbit (23) and bovine (3) 
receptors. 
1.2.1.3 0-linked sugar domain 
Immediately external to the membrane-spanning domain of the 
LDL receptor is a threonine- and serine-rich region of 58 
amino acids, encoded by a single exon (1). Various studies 
have shown that this region contains approximately 18 
clustered 0-linked oligosaccharide chains (30,32,33) 
attached to the serine and threonine residues. There is 
little sequence homology in this region between the bovine~ 
human and rabbit receptors (23) exc~pt for the serine- and 
threonine-rich character. However, this region is 
glycosylated in all three species, suggesting that a primary 
sequence is not the signal for 0-linked glycosylation of 
this region. 
1 1 
The function of this region is unknown, since it can be 
deleted without affecting normal function of the receptor in 
cultured hamster fibroblasts (33) [See Table 1.1). It is 
possible that the clustered 0-linked sugar domain is not 
important in non-hepatic cells, but may be crucial for the 
function of hepatic LDL receptors, which are major factors 
in determining serum cholesterol levels (see section 1.6). 
This possibility is supported by the fact that deletion of 
exon 15, which encodes the 0-linked sugar domain, from one 
LDL receptor allele in 2 Japanese subjects, produces the 
I 
clinical symptoms of heterozygous familial hypercholes-
terolaemia (34). 
1.2.1.4 Membrane-spanning domain 
A region of hydrophobic amino acids forms the membrane-
spanning domain of the LDL receptor. Deletion of this 
domain causes the receptor to be secreted from the cell 
(35,36). The transmembrane domain serves only to anchor 
the receptor in the membrane and shows little sequence 
homology between the human, rabbit and bovine receptors, and 
variation in length (rabbit-25 amino acids, human-22 and 
bovine-27) (23). 
1.2.1.5 Cytoplasmic domain 
The cytoplasmic domain of the LDL receptor consists of 50 
amino acids and shows a high degree of sequence conservation 
human (21), bovine (3) and rabbit (23) between the 
receptors. 
targeting the 
This region of the receptor is responsible for 
protein to coated pits, either through 
interaction with clathrin, or with some protein associated 
with clathrin on the cytoplasmic side of the membrane (1). 
The function of the cytoplasmic domain has been concluded 
from molecular analysis of 3 naturally-occurring 
internalisation-defective mutant LDL receptors (37,38), 
which all have defects in the cytoplasmic tail, and by the 
effects of site-directed mutagenesis of the cytoplasmic 
domain (39) [See Table 1.1). Immediately internal to the 
membrane, the cytoplasmic tail has a cluster of positively-
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TABLE 1. 1 SITE-DIRECTED MUTATIONS IN THE LDL RECEPTOR 
Affected Receptor Domain 






Cys 6 -+- Ala 
Cys6• 18 -+- Ala 
Asl6 -+- Tyr 
Phe 181 -+- Tyr 
Phe181 -+- Gly 
Ile 189 -+- Asp 
Asp 206 -+- Tyr 
Asp 206 -+- Asn 
Asp 2 5 ... Tyr 
Repeats 1-3 Deletion 
Repeats 2-6 Deletion 
Repeats 1-5 Deletion 
Repeats 6 and 7 Deletion 
EGF Precursor Homologous Deletion 
Domain: 
Repeat A Cys 297 -+- Ser 
cy/97, 308 ... Ser 
Repeat B 
Repeats A and B 
0-linked Sugar Domain: 
Cytoplasmic Domain: 
Asp 310 -+- Ala 
Deletion 
Asn349 -+- Ala 
Deletion 
Asp310 , Asn349 -+- Ala 
Deletion 
Deletion 
Val 806 -+- Cys 
Val 806 -+- Pro 
Phenotypic Result of Mutation 
No effect on ligand binding, loss of monoclonal 
antibody binding 
No effect on binding of LDL or B-VLDL 
No effect 
LDL and B-VLDL binding markedly decreased 
507. LDL binding, no effect on B-VLDL binding 
307. LDL binding, 707. 13-VLDL binding 
No binding of lipoproteins, binding of mono-
clonal antibodies in ca2+-dependent fashion 
No binding of lipoproteins 
207. LDL binding, 807. B-VLDL binding 
Receptor binds B-VLDL, not LDL, unable to under-
go acid-dependent dissociation from B-VLDL, not 
recycled, rapidly degraded 
307. LDL binding, no effect on B-VLDL binding 
507. LDL binding, no effect on B-VLDL binding 
307. LDL binding, no'effect on B-VLDL binding 
No significant effect on LDL or B-VLDL binding 
20-257. LDL binding, no effect on B-VLDL binding 
20-25% LDL binding, no effect on B-VLDL binding, 
defective acid-dependent dissociation from B-VLDL 
Normal binding, internalization of LDL, normal 
recycling and t! for receptor, no apparent effect 
of deletion in cultured hamster fibroblasts 
No effect 
207. internalisation index 
Tyr807 + Gly,Pro,Ala,Leu,Cys 207. internalisation index 
Ser,Thr,His,Clu,Lys 
Tyr 807 Phe No effect 
Tyr 807 + Trp 607. internalisation index 
Gln808 + Cys No effect 
Gln808 + Pro 607. internalisation index 
Cytoplasmic Domain: Deletion Glu812 - Glu814 No effect 
(cont.) Glu835 Asp 837 
Trp 792 ... Stop !_ 157. internalisation index 
Tyr 807 -+- Stop 
Glu808 ... Stop 
Glu812 ... Stop 797. internalisation index 






















charged amino acids, a common feature of plasma membrane 
proteins (3). Near the carboxyl terminal, a negatively-
charged group of amino acids is found (3). Site-directed 
mutagenesis experiments (39) have shown that the first 22 
amino acids of the cytoplasmic domain (residues 790-811) are 
sufficient for efficient receptor internalisation and that 
an aromatic residue at position 807 is especially critical. 
This was also shown by the fact that the molecular defect in 
the internalisation-defective mutant, FH 380, is the 
substitution of a cysteine residue for tyrosine-807 (38). 
Residues 812-839 do not seem to be required for 
internalisation or recycling (39), but are highly conserved, 
particularly the C-terminal 14 amino acids, residues 826-
839, which are identical in the human (21), rabbit (23), 
bovine (3) and hamster (39) receptors. Possibly, these 
residues may perform specialized regulatory functions 
required in specific tissues such as the adrenal cortex 
(39). Although there seem to be strict structural 
requirements for efficient internalisation of the LDL 
receptor, no correlation is observed with cytoplasmic 
domains of 5 other coated pit receptors (3). The only 
structural feature shared between all these receptors is the 
presence of a single membrane-spanning region. 
In addition to its 
cytoplasmic domain 
receptor to form 
structures (40). 
role in clustering in coated pits, the 
mediates self-association of the LDL 
non-covalent dimers and higher order 
However, the function of self-association 
is unknown and no causal connection between this process and 
LDL receptor-internalisation has been established, since a 
mutant receptor terminating at position 812 was internalised 
normally, but showed greatly reduced oligomer formation 
(40). 
1.2.2 LDL receptor messenger RNA 
The LDL receptor mRNA appears on Northern 
approximately 5.3 kilobases in length (3). 
blots to be 
Of this, 2.58 
kb represents protein coding sequences, flanked by a s•-
14 
untranslated region of 0.09 kb, and an unusually-long 3'-
untranslated region of 2.5 kb (21). This region terminates 
with a poly(A)+ tract approximately 15 nucleotides 
downstream from a polyadenylation signal (3). The 3'-
untranslated region of the mRNA contains two-and-a-half 
copies of Alu repetitive sequences, which occur once in 
every 5000 base pairs in the human genome (41). Each Alu 
repeat is approximately 300 bp in length, consisting of a 
tandem repeat of two monomeric units, a left arm of 130 bp 
and a right arm of 160 bp, owing to a 30 bp insertion (3). 
Although Alu repeats were originally believed to be confined 
to intrans and intergenic regions (10), they are present in 
exon 18 of the human LDL receptor gene, in the region coding 
for the 3'-untranslated sequence in the mRNA. Since bovine 
LDL receptor mRNA contains no Alu sequences, and mRNA from 
gorilla and chimpanzee, but not from baboon, have Alu 
repeats at the same location as the human LDL receptor mRNA, 
it has been suggested that the insertion of Alu sequences 
into this genetic location occurred late in the evolution of 
primates (42). 
1.2.3 LDL receptor gene 
The haploi~ human genome contains one copy of the LDL 
receptor gene, which has b~en localized by in situ 
hybridfzation to bands p13.1 - 13.3 on chromosome 19 (43). 
The total human LDL receptor gene spans about 45.5 kilobases 
of DNA, and the primary sequence of about 25% of the gene 
has been determined, including all of the 18 exons and 
several of the 17 intrans. 
A striking correlation exists between the exons in the gene 
and the functional domains of the protein (22) (see Figure 
1. 1). The first exon codes for the short 5'-untranslated 
region plus the signal sequence, and exons 2 to 6 code for 
the seven 40 amino acid repeats of the binding domain. The 
seven repeats bear strong homology to a 40 amino acid, 
cysteine-rich sequence in complement component C9. Intrans 
occur exactly at the ends of repeats 1, 2, 5, 6· and 7, with 
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exon 4 coding for repeats 3 to 5. The possibility thus 
exists that the 7 binding repeats arose by exon duplication. 
The region of the LDL receptor homologous to the EGF 
precursor is encoded by exons 7 to 14. A similar 8-exon 
cassette.is found in the gene for the EGF precursor (44). 
The cysteine-rich "growth-factor" repeats, A, Band C in the 
LDL receptor, corresponding to repeats 2, 3 and 4 in the EGF 
precursor, are each encoded by a single exon. Similar 
repeat sequences are found in three proteins of the blood 
clotting system. In one of these clotting factors, a 
single exon also codes for the repeat structure (22). The 
d-linked sugar domain of the LDL receptor is encoded by exon 
; 
15, and the membrane-spanning domain by exon 16 and part of 
exon 17. · Exon 17 and part of exon 18 encode the 
cytoplasmic tail, while the rest of exon 18 codes for the 
long 3'-untranslated region in the mRNA. 





the evidence for exon duplication of repeated 
and the sharing of exons between the LDL 
and other genes, support the exon-shuffling 
Gilbert, suggesting that proteins evolve as 
mosaic combinations of pre-existing functional units encoded 
by discrete exons (45). One possible mechanism for such 
exon-shuffling events is recombination between repetitive 
elements in the gene, such as Alu sequences. The LDL 
receptor gene contains Alu.repeats in.exon 18 (21) and in a 
number of intrans (35). Although recombination between Alu 
sequences may have played a role in evolution of the LDL 
receptor protein, it may also render the gene susceptible to 
mutations. This possibility is supported by analysis of 
mutations in the LDL receptor and globin genes, showing that 
recombinations involving Alu sequences are causes of 
deletions in four LDL receptor mutations and four globin 
gene mutations (35). In addition, Alu-Alu recombination 
has been shown to result in duplication of seven exons in a 
mutant LDL receptor gene (46). Thus, the processes which 
permitted evolution of the LDL receptor may also account for 
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its frequent disruption by mutation in patients with 
familial hypercholesterolaemia (11). 
The 5'-flanking region of the LDL receptor gene contains 2 
TATA-like sequences of 7 base pairs each, 20 to 30 base 
pairs to the 5' side of the 2 major sites of transcription 
initiation between nucleotides -79 to -93 (22). This 
region also contains 3 imperfect direct repeat sequences of 
16 nucleotides each (22). Sensitivity to sterol end-
product repression depends on a 42 base pair element, 
containing two of the 16-base pair direct repeats, known as 
the sterol regulatory element (SRE42) (7). When SRE42 was 
inserted into the promoter of the herpes simplex virus 
thymidine kinase (HSV-TK) gene, this fusion gene promoted 
abundant mRNA production in transfected cells. When 
sterols were present, the mRNA was markedly reduced. 
Further studies have established that a 177 base pair 





expression as well as negative 
This fragment contains the 
three 16-base pair repeats, each of which is required for 
mRNA expression, and the two TATA-like sequences, only one 
of which is required for expression. The three repeats 
contain a sequence homologous to the consensus eukaryotic 
transcription factor, Spl, binding site. Insertion of a 
series of mutant SRE42 sequences, including 16-base pair 
repeats 2 and 3, into the HSV-TK promoter showed that repeat 
3 is a constitutive positive transcriptional element which 
binds Spl, while repeat 2 confers sterol-mediated repression 
upon repeat 3 (9). The results suggest that transcriptional 
regulation is mediated by a mechanism in which sterol-
regulated binding of a protein to repeat 2 inhibits Spl 
binding activity in repeat 3. 
A number of restriction fragment length polymorphisms 
(RFLP's) can be detected in the LDL receptor gene, as a 
result of the following polymorphic sites: Bsm I (47), Pvu 
II and Rsa I (48) in the 5' flanking region; Sph I in 
/ 
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intron 6 (47); Stu I in exon 8 (49); Ava II in exon 13 
(50); Pvu II (42,51), Spe I (47) and Apa LI (52) in intron 
15; Nco I in exon 19 (53); Apa LI (52) and Pst I (54) in 
the 3' flanking region; Bst EI! (55) and Msp I (56) in the 
3' half of the gene; Tag I in the 5' half of the gene (57); 
Hine II in exon 12 (58). The development-of a restriction 
fragment length polymorphism map for the LDL receptor gene 
is of great value in the study of mutations in familial 
hypercholesterolaemia, for the assignment of RFLP haplotypes-
to mutant genes. Haplotypes can be used to distinguish 
different mutations producing the same phenotype, or to show 
the presence of two different mutant alleles in a compound 
heterozygote ( 4 7 ) • In addition, in a genetically 
homogeneous population group, linkage can sometimes be 
established between FH and a particular haplotype in that 
population (49,53,59,104) (see section 3.2.1). 
1.3 Synthesis and post-translational processing of the LDL 
receptor 
The N-terminal signal sequence presumably directs receptor-
synthesizing ribosomes to the endoplasmic reticulum (ER) 
membrane (3) (see Figure 1.2), and is cleaved from the 
protein immediately after it is translated. The formation 
of the many intramolecular disulphide bonds, which stabilize 
the structure of the LDL receptor, is believed to take place 
co-translationally in the ER, as a result of the action of 
protein disulphide isomerase (60,61). 
Glycosylation of 
in the ER and 
the LDL receptor precursor protein begins 
is completed in the Golgi apparatus to form 
the mature receptor (see Figure 1.2). Biosynthetic studies 
using [ 3H)-glucosamine, and the migration behaviour of the 
LDL receptor on SDS-polyacrylami~e gel electrophoresis, 
suggest that it contains two asparagine-linked (N-linked) 
oligosaccharide chains, and approximately 18 serine/ 
threonine-linked (0-linked) chains (32). The N-linked 
oligosaccharides on the precursor are endo-~-N-
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Figure 1.2 Intracellular pathway of the LDL receptor 
(Discussed in sections 1.3 and 1.4) 
The LDL receptor is synthesized in the rough endoplasmic 
reticulum, transported to the Golgi complex for post-
translational modifications and then to the cell-surface, 
where the receptors cluster in coated pits. The receptor 
binds LDL and the receptor-ligand complex is endocytosed. 
At the low pH in the endosome, the ligand dissociates from 
the receptor, which recycles to the cell-surface. The 
ligand is delivered to the lysosome and degraded. 
from reference 12). 
(Adapted 
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to have the composition Man 9GlcNAc 2 and Man8GlcNAc2• The 
core 0-linked oligosaccharides on the precursor in A431 
cells consist of only N-acetylgalactosamine (GalNAc), 
whereas those on the precursor in fibroblasts contain GalNAc 
linked to another saccharide, postulated to be N-
acetylglucosamine (GlcNAc). In fibroblasts, the N-linked 
oligosaccharides of the receptor precursor are processed to 
mature bi-antennary complex-type structures, and in A431 
cells to tri- and tetra-antennary complex-type structures. 
The mature LDL receptor in A431 cells contains 0-linked 
oligosaccharides consisting of galactose and N-
acetylgalactosamine, plus one or two sialic acid residues 
(see Figure 1.3). In fibroblasts, the mature 0-linked 
oligosaccharides are also sialylated, but are larger and 
have a different structure (32). Most of the 0-linked 
chains can be isolated on a single glycopeptide fragment 
after Pronase digestion (32), and are thus clustered 
together in one domain of the receptor. 
The LDL receptor is synthesized in the rough endoplasmic 
reticulum as a precursor which migrates on sos-
polyacrylamide gel electrophoresis with an apparent 
molecular weight of 120 kDa, although the protein component 
has a molecular weight of 93 kDa. Within 30 minutes, the 
receptor is converted to a mature form with an apparent 
molecular weight of 160 kDa. The calculated molecular 
weight of the receptor 
app~oximately 115 kDa (3). 
plus mature carbohydrates is 
This anomalous migration of the 
receptor on SOS-PAGE is largely due to the addition of 
sialic acid and galactose residues to the clustered 0-linked 
N-acetylgalactosamine residues, leading to a conformational 
change (32,33). A small contribution to the increased 
apparent molecular weight of the receptor is made by the N-
linked chains (32). 
Biosynthesis of the N-linked oligosaccharides is a more 
complex process than that of 0-linked oligosaccharides, but 
is better understood. The first step, catalyzed by 
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Figure 1.3 Proposed structures of oligosaccharides attached 
to the LDL receptor during post-translational 
processing 
High mannose asparagine (Asn)-linked (N-linked) oligo-
saccharides are added co-translationally to the LDL receptor 
(R) in the endoplasmic reticulum (ER). The core serine- or 
threonine-(Ser/Thr) linked (0-linked). sugars are added in 
the ER or in transitional elements between the ER and Golgi. 
The precursor receptor (120 kDa) is transported to the Golgi 
apparatus where carbohydrate trimming and additions produce 
the complex N-linked oligosaccharides and mature 0-linked 
sugars. The mature form of the receptor (160 kDa) is then 
transported to the cell surface. The structures indicated 
are those proposed for the oligosaccharides on the LDL 
receptor in A431 cells (32). The N-linked oligosaccharides 
on the receptor from fibroblasts are processed to bi-
antennary complex structures, and the 0-linked 
oligosaccharides are larger than those for A431 cells, 
containing N-acetylglucosamine in addition to N-
acetylgalactosamine, galactose and sialic acid. 
Abbreviations: Fuc, fucose; Gal, galactose; Glc, glucose; 
Man, mannose; GlcNAc, N-acetylglucosamine; GalNAc, N-
acetylgalactosamine; SA, sialic acid. 
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oligosaccharyl transferase, is the co-translational addition 
of Glc 3Man 9GlcNAc 2 from the lipid-linked oligosaccharide 
donor, dolichol pyrophosphat~, to asparagine residues of the 
nascent polypeptide in the rough ER ( 3 2) • The glucose 
residues are removed in the ER by glucosidases I and II 
before the protein is transported to the Golgi. Mannose 
residues are trimmed in the early Golgi region by a-
mannosidase I, followed by addition of N-acetylglucosamine 
by GlcNAc transferase I and further mannose trimming by a-
mannosidase II in the medial Golgi. At this stage the N-
linked oligosaccharides become EndoH-resistant ( 62). 
Further modifications are carried out by other GlcNAc- and 
fucosyl transferases, before galactose and sialic acid 
residues are added in the trans Golgi to complete the 
maturation to complex-type N-linked oligosaccharides. 
There are five potential sites in the LDL receptor protein 
for N-linked glycosylation (Asn-X-Ser or Asn-X-Thr) ( 3) • 
Apparently only the two sites situated in the region 
homologous to the EGF precursor are glycosylated, but not 
the three potential sites in the cysteine-rich N-terminal 
binding domain. 
Addition of 0-linked oligosaccharides to the LDL receptor is 
a post-translational event, initiated by the addition of N-
acetylgalactosamine to serine and threonine residues (32). 
The subcellular localization of 0-linked carbohydrate 
addition is unknown, and proposals range from the rough ER 
to, the cis Golgi (63). The addition of N-
acetylgalactosamine to the LDL receptor precedes the 
conversion of the N-linked oligosaccharides to the EndoH-
resistant form in the medial Golgi (32). Therefore, the 
transfer of GalNAc must occur prior to entry of the protein 
into this region of the Golgi apparatus. Recently, 
immunocytochemi~al localization of mutant LDL receptors that 
fail to reach the Golgi, but do contain core 0-linked 
sugars, has suggested that the enzymes which attach these 
residues must be located in the rough endoplasmic reticulum, 
or in a transitional zone of smooth membrane extensions from 
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the ER (64). The addition of GalNAc to the El glycoprotein 
of Mouse Hepatitis Virus-A59 has also been shown to occur in 
a budding compartment similar to transitional elements or 
vesicles ( 6 3) • Approximately 75% of the 0-linked 
oligosaccharides attached to the LDL receptor are clustered 
in a region immediately external to the cell membrane. The 
receptor also contains isolated 0-1 inked carbohy'drate chains 
in the NH 2 -terminal portion of the protein (33). 
The function of glycosylation of the LDL receptor is 
unknown. Davis et~- (33) have shown that deletion of the 
clustered 0-linked sugar domain of the LDL receptor had no 
effect on receptor function in cultured hamster fibroblasts. 
However, Kingsley et~. (65) have shown that in a mutant 
Chinese hamster ovary cell line, 0-linked carbohydrate 
chains, but not N-linked oligosaccharides, played a crucial 
role in stability of the LDL receptor. Considered 
together, these findings suggest that the isolated 0-linked 
oligosaccharides in the N-terminal region of the receptor 
(33) are important for receptor stability, unless the 
clustered 0-linked sugars protect a proteolytic site in that 
receptor domain. The latter possibility is supported by 
recent findings of Kozarsky et al. (66) showing that 0-
linked sugar-deficient receptors reached the cell-surface, 
but were abnormally unstable due to proteolytic cleavage 
within or near the domain usually containing clustered 0-
linked oligosaccharides, and release into the medium of most 
of the N-terminal extracellular domain. Chatterjee et al. 
(67) have shown that inhibition by tunicamycin of N-linked 
glycosylation of the LDL receptor affects the level, but not 
the functional capacity, of receptor expression. 
Apart from 
to undergo 
glycosylation, the LDL receptor does not appear 
any other significant post-translational 
modification. Although the receptor in human fibroblasts 
can be labelled by 35s-sulphate, which attaches to N-linked 
sugars (32), no functional significance for this 
modification has been demonstrated. Unlike the transferrin 
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receptor, the LDL receptor does not undergo acylation (3). 
There is no evidence for phosphorylation of the LDL receptor 
in vivo, although a kinase has been isolated which can 
phosphorylate the receptor in vitro (68). Recently, it has 
been shown that in bovine adrenal membranes, and in hamster 
fibroblasts transfected with human LDL receptors, a small 
proportion of the receptors undergoes noncovalent self-
association, mediated by the cytoplasmic domain, to form 
dimers and higher order structures (40), but the functional 
significance of this process has not been established 
1.4 LDL Receptor Function and Regulation 
The mature LDL receptor is a cell-surface protein which 
binds plasma LDL particles and transports them into the cell 
by receptor-mediated endocytosis (1) (see Figure 1.3). The 
internalized LDL is delivered to the lysosomes, where the 
cholesterol ester core is hydrolyzed to release free 
cholesterol for plasma membrane, bile acid or steroid 
hormone synthesis, or conversion back to cholesterol ester 
for storage (1). The high affinity of the receptor for. 
LDL, combined with the ability of each receptor to cycle 
many times between the plasma membrane and the cell 
interior, enables large amounts of cholesterol to be 
delivered to the tissues, 
cholesterol at a low level. 
while keeping plasma LDL-
Disruption of the LDL receptor 
function by genetic defects or regulatory signals causes the 
plasma cholesterol 
atherosclerosis (69). 
level to increase and can lead to 
Approximately 45 minutes after their synthesis, LDL 
receptors reach the cell surface, where they gather in 
clathrin-coated pits, which invaginate within 3 to 5 minutes 
to form coated endocytic vesicles (1). The receptors 
spontaneously move to coated pits and enter the cell 
continuously, even in the absence of ligand (3). The 
clathrin coat dissociates from the endocytic vesicles, which 
then fuse to form endosomes. The pH in the endosome is 
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decreased to below 6.5 by ATP-dependent proton pumps, 
causing the LDL to dissociate from the receptor, which then 
recycles to the surface to initiate another endocytic cycle. 
The LDL receptor recycles once every 1-0 minutes in the 
presence or absence of LDL (3). Recycling requires that 
the LDL receptors have a stable structure to pass repeatedly 
through the acidic endosomes. In the endosome, the 
receptor must undergo sufficient conformational change to 
release the ligand without becoming irreversibly denatured 
( 3 ) • The LDL released from the receptor is delivered to 
the lysosome, where the protein component is degraded to 
amino acids, and the cholesterol ester component is 
hydrolyzed by acid lipase to liberate free cholesterol (70). 
This cholesterol (or oxygenated cholesterol derivatives ·(7-
9,71) regulates three events in intracellular cholesterol 
metabolism. Firstly, cholesterol biosynthesis is inhibited 
by suppression of transcription of the rate-limiting enzyme, 
3-hydroxy-3-methylglutaryl-CoA reductase (HMG-CoA 
reductase), and acceleration of its degradation (72). 
Secondly, acyl CoA:cholesterol 0-acyltransferase is 
activated to re-esterify and store excess cholesterol (70). 
The third regulatory response to the cholesterol is 
suppression of the transcription of LDL receptor messenger 
RNA, thereby reducing the LDL receptor level. Sterol 
repression of transcription is mediated by two 16-base pair 
imperfect direct repeat elements in the 5' flanking region 
of the LDL receptor gene (7-9). When cells are deprived of 
exogenous cholesterol, transcription of LDL receptor mRNA 
and expression of LDL receptors is increased (70). In 
contrast to HMG-CoA reductase, regulation of the degradation 
of the LDL receptor does not play a role in determining 
receptor levels (73). By means of the above regulatory 
mechanisms, cells can maintain a constant level of 
unesterified cholesterol, despite fluctuations in their 
cholesterol requirements and supply (70). 
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1.5 Classification and elucidation of LDL receptor 
mutations 
1.5.1 Mutations in subjects with familial 
hypercholesterolaemia 
The biochemical analysis of mutations in subjects with 
familial hypercholesterolaemia ( FH) has revealed much 
information about structure-function relationships in the 
LDL receptor protein, and elucidated many of the steps in 
the complex cellular itinerary of the LDL receptor. 
The earliest classification of FH mutations by clinical 
criteria could only differentiate between the heterozygous 
and homozygous forms of the disease. Heterozygotes, which 
occur at a frequency of one in 500 persons in most 
populations, have an LDL-cholesterol level (350-550 mg/dl) 
about 2.5-fold above normal and develop tendon xanthomata 
and coronary atherosclerosis after the age of 30 ( 7 4) • 
Homozygotes constitute approximately one in a million 
persons in most populations, have severe hyper-
cholesterolaemia (650-lOOOmg/dl), six to ten-fold higher 
than normal and develop planar cutaneous xanthomata in the 
first 4 years of life ( 7 4 ) • Coronary heart disease 
develops in childhood and frequently causes death in the 
first or second decades from myocardial infarction. 
The ability to measure LDL receptor activity in cultured 
cells on the basis of 12 5 r-LDL binding studies showed that 
FH heterozygotes produce approximately half the normal 
number of LDL receptors and homozygotes, virtually no 
functional receptors. 
in FH were identified: 
Three types of LDL receptor defects 
(i) receptor-negative, where less 
than 2% of the normal number of functional receptors are 
produced; (ii) receptor-defective, where markedly decreased 
receptor activities of 5 to 20% of normal are observed; 
( i i i ) receptor 
internalisation of 
internalisation and 
( 75) • 








The LDL receptor was purified to homogeneity (17) and' 
antibodies to the receptor were developed (18). Using 
these antibodies as probes, at least four classes of LDL 
receptor mutations were distinguished (19,20), including 
defects in synthesis, intracellular transport, LDL binding 
ability or internalisation of the receptor. In this way, 
the receptor-negative and receptor-defective classes were 
shown to represent multiple defects on the basis of 
immunoprecipitable receptors (18), whereas variants of the 
internalisation-defective class, 
could be detected (35,36). 
namely secreted receptors, 
FH subjects considered 
."homozygous" from measurements of LDL receptor activity 
could be shown to be genetic compounds in cases where the 
two mutant alleles produced immunoprecipitable receptors of 
different molecular weights. 
Class 1 mutations are 
synthesized. This 
those where no LDL receptors are 
is the most common class of mutations 
accounting for about half the defects analyzed to date (1). 
The designation of a class 1 mutation is based on the 
absence of LDL receptor protein as detected by reaction with 
polyclonal or monoclonal anti-receptor antibodies. 
Class 2 mutations, the second most common class, lead to 
significant receptor synthesis, but slow transport from the 
endoplasmic reticulum to the Golgi apparatus, and therefore 
slow post-translational carbohydrate processing (see section 
1.3). The mutant precursors contain high-mannose N-linked. 
oligosaccharides and core 0-linked N-acetylgalactosamine 
residues, and have molecular weights ranging from 100 kDa to 
135 kDa (19), although most have normal molecular weights of 
120 kDa. Biosynthetic immunoprecipitation studies show 
that the N-linked sugars are abnormally slowly converted to 
the complex EndoH-resistant form, and that the elongation of 
0-linked sugars is markedly retarded. The mutant receptors 
either do not appear on the cell surface, but remain in the 
ER, where they may eventually be degraded (76), or the 
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receptors appear on the surface at about one-tenth the 
normal rate (19,77). The reason for delayed transport in 
class 2 mutations is presumably abnormal folding of the 
mutant LDL receptor protein, since transport from the 
depends on a normal protein endoplasmic reticulum 
conformation (78-80). Some abnormal proteins retained in 
the ER have been shown to bind to a class of proteins 
including immunoglobulin heavy chain binding protein (BiP) 
(78,81). Binding to BiP has not yet been demonstrated for 
LDL receptor Class 2 mutants, although a putative 
"gatekeeper" protein has been proposed (23) and variable 
amounts of a protein migrating with the molecular weight of 
BiP have been detected in LDL receptor immunoprecipitation 
studies (82). 
Class 3 mutant LDL receptors are processed and reach the 
cell surface, but fail to bind LDL normally although they 
bind antibodies to the receptor (18,19). The mature forms 
of these receptors have normal (160 kDa) or abnormal (140 or 
210 kDa) apparent molecular weights ( 1 9 ) , and are 
synthesized as precursors which are 40 kDa smaller than the 
mature receptors. 
Class 4 mutations produce receptors which reach the cell 
surface and bind LDL, but fail to cluster in coated pits 
( 3 ) • The study of these mutants revealed the importance of 
coated pits in the process of receptor-mediated endocytosis. 
Class 4 variants produce LDL receptors which are secreted 
and can therefore be immunoprecipitated from the medium 
(35,36,83). Receptors are transported to the surface where 
some remain associated with the membrane, while the vast 
majority are secreted into the medium, possibly after 
initially being cell-associated (83). Those receptors 
associated with the membrane do not migrate to coated pits 
and are internalisation-defective. 
Classification of genetic defects in the LDL receptor on the 
basis of binding activity and 35$-biosynthetic immuno-
i 
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precipitation studies revealed 
phenotypes associated with FH, 
heterogeneous disease at the 
isolation of full-length cDNA 
a wide diversity 
suggesting that it was 
molecular level. 









and elucidation of the normal receptor gene 
have provided the tools necessary to explore 
genetics of the LDL receptor in FH. The 
of at least one of each of the different 
classes of mutations discussed above has been determined 
(summarized in Table 1.2). The mutations are distributed 
over the entire 45 kilobases of the gene, and affect all the 
different domains of the protein (10). 
Molecular analysis of FH mutations has enabled further sub-
division of class 1 mutations into null alleles that produce 
mRNA and those where no mRNA is detectable (47). Class 1 
mutations are caused by promoter deletions (47,84) or 
deletions of exons coding for parts of the EGF precursor 
homology domain (47,85,86) and, in one case, also the 0-
linked sugar domain (86) [See Table 1.2]. 
Transport-deficient, or class 2, mutant LDL receptor alleles 
are the result of small in-frame deletions (10,23,87) or 
substitutions (82,88) in exons encoding both cysteine-rich 
and cysteine-poor (82) regions of the receptor. Mutations 
in cysteine-rich regions could be expected to distort intra-
repeat disulphide bonding in some way, resulting in abnormal 
protein conformation and delayed transport from the ER to 
the Golgi (78-80). However, the mutation in one transport-
deficient allele (FH429) is located in a part of the gene 
coding for a cysteine-poor region of the molecule (82). 
Presumably, this mutation alters the protein folding without 
involvement of abnormal disulphide bonding. In this 
regard, it is noteworthy that 4 different class 2 mutations 
elucidated at the molecular level (see Table 1.2) involve 
deletions or substitutions of glycine residues 
(10,23,82,88). Glycine, with its single hydrogen side 
chain, is often found at space-restricted regions in 
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proteins, such as ~-turns. Thus deletion of a glycine 
residue, or substitution with a larger amino acid, could 
potentially disrupt protein conformation, leading to 
impaired intracellular transport (78-80). 
Defective LDL binding in class 3 mutants appears to be 
caused by deletions (89) or insertions (46) involving exons 
2 to 8, which code for cysteine-rich repeats in the binding 
and EGF precursor homology domains. It is noteworthy that 
these mutant receptors with deletions or insertions of 
entire repeats exhibit normal rates of intracellular 
transport, in contrast to those produced by small mutations 
within cysteine-rich repeats. This is consistent with the 
idea that disulphide bonds form within each repeat (90), so 
that small deletions or insertions disrupt correct 
disulphide bond formation, whereas deletion or insertion of 
whole repeats has no effect. 
Internalisation-defective (Class 4) alleles all have 
mutations in exon 17 coding for the cytoplasmic tail 
(37,38), whereas the class 4 variants, the secreted 
receptors, have deletions which produce receptors lacking 
the membrane-spanning and cytoplasmic domains (35,36,91,92). 
The analysis of FH mutations on a molecular level has 
revealed a frequent involvement of Alu repeats in large 
deletions (35,36,85,86,89) and insertions ( 4 6) • Four of 
these mutations, FH274 (36), FH626 (89), FH781 (35) and TD 
(85), are deletions caused by homologous recombinations 
between two Alu sequences. The deletion in FH381 (86) is 
the result of recombination between an Alu sequence in 
intron 15 and a sequence in exon 13 homologous to the Alu 
sequence. Although the mutations in FH781 (35) and FH274 
(36) both result from recombination between Alu repeats in 
intron 15 and exon 18, different individual Alu repeats are 
involved in the two deletions (35). In the recombinations 
involved in FH274 and FH381, the Alu (or Alu-like) sequences 
were oriented in opposite directions, and formation of a 
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TABLE 1. 2 NATURAL MUTATIONS AT THE LDL RECEPTOR LOCUS IN FAMILIAL HYPERCHOLESTEROLAEMIA (Adapted from (19)) 
Biochemical Class FH Subject Ethnic Origin Mutation mRNA Protein Ref. 
of Mutation 
Class 1: No detect- FH 49, 549, French- > 10 kb deletion of promoter and None None. 





























Compound heterozygote - one 
·allele:± 6 kb deletion of 
promoter and exon 1, other 
allele: no visible deletion 
None 
Compound heterozygote - complex 6.2 kb 
rearrangement of one allele, 
possible complete deletion of 
other allele 
4 kb deletion of exons 13 and 14 5 kb 
Unequal crossing-over between Alu N.D. 
sequences in intrans 12 and 14--::-
4 kb deletion of exons 13 and 14 
(possibly same mutation as FH651) 
5 kb deletion of exons 13 to 15 5 kb 
as a result of recombination 
between exon 13 and Alu sequence 
in intron 15 
No deletion rearrangement detec-













Mutation mRNA Protein 
Mutation 






















detectable by Southern 
blotting 
N.D. None 
Japanese No deletion/rearrangement 
detectable by Southern 
blotting 
5. 3/ None 
8.4 kb 
12 bp deletion in exon 4 Normal 
American 3 bp deletion in exon 4 Normal 
Lebanese- Nonsense mutation in Normal 
Arab exon 14 
Italian Missense mutation in exon 11 Normal 
Xhosa In-frame deletion of 6 bp N.D. 




4 kb deletion of exons 7 
and 8 
0.8 kb deletion of exon 5 
as a result of unequal 
crossing over between Alu 
sequences in intrans 4~&-5 
5.1 kb 
5.2 kb 
Loss of 4 amino acids (Asp 115 
Gly116.ser117.Asp118) in repeat 3 
of binding domain 
Loss of one Glycine residue in 
5th binding repeat 
Truncated protein lacking 0-
linked sugar, membrane-spanning 
and cytoplasmic domains 
Substitution of Val for Gly544 
Removal of Asp26Gly27 from 
repeat 1, loss of IgG-C7 
recognition 
Loss of Cys-rich repeats A and B 
in EGF precursor-like region, 
binds S-VLDL, but not LDL 
Loss of 6th Cys-rich binding 






































































N.D. Not Determined 
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Mutation mRNA Protein Ref. 
14 kb duplication of exons 6.5 kb Duplication of binding repeats 1 to 46 
7 and repeats A and B from EGF 
precursor-like region 
2 to 8 caused by Alu-Alu 
recombination between"""Introns 
1 and 8 
Nonsense mutation in exon 17 Normal 
- stop codon 2 residues dis-
Only 2 cytoplasmic amino acids 37 
tal to membrane-spanning 
region 
4 kb duplication in exon 17 
·after codon for sixth amino 
acid of cytoplasmic tail~ 
altered reading frame 
Nonsense mutation in exon 17 
5.5 kb deletion of exons 16 
to 18 by intrastrand recom-
bination between 2 Alu 
sequences in intron""Ts and 
exon 18 
7.8 kb deletion of exons 16 
to 18 by recombination 
between Alu sequences in 
intron ls°and exon 18, 
splice acceptor sites 
deleted 
Mutation 
Deletion of exon 15 
encoding 0-linked 
sugar domain 
8 kb deletion of exons 
16 and 17 and part of 
exon 18 
Normal 6 normal amino acids, 8 random 
amino acids, then stop codon 
Normal Tyr807 replaced by Cys 
37 
38 
8.5 kb Truncated receptor lacking membrane- 10,36 
.. spanning and cytoplasmic domains, 
small amount of internalisation-
defective cell-associated receptors 
6.2 kb Truncated receptor, no membrane-
spanning or cytoplasmic domain, 
novel 55 amino acids from trans-








4.2 kb Loss of membrane-spanning and 91, 92 · 
cytoplasmic domain (presumably 
secreted) 
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double stem-loop structure was proposed as the mechanism for 
the deletions (36,86). Unequal crossing-over between Alu 
sequences in the same orientation is the simplest mechanism 
that could give rise to the mutations in FH626 (89), FH781 
(3S), FH29S (46) and TD (BS). Nine different Alu sequences 
have been shown to be involved in mutations in the LDL 
receptor gene, while three Alu sequences have been reported 
to be involved in mutations in globin genes (3S). Eight of 
the deletion points are clustered within a 36-base pair 
sequence of the left arm of the Alu repeat, suggesting that 
this region may adopt an unusual configuration during 
transcription that renders it prone to recombination (3S). 
In general, the frequent involvement of Alu sequences in 
mutations in the LDL receptor suggests that the tendency for 
recombination between these elements may account in part for 
the prevalence of FH. 
1.S.2 Experimentally-induced and site-directed mutations in 
the LDL receptor 
Although invaluable information about structure and function 
of the LDL receptor has been obtained through the study of 
naturally-occurring mutations in FH (summarized in Table 
1.2), the variety of these mutations is limited, and only 
mutations compatible with the growth and survival of the 
organism (or cultured cells) can be studied. The scope of 
these studies has been extended by analysis of 
experimentally-induced mutations in the LDL receptor (12) 
and by in vitro mutagenesis to create specific mutations to 
characterize particular regions of the LDL receptor protein 
(28,29,31,33) [summarized in Table 1.1). 
Krieger and co-workers have treated Chinese hamster ovary 
cells with mutagens, and then screened for mutants 
exhibiting defects in LDL endocytosis (93). The LDL 
receptor-deficient mutants fall into four complementation 
groups, ldlA, ldlB, ldlC and ldlD. Analysis of ldlA 
mutants identified the ldlA locus as the structural gene for 
the LDL receptor. Three classes of mutant alleles were 
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distinguished at the ldlA locus (93): null alleles (class 
1), class 2 mutations causing defective receptor processing, 
and alleles that code for normally-processed receptors which 
cannot bind LDL (class 3). The abnormally-processed (class 
2) receptors were continually converted to novel unstable 
intracellular intermediates. The mutations in ldlB, ldlC 
and ldlD cells appeared to be general glycosylation defects 
(94). The mutation in ldlD cells was shown to be a 
deficiency in the enzyme 
acetylgalactosamine 4-epimerase (65). 
UDP-galactose/UDP-N-
The epimerase 
deficiency leads to reversible defects in the synthesis of 
both N-linked and 0-linked oligosaccharides on 
glycoproteins, including the LDL receptor. The ldlD 
mutants have been particularly valuable in showing that C-
linked, but not N-linked, oligosaccharides play a crucial 
role in stability of the LDL receptor (65) by preventing the 
proteolytic removal of the N-terminal region as observed for 
0-linked sugar-deficient receptors (66). 
The general approach of using FH mutations in the LDL 
receptor to broadly define th~ importance of a region of the 
protein, followed by the in vitro construction of additional 
mutations for further characterization by transfection 
studies, has been applied to all domains of the LDL receptor 
(summarized in Table 1.1). Particularly rigorous analysis 
of the structural requirements for internalisation, mediated 
by the cytoplasmic domain (39), and the contribution of the 
various cysteine-rich repeats in the ligand-binding and EGF 
precursor homologous domains to binding of the ligands, LDL 
and ~-VLDL (28), has been carried out (discussed in sections 
1.2.1.5, 1.2.1.1 and 1.2.1.2, respectively). Site-directed 
mutagenesis of the LDL receptor has also established that 
the first cysteine-rich binding repeat contains the epitope 
for IgG-C7 (29), that the EGF precursor homologous domain 
facilitates acid-dependent conformational changes to release 
bound ligand in the endosome (31), and that the clustered C-
linked oligosaccharides have no important function in 
cultured hamster fibroblasts (33). In addition, site-
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directed mutagenesis of the 5'-flanking region of the LDL 
receptor gene has identified the elements required for 
regulated ex~ression (7-9). 
1.6 Effect of genetic defects in the LDL receptor in vivo -
therapeutic implications 
When Goldstein and Brown began their studies of FH in 1972 
(1) it was generally believed that all important events in 
cholesterol metabolism occurred in the liver and intestine. 
Since it was not feasible to study the LDL receptor in 
livers of human FH patients, cultured skin fibroblasts from 
the patients were used. Thus, the elucidation of LDL 
receptor structure, function and regulation, in both normal 
and FH subjects, was conducted in the artificial environment 
of tissue culture, using non-hepatic cells. The question 
arises as to how relevant these findings are to the 
situation in vivo, particularly as the LDL receptors in the 
peripheral tissues would be continually down-regulated at 
the levels of LDL encountered in the plasma (75). However, 
the LDL receptor obviously has an important role in the 
body, as shown by the serious problems caused by LDL 
receptor deficiency in FH homozygotes, and the 
proportionately less severe abnormalities in heterozygotes 
( 1 ) • 
The first demonstration of LDL receptor activity in vivo was 
in lymphocytes isolated from the bloodstream (95). LDL 
receptor activity was very low in freshly-isolated 
lymphocytes, but when the lymphocytes were incubated for 72 
hours in the absence of lipoproteins to "de-repress" LDL 
receptor activity, a progressive increase in high-affinity 
uptake and degradation of 125 I-LDL was observed. 
Consistent with results from cultured fibroblasts, 
lymphocytes from FH homozygotes developed less than 5%·of 
normal receptor activity after 72 hours in the absence of 
lipoproteins, and FH heterozygotes exhibited an intermediate 
level of expression (95). 
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The function of the LDL receptor in vivo has been studied by 
determining the rate of disappearance from the plasma of 
intravenously injected 125!-LDL (69). The rate in FH 
heterozygotes (mean life-span of 125 1-LDL in the plasma= 
4.5 days) is slower than in normal cells (mean life-span 2.5 
days), and even slower in FH homozygotes (mean life-span 6 
days) (1). This decreased rate of LDL catabolism in vivo 
correlates with the relative deficiency of LDL receptors 
detected in lymphocytes and fibroblasts from FH subjects. 
The fraction of total LDL clearance which represents the 
receptor-dependent fraction can be estimated by comparing 
the rate of 125 I-LDL catabolism in normal individuals an9 FH 
homozygotes. 
subjects is 
The fractional catabolic rate in normal 
3 times higher than in FH homozygotes, 
suggesting that approximately two-thirds of LDL clearance is 
normally mediated through the LDL receptor (1). The same 
conclusion is obtained from the degradation rates of native 
LDL versus lysine- or arginine-modified LDL, which cannot 
bind to the LDL receptor. 
The existence and importance of the hepatic LDL receptors 
has been established in a number of studies (reviewed in 
( 1 ) ) • The bovine adrenal gland and corpus luteum showed 
the highest LDL receptor activity per gram of tissue, but, 
taking the weight into account, the liver expressed the most 
LDL receptors of all the tissues. Similar results were 
obtained with human foetal tissues. Perfused rat liv~rs 
exhibited high-affinity, receptor-mediated uptake of 12 51-
LDL that could be increased by 17a-ethinyl estradiol 
administration. Liver membranes from dogs were also shown 
to contain functional LDL receptors that were susceptible to 
metabolic regulation (96). Steinberg and co-workers, and 
Dietschy and co-workers have shown that approximately 70% of 
total-body uptake of radio-labelled LDL is mediated through 
hepatic LDL receptors (1), thus emphasizing the importance 
of the liver receptors in the regulation of plasma LDL 
levels. 
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An additional· mechanism for determination of LDL levels by 
hepatic LDL receptors has been elucidated through kinetic 
studies in the WHHL rabbit, an animal model for FH (97). 
In addition to degrading LDL more slowly, FH homozygotes and 
heterozygotes appear to over-produce LDL. LDL is not 
secreted directly by the liver, but is produced from VLDL 
(very-low-density lipoprotein) by triglyceride hydrolysis by 
lipoprotein lipase to form IDL (intermediate-density 
lipoprotein), which can be taken up by the liver LDL 
receptors via high-affinity binding of multiple apoprotein E 
molecules on the IDL particle. IDL can alternatively 
undergo further triglyceride hydrolysis to form LDL, 
containing a single molecule of apoprotein B-100. 
Injection of 125 I-labelled VLDL into the WHHL rabbit showed 
that the apparent overproduction of LDL observed in FH is 
due to the failure of IDL to be removed from the plasma 
because of the deficiency in hepatic LDL receptors. The 
IDL remaining in the circulation is converted in increased 
amounts to LDL. Thus 
role in LDL metabolism 
hepatic LDL receptors play a dual 
by ~i) limiting LOL production by 
enhancing removal of precursor IDL from the circulation and, 
(ii) enhancing LDL degradation by mediating receptor-
mediated cellular uptake. The LDL receptors of the liver 
are thus crucial in modulating plasma LDL levels. 
As a result of the central role of the liver in the control 
of plasma cholesterol, therapeutic approaches to lower 
plasma cholesterol are aimed at increasing the production of 
LOL receptors in the liver. FH heterozygotes have one 
normal LDL receptor allele which can be stimulated to 
produce an increased number of receptors, to overcome the 
genetic deficiency (1). Since the liver is the major site 
for LDL receptor expression, this stimulation can be 
achieved by increasing the hepatic demands for cholesterol 
by: (i) inhibition of intestinal re-absorption and re-use by 
the liver of bile acids by the administration of bile acid-
binding resins such as cholestyramine, (ii) inhibition of 
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cholesterol synthesis by HMG-CoA reductase inhibitors, such 
as compactin or mevinolin. The combination of these two 
measures causes an increase in the amount of HMG-CoA 
reductase and LDL receptors synthesized by the liver. 
Total body cholesterol synthesis is slightly reduced, while 
plasma LDL levels fall by 50 to 60%, as a result of the 
increased number of hepatic LDL receptors. The decrease in 
LDL is balanced by the increase in receptors so that the 
absolute amount of cholesterol taken up by the liver is the 
same, but is occurring at a lower level of plasma LDL (1). 
FH homozygotes do not respond to measures that stimulate LDL 
receptor production, since they do not have a normal allele 
which can 
LDL from 
synthesize functional LDL receptors. Removal of 
the plasma of FH homozygous subjects can be 
performed extracorporeally by repeated plasmapheresis. An 
alternative, more direct approach of liver transplantation, 
to provide a source of LDL receptors, was recently applied 
in the case of FH homozygote, SJ. The result was a 
decrease in plasma cholesterol from 1100 mg/dl to 200-300 
mg/dl and treatment with the HMG-CoA reductase inhibitor, 
mevinolin, further decreased the level to 150-200 mg/dl. 
This dramatic response to liver transplantation emphasizes 
the importance of hepatic LDL receptors in vivo in 
regulating plasma LDL cholesterol levels. 
An alternative to therapy for homozygous FH subjects is 
prevention of the incidence of homozygous FH by genetic 
counselling to heterozygous FH subjects. However, 
unequivocal assignment of the condition of heterozygous FH 
is not always possible. Clinical symptoms similar to those 
in FH may be observed in other lipid disorders, and assays 
of receptor activity are too complicated and time-consuming 
for routine screening. In addition, overlap in the ranges 
of LDL receptor activity for normal and heterozygous cells 
can occur (98). The most reliable diagnostic test for 
heterozygous FH would be at the genetic level. However, 
the heterogeneity of the disease at the molecular level 
hampers approaches 
may be different 
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for genetic diagnosis. 
in populations with 
The situation 
a relatively 
homogeneous genetic background, where founder gene effects 
can occur. In such populations, diagnostic Southern 
blotting or haplotype analysis may be possible, facilitating 
simple and definitive screening of potential FH 
heterozygotes. Founder gene mutations in the LDL receptor 
in populations exhibiting a high incidence of FH are 
discussed in section 1.7. 
1.7 Founder-gene mutations in the LDL receptor 
Founder effects are produced by "the establishment of a new 
population by a few original founders which carry only a 
small fraction of the total genetic variation of the 
parental population" resulting in a 
population (99) in which certain 
new, genetically unique, 
genetic disorders are 
unusually prevalent. FH is a heterogeneous disease, even 
within the same ethnic groups (10). However, exceptions to 
this heterogeneity are observed in genetically-isolated 
populations, where founder gene effects are present. 
1.7.1 French-Canadian FH 
Four unrelated French-Canadian homozygous FH subjects (FH49, 
549, 808 and 859) have been shown to have the same LDL 
receptor mutation, a large deletion eliminating the promoter 
and exon 
allele. 
1 of the gene, 
This deletion 
giving rise to a "null" (class 1) 
accounted for 63% of all FH 
mutations in this ethnic group (84). The present-day 
French-Canadian population is descended from a small group 
of 8000 French immigrants 'to Canada in the 17th and 18th 
centuries. Since this population has remained relatively 
isolated genetically, it seems likely that the high 
frequency of the promoter deletion is due to a founder gene 
effect.' Since the mutation is readily detected by Southern 
blotting (84), rapid and accurate diagnosis of FH in the 
majority of French-Canadian hypercholesterolaemic patients 
should be possible. 
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1.7.2 Lebanese FH 
The prevalence of heterozygous FH is approximately 1 in 500 
in most populations in the world. However, 
heterozygote frequency is approximately 1 
in Lebanon, the 
in 100, and, 
coupled with a high incidence of consanguinity, results in a 
10-fold higher prevalence of the homozygous disease (88). 
The occurrence of a single Class 2 mutation in the 
homozygous form in four unrelated Arab patients with FH 
(three from Lebanon, one from Syria) may be attributable to 
a founder gene effect. This "Lebanese allele" produces an 
abnormally small receptor as a result of a single base 
substitution in exon 14 producing a premature termination 
codon. The truncated receptor lacks the 0-linked sugar, 
membrane-spanning and cytoplasmic domains, and i~ not 
transported to the cell surface, but retained in the ER, 
probably as a result of abnormal folding. The mutation 
creates a novel HinfI site in exon 14, permitting diagnosis 
by Southern blotting. The postulate that the mutation . 
represents a founder gene mutation in this population can 
thus be readily tested in future. 
1.7.3 Finnish FH 
Recent studies (91,92) have identified an 8 kilobas~ 
deletion from the 3'-end of the LDL receptor gene, in about 
one-third of Finnish patients with heterozygous FH (91). 
The mutation eliminates exon 16, 17 and part of 18 (92). 
Thus, the receptor would be expected to lack the membrane-
spanning and cytoplasmic domains, 
cell (35,36). The deletion can 
Southern blotting (91). 
and be secreted from the 
be easily diagnosed by 
The Finns are descended from relatively few ancestors, and 
no significant immigration from Sweden or Russia has 
occurred. The barrier of the Finnish language has further 
contributed to the genetic isolation of this population, 
which has a high coronary heart disease mortality rate. 
The possibility thus exists that the prevalence of the 
4 1 
deletion mutation is the result of a founder gene effect in 
the Finnish population. 
1.7.4 South African Afrikaner FH 
FH is particularly prevalent in the South African Afrikaner 
population (100-102), with an estimated heterozygote 
frequency of 1 in 100 (101), similar to that in the Lebanese 
population. The incidence of the homozygous form of FH, 
which is rarely found in most countries (frequency of 1 in 1 
million), is as high as 1 in 30000 in the Afrikaner 
population (101). Homozygotes from this group exhibit 
variable and somewhat milder clinical features than observed 
for FH in other populations (102). 
The reason for the prevalence of FH in this group is that 
the Afrikaners have remained genetically relatively 
homogeneous because of a history of geographical, religious 
and cultural isolation (103) and a great expansion of an 
originally small settler population (102). A founder gene 
effect has thus been proposed to account for the high 
incidence of FH in the Afrikaner population (101,102). It 
has been calculated that one or two defective genes among 
founder members of the Afrikaners would be sufficient to 
explain the high FH prevalence (101). 
Support for the founder gene hyp~thesis has been obtained in 
studies of LDL receptor activity (98,103) and from haplotype 
studies (59,104). LDL receptor activity was determined in 
cultured cells from 21 clinically-defined Afrikaner FH 
homozygotes from two geographical areas, the Cape Province 
The results showed a (98) and the Transvaal (103). 
"receptor-defective" (7S) type of mutation in all but one 
pair of siblings, which were apparently "receptor-negative". 
Using PvuII (42,Sl) and Stu! (49) polymorphisms in the LDL 
receptor gene, Brink et al. (S9) and Henderson et al. (104) 
showed that 16 out of 17 unrelated FH homozygotes from the 







predominance of a mutation coding for receptors which 
undergo retarded post-translational processing. All the 
above findings are consistent with the proposal of a founder 
gene(s) to account for the high incidence of FH. in t~e South 
African Afrikaner. 
The unusually high frequency of FH in 
population affords a unique opportunity 
the Afrikaner 
to study LDL 
receptor mutations, in many cases, in the truly homozygous 
form, without interference from a normal gene (in FH 
heterozygotes) or from a different mutant gene (in compound 
heterozygotes). In addition, the development of a 
comprehensive restriction map of the LDL receptor gene, and 
the subsequent determination of haplotypes or markers 
associated with FH, particularly in the founder gene 
situation, should enable population screening and thus 
prenatal diagnosis of homozygous FH, or diagnosis of 
heterozygous FH and genetic counselling to reduce the 
incidence of the severe homozygous form. This is 
particularly relevant in the South African population where 
deaths from coronary heart disease are the highest in the 
world (102). The high incidence of FH must make ·a 
significant contribution to these cases, and therefore the 
diagnosis, understanding and, hopefully, prevention of this 
disease is medically very relevant to this country. 
1.8 Research objectives 
Although studies of LDL receptor activity in cells from 
Afrikaner FH homozygotes indicated the predominance of a 
receptor-defective phenotype, believed to be the result of 
one or more founder mutations, considerable heterogeneity in 
the level of functional activity was observed 
(98,103).Analysis of receptor synthesis, processing and 
degradation rates, and ligand binding affinity could 
potentially elucidate the mechanism(s) underlying the 
heterogeneity, and thus provide valuable information, in a 
broader context, on the defects responsible for Afrikaner 
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FH, and, more specifically, on interesting cellular 
processes affecting the level° of receptor expression. 
The biochemical analysis of FH mutations has contributed 
significantly to the understanding of structure-function 
relationships and the cellular events in the LDL receptor 
pathway (discussed in section 1.5). The elucidation of 
Class 4 mutations, for example, has provided valuable 
insights into the role of the cytoplasmic domain of the 
receptor in the interaction with coated pits required for 
receptor-mediated endocytosis (37,38). The Class 2 
mutations, which exhibit defects in receptor transport from 
the endoplasmic reticulum to the Golgi apparatus, have the 
potential to provide fundamental information on the complex 
regulation of intracellular transport, a topic of great 
current interest in cell biology (78-80). It was therefore 
noteworthy that preliminary biosynthetic studies of selected 
Afrikaner subjects (103) showed retarded post-translational 
transport and processing of the mutant receptors (Class 2 
mutations). 
The aim of this research project was to characterize fully 
the phenotypic expression of mutant LDL receptors in 
selected homozygous Afrikaner FH subjects (and FH 
homozygotes from other South African ethnic groups), because 
of (i) their potential medical and genetic significance 
(section 1.7.4) and (ii) the fundamental importance of the 
cell biological mechanisms underlying the wide range of LDL 
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2.1 Materials 
2.1.1 Culture media and supplements 
Eagle's Minimum Essential Medium ( MEM), Dulbecco's 
Modification of Eagle's Medium (DMEM), RPMI medium and 
methionine- and glutamine-free Eagle's Minimum Essential 
Medium with Earle's salts (EMEM) were obtained from Flow 
Laboratories (Ayrshire, Scotland). Trypsin and tryptose 
phosphate broth were from Difeo Laboratories (Detroit, MI, 
USA). Heat-inactivated foetal calf serum was prepared by 
heating foetal calf serum (State Vaccine Institute, Cape 
Town, South Africa) to 56°C for 30 minutes. Human 
lipoprotein-deficient serum was prepared as described below 
in section 2.2.1. Penicillin G and streptomycin sulphate 
were from 
Africa). 
Hoechst Pharmaceuticals (Johannesburg, South 
2.1.2 Radio-isotopes 
Sodium [ 12 5 I] iodide was 
(Buckinghamshire, England). 
chemicals, Irvine, CA, USA), 
obtained from 
Tran 35s labelTM 




methionine, and is the hydrolysate of!• coli grown in the 
presenc~ of H2
35so 4 , consisting of 70% [
35sJ-methionine, 20% 
[ 35sJ-cysteine, 7% [ 35s]-methionine sulphoxide, 2% c35s]-
cysteic acid and 1% other 35s-labelled compounds. 
2.1.3 Reagents for SDS-polyacrylamide gel electrophoresis 
and fluorography 
BDH Chemicals Ltd. (Poole, England) was the source for 
sodium salicylate and acrylamide, while N,N'-methylene-
bisacrylamide and TEMED (N,N,N',N'-tetramethylethylene-
d~amine) were obtained from Bio-Rad Laboratories (Richmond, 
CA, USA). Ammonium persulphate, 2-mercaptoethanol, dithio-
threitol and Coomassie Brilliant Blue R250 were purchased 
from E. Merck A.G. (Darmstadt, West Germany). 
2.1.4 Detergents 
Sigma Chemical Co. (St. Louis, MO, USA) was the source 
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for CHAPS (3-[(3-cholamidopropyl)dimethylammonio)-1-propane 
sulphonate), Nonidet P-40 and Triton X-100. Tween 20 was 
obtained from Bio-Rad Laboratories (Richmond, CA, USA) and 
sodium dodecyl (lauryl) sulphate (SOS) from Saarchem Pty 
Ltd. (Krugersdorp, South Africa). 
2.1.s Enzymes 
"Trypsin-EDTA", for dispersion of cultured cell monolayers, 
contained Trypsin (0.05% (w/v), Difeo Laboratories, Detroit, 
MI, USA) and EDTA (0.02% (w/v), Merck) in phosphate-buffered 
saline (PBS). Neuraminidase was obtained from Calbiochem-




dase H) was a 
Pronase and Endo-a-N-acetylgalactosaminidase 
were from Boehringer Mannheim (Mannheim, West 
Endo-~-N-acetylglucosaminidase H (Endoglycosi-
product of Miles Scientific (Naperville, IL, 
USA). Proteinase K was obtained from E. Merck A.G. 
(Darmstadt, West Germany). 
2.1.6 Inhibitors 
Aprotonin (Midran™) was obtained from Novo Industries 
(Pharmaceuticals) (Pty) Ltd. (Johannesburg, South Africa). 
Phenylmethylsulphonyl fluoride (PMSF) was from Merck and 
leupeptin from the Peptide Institute Inc. (Osaka, Japan). 
Chloroquine was purchased from Sigma Chemical Co., and 
ammonium chloride from BDH Chemicals, Ltd. Tunicamycin, 
obtained from Calbiochem-Behring Diagnostics, was dissolved 
in dimethyl sulphoxide at a concentration of 2 mg/ml (32). 
2.1.7 Miscellaneous reagents 
Pristane (2,6,10,14-tetramethylpentadecane) was purchased 
from Aldrich Chemical Co. (Milwaukee, WI, USA). Iodo-Gen 
and Immobilized Protein A were supplied by Pierce Chemical 
Company (Rockford, IL, USA). Sigma Chemical Co. was the 




heparin and cholesterol. Suramin 
purchased from Bayer-Miles (Pty) Ltd. 
Afrita) and 25-h~droxycholesterol from 
48 
Research Plus, Inc. All other reagents used were 
analytical grade from Merck. 
2.1.a Antibodies 
IgG-C7, a mouse monoclonal antibody to the LDL receptor, was 
prepared as described below in section 2.2.2. Polyclonal 
anti-LDL receptor antibodies, 698-7 and 498-1, raised in 
rabbits against purified bovine LDL receptor (105) and non-
immune IgG from rabbits were gifts from Ors. M.S. Brown and 
J.L. Goldstein (Departments of Molecular Genetics and 
Internal Medicine, University of Texas Southwestern Medical 
Center, Dallas, TX, USA). 83/25, a mouse monoclonal 
antibody to the human transferrin receptor, was provided by 
Dr I.S. Trowbridge (The Salk Institute for Biological 
Studies, San Diego, CA, USA). Goat anti-mouse IgG (heavy 
and light chain specific) and goat anti-rabbit IgG (heavy 
and light chain specific) were obtained from Cappel 
Laboratories (Malvern, PA, USA). 
Goat anti-mouse IgG was radio-iodinated as described later 
for IgG-C7 (section 2.2.2.3) after prior dialysis against 
several changes of 0.9% (w/v) NaCl, 0.01% (w/v) EDTA (pH 7) 
to remove sodium azide from the preparation. 
2.1.9 Lipoprotein ligands 
Human low density lipoprotein (LDL), which binds to the LDL 
receptor via apolipoprotein B-100, and rabbit ~-migrating 
very-low-density lipoprotein (~-VLDL), which binds via the 
interaction of apolipoprotein E with the 
(discussed in section 1.2.1.1) were prepared 




2.2.1 Preparation of low-density lipoprotein (LDL), 
lipoprotein-deficient serum (LPDS) and ~-migrating 
very-low-density lipoprotein (~-VLDL) 
Human low density lipoprotein (LDL) (density 1.019 - 1.063 
g/ml) and human lipoprotein-deficient serum (LPDS) 
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(density> 1.25 g/ml) were 
normolipidaemic donors 




centrifugation (106) in a Beckman LB-70 ultracentrifuge as 
follows. Plasma (containing 0.01% (w/v) EDTA and protease 
inhibitors, aprotonin (0.4% (v/v) of a 10000 U/ml solution) 
and phenylmethylsulphonyl fluoride (PMSF) (0.2 mM)) was 
adjusted to a density of 1.3 g/ml with potassium bromide and 
0.9% (w/v) NaCl, 0.01% (w/v) EDTA (pH 7.0) (density~l.006 
g/ml) was layered over the adjusted plasma. The various 
lipoproteins were separated according to their densities by 
centrifugation at 50000 rpm (206000 g) for 2.5 hours at 10°C 
in a vertical VTi50 rotor. The LDL fractions (density 
1.019 to 1.063 g/ml) were pooled and washed at density 1.063 
g/ml by centrifugation for 16 hours at 50000 rpm (170000 g) 
in a Ti60 rotor. After the initial 2.5 hour centri-
fugation, the lower portion of the discontinuous gradient 
was adjusted with potassium bromide to a density of 1.25 
g/ml and high-density lipoprotein (HDL) was separated from 
the denser lipoprotein-deficient fraction by centrifugation 
at 50000 rpm (206000 g) for 6 to 8 hours in a VTi50 rotor. 
The LDL and lipoprotein-deficient fractions were dialyzed 
exhaustively against 0.9% (w/v) NaCl, 0.01% (w/v) EDTA (pH 
7.0). After dialysis, the lipoprotein-deficient plasma was 
converted to lipoprotein-deficient serum by incubation at 
4°C for 24 hours with thrombin (2 units/ml). The resulting 
clot was removed by centrifugation f~r 10 minutes at 20000 
rpm (30000 g) for 10 minutes in a JA20 rotor. 
In some cases, an alternative, shorter method for the 
preparation of LPDS only was used. Plasma (containing 0.25 M 
EDTA) was adjusted to a density of 1.215 g/ml with potassium 
bromide and centrifuged at 59000 rpm (250000g) for 36 hours 
at 4°C in a Ti60 rotor. The VLDL, LDL and HDL fractions in 
the upper portion of each tube were discarded, and the 
yellow, lipoprotein-deficient layers in the lower portion of 
the tubes were pooled, dialyzed against 0.9% (w/v) NaCl, 
0.01% (w/v) EDTA (pH 7.0) and treated with thrombin as 
described above. 
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The LDL and LPDS were sterilized by filtration through a 
Millipore filter (0.45 µM pore diameter). The LPDS was 
heated to 56°C for 30 minutes to inactivate complement 
activity. Protein concentrations of the LPDS and LDL 
preparations were determined by the method of Lowry et al. 
(107) using bovine serum albumin (Fraction V, Boehringer 
Mannheim) as standard. The protein concentrations usually 
ranged from 8 to 20 mg protein/ml for LDL and 50 to 80 mg/ml 
for the LPDS. The LPDS was stored frozen at -10°C and the 
LDL was kept at 4°C. The LDL preparation was shown by 
lipoprotein electrophoresis (Beckman Paragon Lipoprotein 
Reagent Kit) to be essentially free of other human 
lipoproteins, and by SDS-polyacrylamide gel electrophoresis 
(5-12% polyacrylamide gradient), according to the method of 
Laemmli et~. (108), to contain mainly apolipoprotein B-100 
(apparent molecular weight 340000 daltons) and thus to be 
essentially free (<1%) of contaminating plasma proteins. 
,-migrating very low density lipoprotein <,-vLDL) was 
prepared from the plasma of cholesterol-fed rabbits, 
essentially as described by Kovanen et ~. (109). The 
rabbit is extremely sensitive to dietary cholesterol. 
Within days after the initiation of a high cholesterol diet 
(2% cholesterol - 10% corn oil), the plasma cholesterol 
concentration increases by more than 10-fold. A large 
proportion of this cholesterol is contained in ,-vLDL 
particles in which cholesteryl e~ters are the predominant 
lipids, and apoprotein Ethe major protein (109). 
,-vLDL was isolated from rabbits fed the high cholesterol 
diet for 2 to 5 weeks. The hyperlipidaemic (density< 1.006) 
fraction was isolated by centrifugation at 40000 rpm in a 
SW40 rotor for 16 hours at 10°C. · This fraction was washed 
twice by adjusting the sample to 0.22 M sodium chloride and 
then applying the adjusted solution under a layer of 
phosphate-buffered saline followed by centrifugati9n under 
the same conditions as above. SDS-polyacrylamide gel 
5 1 
electrophoresis of the ~-VLDL preparation showed that 80-90% 
of the protein content was apoprotein E. The protein 
concentration was determined by the method of Lowry et _!l. 
(107). Because of the lipid-rich nature of the ~-VLDL, it 
was necessary to extract the turbid samples (and bovine 
serum albumin standards) three times with hexane, before the 
level of colour development in the protein assay could be 
determined spectrophotometrically. 
2.2.1.2 Radio-iodination of lipoproteins 
125I-labelled LDL was routinely prepared using the iodine 
monochloride method of MacFarlane (110), as modified by 
Bilheimer et al. (111). An amount of glycine-NaOH buffer 
(2M, pH 10) was added to the LDL, such that the final 
glycine concentration in the total iodination mixture would 
be 0.4 M. Carrier-free sodium c12 5 IJ iodide (1 mCi/mg LDL 
protein or 0.5 mCi/mg protein) was then added and 40 µl of 
diluted iodine monochloride solution (35 µl 33 mM iodine 
monochloride in 2 ml 2M sodium chloride) per mg LDL protein 
was forcefully injected into the reaction mixture. The 
radiolabelled LDL was then dialyzed against several changes 
of 0.9% (w/v) NaCl, 0.01% .(w/v) EDTA (pH 7.0) to remove free 
125 iodine. The specific radioactivity of 125 I-labelled LDL 
prepared in this way usually ranged from 300 to 700 cpm per 
nanogram of protein (150-350 cpm/fmol) and 98% of the 1251-
radioactivity was protein-bound as determined by 
precipitation with 5% (w/v) trichloroacetic acid. Less 
than 5% of the l2 5 I-label was extractable into chloroform-
methanol (2:1), representing lipid labelling. The protein 
concentration of 125 I-labelled LDL was approximately 3 
mg/ml. Radio-iodinated LDL was used within 2 weeks of 
iodination and was always centrifuged briefly (11000 g for 2 
minutes) before 
particulate matter. 
use, to remove any precipitated or 
~-VLDL was radiolabelled as described above for LDL except 
that a 20-fold higher concentration of iodine monochloride 
was used. Approximately 90% of the label was precipitable 
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by 5% trichloroacetic acid, and 15-30% of the label could be 
extracted into chloroform:methanol (2:1), representing lipid 
labelling. 
2.2.2 Preparation of monoclonal anti-LDL receptor antibody 
IgG-C7 
IgG-C7, a monoclonal antibody directed against an epitope in 
the first cysteine-rich repeat of the LDL receptor binding 
domain (29), was prepared from a commercially available 
hybridoma cell line (American Type Culture Collection, 
CRL1691). This cell line was originally established by 
Beisiegel et ~. (18) by immunizing mice with a partially 
purified receptor from bovine adrenal cortex. Spleen cells 
from the mice were then fused with mouse myeloma cells usin9 
polyethylene glycol. Aliquots of medium from the hybridoma 
cultures were screened for antibodies to the LDL receptor 
and positive hybridomas were cloned by limiting dilution. 
2.2.2.1 Production of ascites fluid 
Female BALB/C mice (6-8 weeks old) were primed for ascites 
tumour formation by injection with pristane (2,6,10,14-
tetramethyl pentadecane) at least ten days before injection 
of hybridomas. Hybridoma cells were grown in suspension at 
approximately 3x105 cells per ml in 90 mm diameter Petri 
dishes containing 10 ml of either DMEM, supplemented with 
4.5 g glucose per litre and 10% (v/v) foetal calf serum, or 
RPMI, supplemented with 300 mg L-glutamine per litre, 500 µM 
mercaptoethanol, 10% (v/v) heat-inactivated foetal calf 
serum, 60 µg/ml penicillin G and 100 µg/ml streptomycin 
sulphate. Medium was changed every alternate day. For 
long-term storage, cells were collected by centrifugation, 
resuspended at 2x106 cells per ml of 90% (v/v) heat-inacti-
vated foetal calf serum, 10% (v/v) dimethylsulphoxide, and 
stored frozen under liquid nitrogen. 
Hybridoma cells were harvested by aspiration when in the 
actively growing, logarithmic phase, washed once with serum-
free DMEM and resuspended to a final density of 2x106 to 
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5x10 6 hybridomas per 0.5 ml DMEM. Each primed mouse was 
injected intra-peritoneally with 0.5 ml of hybridoma cell 
suspension. Within 14 to 21 days, ascites tumours 
developed in most of the mice. The mice were sacrificed by 
cervical dislocation, the peritoneal cavities opened and the 
ascites fluid aspirated. Each mouse yielded 2 to 4 ml of 
ascites fluid which was centrifuged at 2000 rpm in a Beckman 
Model TJ-6 centrifuge for 15 minutes at room temperature to 
remove cells, and then stored at 4°C in the presence of 
0.02% sodium azide. In some cases, the ascites fluid 
proteins were precipitated with an equal volume of saturated 
ammonium sulphate, and stored as a wet pellet at -20°C. 
2.2.2.2 Purification of IgG-C7 from ascites fluid 
The ascites fluid was applied to a column of immobilized 
Protein A (Pierce) that was equilibrated with 0.1 M sodium 
7.0). After elution of unbound material at phosphate (pH 
pH 7, the IgG fraction was eluted with a solution of 1 M 
acetic acid and 0.1 M glycine (pH 3). The pH of the IgG 
fraction was immediately raised to pH 7.4 by the addition of 
the required volume of a 2 M Tris solution, and the IgG-
containing solution was then dialyzed against 10 mM sodium 
phosphate, 50 mM NaCl (pH 7.4) (18) for 24 hours at 4°C. 
The dialyzed solution was concentrated using an Amicon 8200 
ultrafiltration system (YM10 membrane) to a protein 
concentration (determined by the method of Lowry et al. 
(107)) of 1 to 2 mg/ml. The IgG-C7-containing solution was 
stored frozen under liquid nitrogen in aliquots which were 
never freeze-thawed more than once before use. 
2.2.2.3 Radio-iodination of IgG-C7 
The monoclonal antibody IgG-C7 was radio-labelled with 125 1 
using Iodo-Gen (1,3,4,6-tetrachloro-3a,6a-diphenylglycol-
uril) a solid-phase iodinating reagent (112) essentially as 
described by Beisiegel et al. (18). A typical iodination 
reaction contained 200 µg of Iodo-Gen adsorbed to a glass 
vial, to which was added 0.6 mg IgG-C7 and 0.25 - 0.5 mCi of 
carrier-free sodium c125 I] iodide in a total volume of 0.4 
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ml. After incubation for S minutes (112) or 20 minutes 
(18) at 4°C, the iodination mixture was removed from the 
reaction vial and dialyzed against several changes of 0.9% 
(w/v) NaCl, 0.01% (w/v) EOTA (pH 7.4) to remove free 
125 iodine. The specific radioactivity of the 125I-labelled 
IgG-C7 ranged from 400 to 2000 cpm per nanogram of protein 
(60-300 cpm/fmol), depending on. the amount of sodium 
c125 I]iodide used and the incubation time. Approximately 
98% of the 125 I-radioactivity was protein-bound as deter-
mined by precipitation with 5% (w/v) trichloroacetic acid. 
2.2.2.4 Characterization of isolated IgG-C7 
The purity of the isolated IgG-C7 was assessed by SOS-
polyacrylamide gel electrophoresis and biological activity 
of the antibody was determined by the ability of l2 5r-
labelled IgG-C7 to bind to cell-surface LOL receptors (18), 
and by the ability of an immune complex containing IgG-C7 to 
specifically immunoprecipitate LDL 
2.2.7.6) from a total cell lysate (20). 
receptors (section 
The efficiency of IgG-C7 purification by Protein A affinity 
chromatography was routinely assessed by SOS-PAGE of the 
ascites fluid, the unbound material at pH 7, and the 
putative IgG fraction eluted at pH 3. The samples were 
subjected to electrophoresis in the presence of SOS, under 
both reducing and non-reducing conditions, in a 5% to 20% 
polyacrylamide gradient gel (108). The ascites fluid 
contained IgG (molecular weight 150 kOa (non-reduced) or 50 
kOa and 25 kOa (reduced)) and various other proteins, 
particularly albumin (molecular weight 67 kOa). The 
unbound material at pH 7 contained mostly contaminating 
proteins, but also a small amount of IgG. However, the 
peak which eluted at pH 3 was essentially pure IgG, thus 
confirming the 
.chromatography. 
efficiency of the Protein A affinity 
The monoclonal antibody to the LOL receptor, IgG-C7, was 
shown .bY Beisiegel et~· (18) to bind with high affinity to 
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human skin fibroblasts, reaching levels equimolar to the 
amount of LDL bound at saturating concentrations. Typical 
concentration curves for the binding of 125 I-labelled LDL 
and 12Sr-labelled IgG-C7 to normal human skin fibroblasts 
are shown in Figures 5.l(a) and (b), p. 151, respectively. 
For either antibody or ligand, the curves showed two 
components: a high affinity component which approached 
saturation at an LDL concentration of S µg protein/ml (10 
nM) (Fig. 5.l(a)) or at an IgG-C7 concentration of 0.5 µg 
protein/ml (3 nM) (Fig. 5.l(b)), and a non-specific 
component which increased linearly above these 
concentrations. High-affinity binding values, calculat~d 
by non-linear regression analysis (section 2.2.8), showed 
that half-maximal binding for 125 I-LDL to the receptor in 
normal cells occurred at 2.4 µg protein/ml (4.8 nM), and for 
125 I-IgG-C7 at 0.08 µg/ml (0.5 nM). Maximum high affinity 
binding of 125 I-labelled LDL was calculated to be 237 ng/mg 
cell protein (474 fmol/mg), and for 125 I-labelled IgG-C7 to 
be 41 ng/mg cell protein (273 fmol/mg). The maximal 12Sr-
IgG-C7 binding was 60% of the 125 I-LDL binding level, and 
not exactly equimolar as expected. This molar ratio was 
found to be variable between 0.6 and 1.0 for different 
batches of radio-iodinated IgG-C7 and LDL. The variabilit~ 
could be minimized by performing iodination of the IgG-C7 in 
the presence of Iodo-Gen for only S minutes at 4°C, as 
originally suggested by Fraker and Speck (112) instead of 20 
minutes, as described by Beisiegel et~. ( 1 8 ) • 
procedure, approximately equimolar ratios of 
Using this 
125 I-LDL to 
12SI-IgG-C7 binding to normal fibroblasts were consistently 
obtained. To correct for any variability in the molar 
ratio of binding of different batches of radio-iodinated LDL 
and IgG-C7, the ratio of LDL to IgG-C7 binding at saturation 
in LDL receptor-normal cells was assumed to be unity, and 
binding values for cells from FH subjects were always 
compared by expression as percentages of LDL- and IgG-C7 
binding to normal cells in the same experiment (as shown in 
Figure S.1 for FHla cells). Besides binding with high-
affinity to cells in approximately equimolar amounts to LDL 
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binding, the IgG-C7 was able to inhibit binding of 125r-LDL 
binding to the LDL receptor. When cell monolayers were 
pre-incubated for 1 hour at 4°C with IgG-C7 (1 µg/ml), 
subsequent binding of 125 I-LDL (2 hours at 4°C) was 
inhibited by approximately 50% (data not shown). In 
contrast, pre-incubation with LDL 





consistent with those obtained by Beisiegel et al (18). 
2.2.3 Cell culture 
All media used for cell culture were routinely tested to 
ensure that they were pyrogen-free. Cell cultures were 
periodically checked for mycoplasma contamination using the 
BRL Mycotect Mycoplasma Detection system (Bethesda Research 
Laboratories, Maryland, USA). Culture media usually 
contained antibiotics (penicillin G and streptomycin 
sulphate) to prevent bacterial contamination. 
2.2.3.1 Human skin fibroblasts 
Skin fibroblast cultures were established from skin biopsies 
obtained from the ventral surface of the forearms of 
subjects (98,103). In addition, LDL-receptor-normal 
fibroblast strains GM3348 and GM0203 were obtained from the 
Human Genetic Mutant Cell Repository (Camden, NJ, USA). 
The cells were maintained in monolayer cultures in 75 cm 2 
flasks in a humidified incubator (95% relative humidity, 5% 
Fibroblasts were grown in approximately 12 
ml of Dulbecco's Modification of Eagle's Minimum Essential 
Medium (DMEM), buffered with 43mM or 25mM bicarbonate, and 
supplemented with 10% (v/v) heat-inactivated foetal calf 
serum, 60 µg/ml penicillin G and 100 µg/ml streptomycin 
sulphate. 
in culture. 
Cells were not used beyond the·twentieth passage 
Confluent monolayers were dissociated by 
incubation with 5 ml 0.05% (w/v) trypsin/0.02% (w/v) EDTA 
for approximately 5 minutes at 37°C and then seeded at 0.1 x 
106 to 0.15 x 106 cells per 60 mm Petri dish and used for 
experiments within 2 to 5 days as described in sections 
2.2.s, 2.2.6. and 2.2.1. For long-term storage, trypsin-
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EDTA dissociated fibroblasts were resuspended at 106 cells 
per ml of medium containing 10% (~/v) dimethyl sulphoxide, 
and stored frozen under liquid nitrogen. 
2.2.4 Induction of maximal LDL receptor expression in 
cultured fibroblasts 
The expression of maximal LDL receptor activity requires 
that: (i) the cells be actively growing, since confluent 
cells no longer require cholesterol for new membrane 
synthesis and the number of LDL receptors thus declines, and 
(ii) the cells be deprived of exogenous cholesterol (70). 
Active growth of cultured cells was established by seeding 
them initially in medium containing 10% (v/v) foetal calf 
serum. After a few days of growth, the cells were deprived 
of exogenous cholesterol by washing with phosphate-buffered 
saline and then incubating them for 48 hours in lipoprotein-
deficient medium (DMEM, supplemented with 5 mg LPDS 
protein/ml). In some cases, the medium was supplemented 
with LPDS at 2.5 mg protein/ml instead of 5 mg/ml. This 
lower concentration of LPDS produced the same upregulated 
LDL receptor level in normal cells after 48 hours as was 
obtained for 5 mg/ml LPDS (results not shown). Although 
fibroblasts cannot grow indefinitely in lipoprotein-
deficient medium, they continue dividing for 48 hours, and 
maximal surface LDL receptor expression is reached after 
this period (70). Therefqre, unless stated otherwise, LDL 
receptor activity was upregulated in lipoprotein-deficient 
medium for 48 hours prior to each experiment. 
Although 48 hours in LPDS were required to achieve a new, 
maximal steady state receptor level, receptor synthesis 
rates increased more rapidly, reaching a maximum after 20 to 
30 hours in LPDS (see Fig. 5.13, p. 190). Therefore, 
upregulation periods of only 16 to 24 hours were required to 
achieve sufficient c3 5s]-methionine incorporation into LDL 
receptors for biosynthetic studies (19,77). 
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2.2.5 Surface binding of 125 I-labelled lipoproteins and 
125 r-labelled IgG-C7 at 4°C 
Normal human skin fibroblasts were seeded at a density of 
0.1 x 106 cells per 60 mm diameter Petri dish and grown for 
5 days and then induced for maximal LDL receptor expression 
by incubation for 48 hours in lipoprotein-deficient medium. 
The cells then received 1.5 ml of ice-cold lipoprotein-
deficient medium (MEM buffered with 10 mM HEPES (pH 7.4), 
supplemented with 2.5 or 5 mg protein/ml LPDS) containing 
the indicated concentrations of 125 I-labelled LDL, 125r-
labelled ~-VLDL (section 2.2.1.2) or 125 I-labelled IgG-C7 
(section 2.2.2.3). After incubation for 2 hours at 4°C, 
cells were washed four times at 4°C.with phosphate-buffered 
saline (PBS) containing 0.2% bovine serum albumin, followed 
by three washes at 4°C with PBS. The cells were 
solubilized in 1 M NaOH and total radioactivity bound to the 
cells was measured. Cell protein was determined by the 
method of Lowry et E-l• (107) using bovine serum albumin as 
standard. 
High-affinity binding values for 125 I-LDL and l25I-IgG-C7 
were calculated from concentration curves of total binding 
by non-linear regr~ssion analysis~ assuming ligand binding 
to a single class of high-affinity sites plus non-specific 
binding (See section 2.2.8). Alternatively, surface 
binding levels of 125 r-labelled IgG-C7 (1 µg/ml, 6.7 nM) and 
125 I-labelled-LDL (7 µg/ml, 14 nM) at 4°C were determined as 
described above, and high-affinity values were calculated 
from total binding by subtraction of non-specific values 
obtained in the presence of excess unlabelled IgG-C7 (50 
µg/ml, 330 nM) or LDL (300 µg/ml, 600 nM), respectively. 
Surface-bound 125 r-~-VLDL (1 µg/ml) was determined, in the 
absence or presence of excess unlabelled ~-VLDL (90 µg/ml), 
as the fraction of total binding released by the anionic 
compound, suramin. After binding a€ 4°C for 2 hours, and 
washing as described above, each monolayer was incubated for 
1 hour at 4°C with 1.s ml of buffer containing 10 mM 
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suramin, 50 mM NaCl, 3 mM CaC1 2 , 10 mM HEPES (pH 7.4) (31). 
After the incubation period, the medium was collected and 
the suramin-releasable fraction of 125 I-B-VLDL bound was 
determined. This procedure was necessary because of the 
high, variable (25-60% of total) background of 125 I-B-VLDL 
binding obtained after solubilization in 1 M NaOH. 
LDL receptor activity .in fibroblasts from subjects with 
homozygous FH was always expressed as a percentage of the 
high-affinity binding to a normal cell line in the same 
experiment. 
2.2.6 Binding and metabolism of l25I-labelled lipoproteins 
and l2 5 I-labelled IgG-C7 at 37°C 
Fibroblasts were grown for 5 days as described for 4°C 
surface _binding assays, and then LDL receptor activity was 
either upregulated for 48 hours in lipoprotein-deficient 
medium (2.S or S mg/ml LPDS protein) or down-regulated in 
medium containing 1 µg/ml 25-hydroxycholesterol plus 12 
µg/ml cholesterol to suppress LDL receptor synthesis 
(6,21,75). On day 7, cells received 2 ml of lipoprotein-
deficient medium (DMEM/LPDS) containing the indicated 
concentrations of either 125I-labelled LDL, 12 51-laQelled B-
VLDL or l2Sr-labelled IgG-c7· in the absence or presence of 
excess unlabelled LDL, B-VLDL or IgG-C7, respectively. 
After incubation for 4 hours at 37°C, the cells were chilled 
to 4°C and the medium was collected for determination of 
125I-LDL or l25I-IgG-C7 degradation. The cells were washed 
as described in section 2.2.S and solubilized in 1 M NaOH 
for the determination of cell-associated (surface-bound and 
intracellular) 12 5I-LDL or -IgG-C7, and cell protein by the 
method of Lowry et..!.!_. (107). Degradation of l2 5 r-labelled 
LDL or IgG-C7 was determined from non-iodine trichloroacetic 
acid-soluble radioactivity in the medium, as described 
previously (98,103). Briefly, protein was precipitated 
from the medium by the addition of 0.6 ml SO~ (w/v) 
trichloroacetic acid and incubation on ice for at least.30 
minutes, and then sedimented by centrifugation at 2000 rpm 
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(Beckman TJ-6 centrifuge) for 30 minutes at 4°C. An 
aliquot of the supernatant (1 ml) was removed, 20 µl 40% 
potassium iodide was added as a carrier, and 50 µl 30% 
hydrogen peroxide was then added to convert the free iodide 
to iodine. The iodine was extracted with 2 volumes of 
chloroform and the 1251-tyrosine in the aqueous phase was 
measured to determine the extent of degradation of 1251-
labelled LDL, ~-VLDL or IgG-C7. Background degradation 
values, obtained from 125 I-LDL, 125 I-6-VLDL or 125 I-IgG-C7 
incubation in cell-free dishes, were subtracted from values 
obtained for degradation by fibroblasts. 
High-affinity uptake and degradation values for 125r-
labelled LDL, ~-VLDL and IgG-C7 were calculated by 
subtraction of non-specific values obtained in the presence 
of an unlabelled excess of each ligand or antibody, 
respectively. 
125 I-LDL or 
In some cases, high affinity values for 
125I-IgG-C7 uptake and degradation were 
determined by subtraction of the values obtained for LDL 
receptor down-regulated cells, or by non-linear regression 
(section 2.2.8) of a concentration curve of total binding, 
assuming ligand or antibody binding to a single class of 
high-affinity sites • 
2.2.7 Immunoprecipitation of 35s-labelled LDL receptors 
from cultured fibroblasts 
2.2.7.1 Preformed immune complexes 
Preformed immune complexes of ( i ) mouse monoclonal 
antibodies, IgG-C7 or anti-transferrin receptor B3/25, and 
goat anti-mouse IgG second antibody, or (ii) rabbit 
polyclonal anti-LDL receptor antibodies, 698-7 or 498-1, and 
goat anti-rabbit IgG, were prepared essentially as described 
by Tolleshaug et al. (20), with some modifications. 
Monoclonal (or polyclonal) antibody (0.3 mg in approximately 
150 µl 10- mM sodium phosphate, 50 mM NaCl (pH 7.4)) was 
added to goat anti-mouse (or anti-rabbit) IgG (3 mg i~ 300 
µl 20 mM phosphate-buffered saline (pH 7.3)) and 300µ1 of 
immune complex buffer containing 50 mM Tris-HCl (pH 8), 200 
6 1 
mM NaCl, 1 mM EDTA and 0.5% (v/v) Nonidet P-40. After 
incubation at room temperature for 30 minutes, the complex 
' was placed at 4°C for an additLonal 24 to 48 hours. The 
complex was then washed once by mild centrifugation (5 
minutes at 2000 rpm at 4°C) and resuspended in 1 ml of 
immune complex buffer. Protein concentrations of immune 
complex suspensions were typically 2-3 mg/ml, representing 
precipitation of approximately 70% to 80% of the total 
protein • Increasing the time of precipitation to longer 
. than 24 hours, or increasing the ratio of second to first 
antibody to greater than 10:1, did not result in more 
efficient precipitation 
observations). 
(Casciola, L.A.F., unpublished 
2.2.7.2 Labelling of cell proteins with [ 35s]-methionine 
Human skin fibroblasts were seeded at 1.5 x 106 cells per 60 
mm dish, and after 2 days' growth, the cells were incubated 
for 16 hours in lipoprotein-deficient medium (DMEM, 
supplemented with LPDS at 2.5 or 5 mg protein/ml) to induce 
LDL receptor synthesis (19,77). The cells were washed 
twice with 2 ml PBS, and then pulse-labelled at 37°C in 1.3 
ml methionine-free Eagle's Minimum Essential Medium buffered 
with Earle's salts (EMEM) (supplemented with 5 mg/ml LPDS) 
with 30-130 µCi/ml ( 35s]-methionine 
cribed in Materials section 2.1.2). 
(Tran 35S-label™, des-
After pulse-labelling (usually 0.5 to 2 hours as indicated 
in figure legends), the cells were either immediately washed 
and solubilized, or the medium was changed to complete 
DMEM/LPDS (containing 200 µM unlabelled methionine) and 
incubation at 37°C was continued for various chase times. 
The cells were then washed twice at 4°C with 2 ml of buffer 
containing 10 mM HEPES (pH 7.4), 150 mM NaCl and 2 mM CaC1 2 
and lysed and scraped from the dishes in 200 µl of ice-cold 
buffer containing 10 mM HEPES (pH 7.4), 200 mM NaCl, 2 mM 
1 mM phenylmethylsulphonyl fluoride 
(dissolved in dimethylsulphoxide, final concentration 0.25% 
(v/v)), 0.1 mM leupeptin and 1% (v/v) Triton X-100. Each 
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dish was rinsed with a second 200 µl of this buffer, which 
was pooled with the first 200 µland centrifuged at 4°C for 
10 minutes at 11000 gin a microfuge to remove insoluble 
material. An aliquot of 320 µl was taken from each 
supernatant and the pellet fractions were discarded. The 
320 µl aliquots of the lysates were either used immediately 
for immunoprecipitation or stored frozen at -70°C. 
2.2.7.3 Immunoprecipitation of 35s-labelled receptors 
The method for immunoprecipitation was based on a 
modification of the procedure of Terhorst et JLl.• (113) as 
describ~d by Tolleshaug et al. (19). 35S-labelled receptors 
were precipitated by the addition of 80 µl of preformed 
immune complex (section 2.2.7.1) to 320 µl of cell lysate 
and incubation at 4°C for 1 hour on a horizontally-shaken 
platform. Immunoprecipitates were collected by centri-
fugation at 2000 rpm at 4°C for 5 minutes. The supernatant 
was removed and either discarded or, in some cases, used for 
a second immunoprecipitation reaction with an immune complex 
containing either the same monoclonal or polyclonal antibody 
(to assess the efficiency of the first precipitation) or a 
different antibody to immunoprecipitate another specific 
protein. The immunoprecipitates were then resuspended in 
lysis buffer and washed by centrifugation through a 4-step 
sucrose gradient as described by Tolleshaug et al. (19). 
The sucrose gradient contained 10 mM Tris-HCl (pH 8) and lmM 
phenylmethylsulphonyl fluoride throughout, and in addition, 
the first layer contained 10% sucrose, 0.5% (w/v) CHAPS; 
the second layer, 20% sucrose, 0.5 M NaCl, 0.2% (v/v) 
Nonidet P-40; the third layer, 30% sucrose, 0.1% (w/v) SOS, 
0.2% (v/v) Nonidet P-40; and the fourth (bottom) layer, 40% 
sucrose. After centrifugation at 4°C for 30 minutes at 
2000 rpm in a Beckman TJ-6 centrifuge, the supernatant 
(gradient solutions) was carefully decanted, and the tube 
left upside down to drain. 
each tube was resuspended 
50 mM Tris-HCl (pH 8), 
The immunoprecipitate pellet in 
in 200 µl of a buffer containing 
2 mM CaC1'2 , transferred to a 
microfuge tube and pelleted by centrifugation at 12000 rpm 
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(11000 g) for 20 seconds. This final immunoprecipitate was 
dissolved in 35 µl of a solution containing 75 mM Tris-HCl 
(pH 6.8), 4 M urea, 100 mM dithiothreitol, 10% (v/v) 
glycerol, 5% (v/v) ~-mercaptoethanol and 2.45% (w/v) SOS. 
Fig. 2.10 shows the different stages in the isolation of the 
LDL receptor by immunoprecipitation with IgG-C7, from the 
initial cell lysate to the final, washed, immunoprecipitate. 
The transferrin receptor was isolated simultaneously by 
including the monoclonal antibody, 83/25, in the preformed 
immune complex. The results show that although the immune-
precipitation causes an enrichment of the receptor band, the 
most important step in isolating the receptor from 
contaminating proteins is the washing of the immune-
precipitate by centrifugation through the stepwise sucrose 
gradient, containing different combinations of detergents 
and ionic strengths. A second immunoprecipitation carried 
out on the supernatant of the first showed that the first 
immunoprecipitation precipitated 80% of the 35s-labelled LDL 
receptors and transferrin receptors. It was previously 
shown by Casciola et al. (73) that the antibody would 
precipitate a constant proportion of the antigen (LDL 
receptor) over an appropriate range of antigen 
concentration. Their results showed a linear response of 
immunoprecipitated 35S-labelled LDL receptor band to LDL 
receptor content. 
2.2.7.4 Immunoprecipitation from culture medium 
In order to investigate the possibility of LDL receptor 
secretion from fibroblasts of FH subjects 3a and 3b (section 
4.2.4) immunoprecipitation was carried out on the culture 
medium after a long pulse period, as described by Lehrman et 
al. (36) or after a 2-hour pulse period, followed by a 4-
hour chase, similar to the protocols used by Miyake et~-
(83) and Kozarsky et~- (66) for the detection of secreted 
LDL receptors. For the immunoprecipitation following a 
long pulse period, cells were labelled with c35s]-methionine 
(50 µCi/ml) in 1.3 ml EMEM supplemented with 5 µM unlabelled 
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methionine for 18 hours at 37°C. The medium was then 
collected, centrifuged at 11000 g for 10 minutes to remove 
any cellular material and immunoprecipitation was then 
performed for 1 hour at 4°C on half the total volume (0.75 
ml) using 150 µl IgG-C7- and 83/25(anti-transferrin 
receptor)-containing immune complex suspension. The cells 
were washed and solubilized and immunoprecipitation 
performed as usual on 320 µl cell lysate using 80µ1 immune 
complex suspension. The second protocol for immune-
precipitation from the medium was as follows: cells were 
pulse-labelled in methionine-free EMEM with [ 35s]-methionine 
(80 µCi/ml) for 2 hours at 37°C, and then chased in 2 ml 
medium containing 200 µM unlabelled methionine for 4 hours 
at 37°C. The medium was then removed and the cells were 
washed and solubilized and centrifugation performed on the 
cell lysate to remove insoluble material (see section 
2 • 2 • 7 • 2 ) • The medium was similarly centrifuged at 11000 g 
for 10 minutes, to remove any cellular material, and then a 
1.8 ml aliquot was immunoprecipitated with 140 µl of immune 
complex suspension, containing either monoclonal IgG-C7 or 
polyclonal 489-1. The cell lysates were simultaneously 
subjected to immunoprecipitation with 80 µl of either immune 
complex. All immunoprecipitates were washed and subjected 
to SDS-polyacrylamide gel electrophoresis and fluorography 
as described below (section 2.2.7.5). 
2.2.7.5 SDS-polyacrylamide gel electrophoresis and 
fluorography 
SOS-PAGE was performed according to La~mmli (108), using a 
resolving gel containing 5-20% 10-20%, 5-12% or 7% 
acrylamide (as indicated in the figure legends) and 0.1% 
SOS, with a 5% acrylamide stacking gel. Samples were 
heated to 90°C for 3 minutes and then applied to the gel. 
Electrophoresis was performed at 30-35 mA per slab gel 
(Hoefer Scientific Instruments DC or Pharmacia Fine 
Chemicals Electrophoresis power supply, run at constant 
current). The mobilities of molecular weight standards 
(myosin (200 kDa), phosphorylase b (94kDa), bovine serum 
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albumin (67 kDa), ovalbumin (43 kDa)), separated on the same 
gel, were used to calculate apparent molecular weights of 
labelled receptor bands. After electrophoresis, gels were 
stained for 30 minutes in 40% methanol, 20% acetic acid, 
0.1% (w/v) Coomassie Brilliant Blue R250, and then destained 
in 10% methanol, 10% acetic acid. Destained gels were 
first soaked for 30 minutes in water, followed by 30 minutes 
at room temperature in the water-soluble fluor, sodium 
salicylate (1 M), as described by Chamberlain (114). The 
gel was then dried under vacuum for 2 hours at 60°C and 30 
minutes at room temperature (Hoefer Dual Temperature Slab 
Gel Dryer), and then exposed to X-ray film (Kodak XAR-5 X-
OMat) at -70°C for 16 hours to 5 days, depending on the 
amount of radioactivity in the receptor bands. After 
exposure, films were warmed to room temperature and 
developed in an automated processor. 
For quantitative determinations, the enhanced, dried gel was 
exposed to the X-ray film for a sufficient period at -70°C 
to allow the emission from low intensity bands to reach a 
level that was within the linear response of the X-ray film, 
i.e. such that the darkening of the film was proportional to 
the amount of radioactivity. . The amount of 35s-
radioactivity in the receptor bands on the fluorograms was 
quantified by densitometric scanning using either a Beckman 
DU-8 spectrophotometer 
Cliniscan densitometer 
(with a Slab Gel program) or a 
(Helena Laboratories, Texas). The 
response of the film was shown to be linear at band 
intensities between 1.5 and 8 arbitrary integration units 
(Beckman DU-8 spectrophotometer, gel scanning slit 0.1x4 mm) 
Although the integration values are proportional to the 
amount of 35s-radioactivity in receptor bands within an 
experiment, they are referred to as "arbitrary" because they 
cannot be considered as absolute values which can be 
compared directly between experiments. The number of 
integration "units" in a band, representing 35s-labelled 
receptors immunoprecipitated from one Petri dish of cells, 
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will depend on the amount of c35sJ-methionine in the 
original pulse-labelling period, the length of the pulse, 
the number of cells per dish and their level of metabolic 
activity, and finally on the time and conditions of exposure 
of the dried gel to X-ray film. Although these parameters 
vary between experiments and cell lines, they are constant 
within an experiment for a particular cell line and in this 
case the integration values for receptor bands can be 
directly compared. 
2.2.7.6 Specificity of LDL receptor immunoprecipitation by 
IgG-C7 
When normal fibroblasts were pulse-labelled with [~ 5S]-
methionine for 30 minutes at 37°C, and the label then chased 
by incubation for 30 minutes at 37°C in complete DMEM/LPDS 
(containing 200 µM unlabelled methionine), two major 35s-
labelled bands were immunoprecipitated by the IgG-C7-
containing immune complex (Fig. 2.1A)~ These bands had 
apparent molecular weights of approximat~ly 120 kDa and 160 
kDa, as reported by Tolleshaug et al. (20) for the precursor 
·and mature forms of the LDL receptor, respectively. These 
two bands were undetectable in immunoprecipitates from cells 
which had been incubated for 16 hours in lipoprotein-
deficient medium containing 1 µg/ml 25-hydroxycholesterol, 
in order to suppress LDL receptor synthesis (7-9), thus 
confirming their identity as LDL receptor bands. Immune 
complex containing a rabbit polyclonal antibody to the LDL 
receptor precipitateq the same precursor and mature bands as 
IgG-C7 (Figure 2.1B), whereas non-immune rabbit IgG did not 
show any precipitation of these two bands, indicating that 
they are specifically LDL receptor bands. Cells from 
homozygous FH subject, TT (discussed in detail in section 
3.2.2) express receptors which are able to bind LDL, but do 
not recognize IgG-C7. Thus, no receptor bands were 
immunoprecipitated by IgG-C7 from TT cells (Fig. 2.1B), 
whereas the polyclonal antibody was able to recognize and 
immunoprecipitate precursor and mature LDL receptor bands~ 
In the experiment shown in Figure 2.1c, normal cells and TT 




Figure 2.1 Specificity of LDL receptor immunoprecipitation 
by IgG-C7 
Fibroblasts from a 'normal subject or FH homozygote TT were 
incubated for 16 hours in lipoprotein deficient-medium to 
induce LDL receptor synthesis, or down regulated in 
lipoprotein-deficient medium containing 1 µg/ml 25-hydroxy-
cholesterol (A, lanes 3 and 4). The cells were then pulse-
labelled with c35S]-methionine (A - 60 µCi/ml, B - Normal 
120 µCi/ml, TT - 60 µCi/ml, C - 70 µCi/ml,D - 30 µCi/ml) in 
methionine-free EMEM for 30 minutes (D - 2 hours) at 37°C, 
followed by a 30 minute chase (D 10 hour chase) in 
DMEM/LPDS containing 200 µM unlabelled methionine. The 
cells were then washed and solubilized, and 35S-labelled 
receptors immunoprecipitated with preformed immune complexes 
containing either IgG-C7, plus (C and D) or minus B3/25 
anti-transfer~in receptor antibody (A; B - lanes 2 & 5), or 
polyclonal anti-LDL receptor IgG 698-7 (B - lanes 3 & 4) or 
non-immune rabbit IgG (B lanes 1 + 6 ). The 
immunoprecipitates were washed and subjected to SOS-
polyacrylamide gel electrophoresis (5 - 20% acrylamide) and 
fluorography. The positions of the 160 kDa (mature), 120 
kDa (precursor) LDL receptors, and of the 90 kDa transferrin 
receptor, are indicated. The band above the 160 kDa band 
·is a. non-~pecific contaminant. Various stages in the 
isolation of 35S-labelled LDL receptors by immuno-
precipitation with IgG-C7 (and transferrin receptor 
immunoprecipitation by B3/25) are shown in D. Samples: 35 s-
labelled cell lysate after centrifugation to remove cell 
debris (lane 1), immunoprecipitate before (lane 2) and after 
(lane 3) the sucrose gradient wash, and a second immuno-
precipitate from the supernatant of the first (lane 4). 
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cells were subjected to immunoprecipitation with an immune 
complex containing both IgG-C7 and 83/25, the monoclonal 
antibody to the transferrin receptor. In normal cells, 
three bands were precipitated, the 90 kDa transferrin 
receptor, the 120 kDa LDL receptor precursor and 160 kDa 
mature form. However, in TT cells, only the 90 kDa 
transferrin receptor was immunoprecipitated because the LDL 
receptors in these cells have a mutation in the epitope for 
IgG-C7 (see section 3.2.2). 
Further evidence that the 35s-labelled bands precipitated by 
IgG-C7 represented LDL receptors is shown in Figure 3.1A, 
p. 87. When normal fibroblasts were pulse-labelled for 1 
hour with [3 5sJ-methionine, IgG-C7 immunoprecipitated two 
bands corresponding to the molecular weights of the 
precursor and mature forms of the LDL receptor. When the 
cells were then incubated in DMEM/LPDS containing 200 µM 
unlabelled methionine, the 35S-label was chased from the 120 
kDa band into the 160 kDa position, as .conversion of 
precursor to mature receptors occurred. Within 15 minutes, 
50% conversion to the mature form had taken place, and 
processing was complete within 60 minutes. 
course of processing corresponds to that 
This time 
originally 
described by Tolleshaug et al. (20) for the normal LDL 
receptor. 
2.2.8 Data analysis using the computer prog~am "Enzfitter" 
Data for the concentration dependence of binding and 
degradation of 125!-labelled ligands or antibody, or for LDL 
receptor half-life determinations from loss of 35S-label in 
fluorographic bands, were analyzed by non-linear regression, 
using the computer program "Enzfitter" (Elsevier/BIOSOFT, 
Cambridge, U.K.). The advantage of non-linear regression 
is that it allows data to be fitted to the original non-
linear form ·of the equation, avoiding transformation to the 
linear form which leads to an unequal error distribution 
throughout the data and therefore inaccuiate estimation of 
parameters from the data. Using non-linear regression, 
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"Enzfitter" calculates the best-fit curve to one of several 
different equations provided. As well as producing best-
fit values, the program also estimates the standard error of 
each of the parameters, thus showing how accurate their 
estimations are. 
For half-life determinations, the rate of degradation (k) 
was calculated by fitting the data to a single exponential 
decay equation and the t~ was calculated from the 
relationship, t~ = 0.693/k. Ligand and antibody binding 
and degradation data were fitted assuming binding to a 
sin~le class of high-affinity sites, plus non-specific 
binding in the case of total binding data. In all the 
analyses, "simple" weighting of the data was used, assuming 
a constant error for all data points, together with the 
option of "robust" weighting to apply negligible weight to 
data points in extreme error, so that such points did not 
disproportionately affect calculations of parameters. 
2.2.9 Pre-incubation of fibroblasts in the presence of 
ammonium chloride and LDL 
In some experiments, prior to surface receptor binding 
assays or immunoprecipitation of 35s-labelled LDL receptors, 
fibroblasts were pre-incubated in the presence of 10 mM 
ammonium chloride and 40 µg/ml LOL. In normal cells, this 
treatment led to a rapid decline in surface receptor 
activity, as measured by 125 I-LDL binding (see Figure 2.2A). 
A 70% decrease was observed within one hour of incubation 
with LDL and ammonium chloride (Casciola, L.A.F. et al., 
manuscript in preparation). The loss in surface receptor 
activity was LDL-dependent, and therefore believed to be due 
to intracellular trapping of receptor through inhibition by 
the ammonium chloride of acid-dependent ligand dissociation 
in the endosome. Casciola et.!.!.• showed that the trapped 
receptors were degraded with a half-life of approximately 2 
hours (see figure 2.28). To assess the effects of this 
treatment on mutant LDL receptors, fibroblasts from normal 
and FH subjects were pre-incubated with 40 µg/ml LDL for 30 
7 1 
minutes at 37°C, followed by a one-hour incubation at the 
same temperature in the presence of both 40 µg/ml LDL and 
lOmM ammonium chloride. After releasing bound unlabelled 
LDL by incubation with 0.3% (w/v) heparin in phosphate-
buffered saline for 40 minutes at 4°C, surface receptor 
activity was determined from 125 r-LDL or -IgG-C7 binding at 
4°C (section 2.2.5). Alternatively, 35s-labelled cells from 
normal and FH subjects were pre-incubated for 3- and 6-hour 
periods in the presence of LDL and ammonium chloride, 
followed by immunoprecipitation of cellular LDL receptors 
(section 2.2.7.3). 
2.2.10 Determination of [ 35s]-methionine incorporation into 
total trichloroacetic acid-precipitable protein 
The amount of 35s-radioactivity incorporated into total 
trichloroacetic acid-precipitable cell protein during a 
pulse-labelling period (as a measure of total protein 
synthesis) was determined by a filter-disc method (115) as 
modified by Bester (116). A small aliquot of the 35s-
labelled cell lysate (after 10 minutes centrifugation at 
11000 g) was diluted with water (1/10) and then applied to a 
Whatman GF/C filter. The filter was subsequently 
consecutively immersed in 10% trichloroacetic acid (TCA) at 
4°C for 30 minutes, 5% TCA for 15 minutes at room 
temperature, 5% TCA at 90°C for 







temperature for 5 minutes, ethanol:diethyl ether (1:1) for 5 
minutes, and finally, diethyl ether for 5 minutes. The 
3 5s-labelled trichloroacetic acid-precipitable protein was 
then measured by scintillation counting (Beckman Ready-
Solv™ EP scintillation cocktail) of the filter disc in a 
Packard TriCarb 4690 scintillation counter. 
2.2.11 Pronase treatment of fibroblast monolayers 
Pronase digestion of intact cells was carried out as a means 
of differentiating surface LDL receptors, which are 
accessible to a short Pronase digestion, from intracellular, 
Pronase-resistant receptors. Cells were pulse-labelled 
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Figure 2.2 Effect of incubation of fibroblasts with 
ammonium chloride and LDL in 125 I-LDL surface 
binding activity (A) and on IgG-C7-immuno-
precipitable 35S-labelled LDL receptors (B) 
A. Upregulated normal fibroblasts were preincubated for 30 
minutes at 37°C with 40 µg/ml LDL, followed by incubation 
with 40 µg/ml LDL plus 10 mM ammonium chloride for the 
indicated times at 37°C. At each time point, release of 
bound, unlabelled LDL by incubation at 4°C for 40 minutes 
with 0.3% (w/v) heparin, surface receptor activity was 
determined from the level of 125 r-LDL (7 µg/ml, 559 cpm/ng) 
binding at 4°C. 
B. Normal fibroblasts were pulse-labelled with [ 35s]-
methionine (25 µCi/ml) for 15 hours at 37°C, and then chased 
for 2 hours at 
containing 10 mM 
40 µg/ml LDL and 
times at 37°C. 
receptors were 
37°c. The medium was then changed to one 
NH 4Cl in the presence (. ) or absence -(o) of 
the cells were those for the indicated 
At each time point, 35S-labelled LDL 
immunoprecipitated, subjected to SDS-
polyacrylamide gel electrophoresis and fluorography, and 
quantitated spectrophotometrically after NaOH extraction of 
the fluorographic bands (127). 
a. 
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with [ 35SJ-methionine, and chased for a period (indicated in 
figure legends) long enough to allow significant conversion 
of the precursor to the mature form of the LDL receptor 
which presumably reaches the cell-surface. The chase 
medium was removed and the cells were washed and incubated 
at 37°C for 20 minutes in 1.3 ml of buffer containing 10 mM 
HEPES (pH 7.4), 150 mM NaCl and 2 mM CaC1 2 in the presence 
or absence of 20 µg/ml Pronase (19). The incubation was 
stopped by chilling the cells to 4°C and adding 1 ml of ice-
cold PBS containing 25% (v/v) LPDS, 25 mM EDTA and 2 mM 
phenylmethylsulphonyl fluoride (19). The cells were 
scraped from the dish and washed twice with PBS by 
centrifugation to remove any traces of Pronase, followed by 
lysis in buffer containing 1% (v/v) Triton X-100. LDL 
receptors were then immunoprecipitated from the cell 
lysates, washed and subjected to SDS-polyacrylamide gel 
electrophoresis and fluorography as described previously 
(section 2.2.7). 
2.2.12 Analysis. of LDL receptor glycosylation and the 
effects thereof on receptor activity 
Although the function(s) of protein glycosylation has not 
been clearly elucidated (see section 5.3.4, p.207 for 
discussion), various glycosylation inhibitors and glycos-
idase enzymes are available as tools for the study of 
glycosylation and its role in protein function and/or 
structure. Some of these agents were used as described 
below to study glycosylation of the LDL receptor in normal 
and FH cells. 
2.2.12.1 Neuraminidase and 0-glycanase treatment of intact 
cells 
Neuraminidase (sialidase) removes terminal sialic acid 
residues from N-linked and 0-linked oligosaccharides (117). 
Endo-a-N-acetylgalactosaminidase (0-glycanase) liberates the 
disaccharide, Gal(~l-'>3)GalNAc from 0-linked oligosacchar-
ides bound to serine or threonine (118), provided the 
disaccharide is not substituted by other sugars (~·~· sialic 
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acid, fucose or N-acetylglucosamine). Susceptibility of 
the oligosaccharide residues on a protein to neuraminidase 
treatment can be used as an indication that the ·protein is 
exposed at the cell surface. 
Cells were pulse-labelled with [ 35s]-methionine and chased 
for 1 hour at 37°C. The cells were then washed and . 
incubated for 30 minutes at 37°C in 1.3 ml of buffer (50 mM 
sodium acetate (pH 6), 100 mM NaCl, 2 mM CaC1 2 ) in the 
absence or presence of neuraminidase (Calbiochem-Behring, 
0.05 units/ml). The cells were then chilled, washed and 
solubilized as usual. LDL receptors were immunoprecipitated 
from the cell lysates and subjected to SDS-polyacrylamide 
gel electrophoresis and fluorography. 
To examine the role of sialic acid residues and 0-linked 
oligosaccharides in LDL receptor function, upregulate~ 
fibroblasts were washed once with PBS and then incubated for 
40 minutes at 37°C in 1.3 ml of the buffer described above 
containing (i) no additions, (ii) 0.1 units of neuraminidase 
(SLgma), (iii) 0.1 units of neuraminidase for 20 minutes, 
followed by the addition of 2.5 milliunits of 0-glycanase 
for the last 20 minutes. The medium was removed and the 
cells were incubated for 1 hour at 37°C in lipoprotein-
deficient medium to allow restoration of normal fibroblast 
morphology to cells which had "rounded-up" during incubation 
under acidic conditions. The cells were then chilled to 
4°C and 12 5I-LDL and 125 I-IgG-C7 surface binding activity 
determined. 
2.2.12.2 Neuraminidase and 0-glycanase treatment of immuno-
precipitated LDL receptors 
35S-labelled, immunoprecipitated LDL receptors from normal 
and FH cells were resuspended in 50 µl of buffer containing 
20 mM sodium citrate, 20 mM Tris-maleate (pH 6) and 
incubated for 18 hours at room temperature, in the absence 
or presence of 50 milliunits of neuraminidase (33). Some 
of the neuraminidase-treated samples were then treated with 
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4 milliunits of Endo-Q-N-acetylgalactosaminidase (0-
glycanase) for 24 hours at room temperature. After 0-
glycanase and/or neuraminidase treatment, SO µl of buffer 
containing 20% glycerol, 125 mM Tris-HCl (pH 6.8), 4.6% SOS 
and 0.2 M dithiothreitol were added to each sample, followed 
by heating to 90°C for 3 minutes, SDS-polyacrylamide gel 
electrophoresis (5-12% acrylamide) and fluorography. 
2.2.12.3 Tunicamycin treatment of fibroblast cultures 
Tunicamycin inhibits the first step in the synthesis of the 
lipid-linked oligosaccharide donor for N-linked glycosyl-
ation (119). To determine the effect of N-linked glycosyl-
ation on surface LDL receptor activity, fibroblasts were 
incubated at 37°C for 24 hours in lipoprotein-deficient 
medium, in the absence or presence of 1 µg/ml tunicamycin. 
Under these conditions, Chatterjee et al. (67) showed that 
glycoprotein synthesis (as measured by [ 3HJ-glucosamine 
incorporation into t~ichloroacetic acid-precipitable 
protein) was inhibited by approximately 50%, while minimal 
inhibition of protein and nucleic acid synthesis ([ 3H]-
leucine and [ 3H]-thymidine incorporation, respectively) was 
observed. 
The effect of tunicamycin on the biosynthesis and processing 
of LDL receptors in normal and FH cells was determined by 
incubation for 24 hours in lipoprotein-deficient medium, 
followed by 3 hours in the absence or presence of 10 µg/ml 
tunicamycin. A dose-response study showed that, for the 
particular batch of tunicamycin used, this concentration was 
required for complete inhibition of N-linked LDL receptor 
glycosylation (Figure 2.3) within the 3-hour pre-incubation 
period. This treatment caused 60% inhibition of receptor 
synthesis as measured by incorporation of c35s]-methionine 
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Figure 2.3 Concentration-dependence of inhibition of N-
linked glycosylation of the LDL receptor by 
tunicamycin. 
After induction of LDL receptor synthesis by pre-incubation 
in lipoprotein-deficient medium for 24 hours, normal 
fibroblasts were pre-incubated for 3 hours in the presence 
of tunicamycin at the indicated concentrations, after which 
the cells were pre-incubated for 30 minutes, and then pulse-
labelled with [ 35 sJ-methionine (30 µCi/ml) for 2 hours, at 
37°C in methionine-free medium containing the same 
concentration of tunicamycin as in the pre-incubation. 
35s-labelled LDL receptors were immunoprecipitated and 
subjected to SDS-polyacrylamide gel electrophoresis (5-12% 
acrylamide) and fluorography. 
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2.2.12.4 Endoglycosidase H treatment of immunoprecipitated 
LDL receptors 
Endo-~-N-acetylglucosaminidase H (Endoglycosidase H) removes 
"high mannose" N-linked oligosaccharides from asparagine 
residues ( 120). LDL receptors from normal and FH 
[35s]-methionine and fibroblasts were labelled with 
immunoprecipitated with IgG-C7. The immunoprecipitates were 
resuspended in 50 µl of buffer containing 30 mM sodium 
citrate (pH 5.5), 0.75% SOS, 1 mM phenylmethylsulphonyl 
fluoride and 1 mM dithiothreitol, and incubated for 18 hours 
at room temperature in the absence or presence of 10 
milliunits of Endoglycosidase H (88). After the incubation, 
50 µl of buffer containing 20% glycerol, 125 mM Tris-HCl (pH 
6.8), 4.6% SOS and 0.2 M dithiothreitol were added to each 
sample. The samples were then heated to 90°C·for 3 minutes 
and subjected to SDS-polyacrylamide gel electrophoresis (5-
12% acrylamide) and fluorography. 
2.2.13 Immunoblotting of solubilized LDL receptors 
Immunoblotting was performed, with some modifications, 
according to the method of Van Oriel et -21• (40). 
Fibroblasts were seeded at approximately 1 x 106 cells per 
145 mm diameter Petri dish in medium containing 10% heat-
inactivated foetal calf serum (Day 0). On day 2 of cell 
growth, medium was changed to lipoprotein-deficient medium 
in the absence (upregulation) or presence (downregulation) 
of 2 µg/ml 25-hydroxycholesterol, and the cells were 
incubated in this medium for 48 hours. Upregulation medium 
was changed after 24 hours. The fibroblast monolayers were 
then washed twice at 4°C with buffer containing 10 mM HEPES 
(pH 7.4), 150 mM NaCl and 2 mM CaC1 2 , and then scraped from 
the dishes in the same buffer, supplemented with 1 mM 
phenylmethylsulphonyl fluoride (PMSF) and 0.5 mM leupeptin. 
The cells were collected by centrifugation and solubilized 
in 200 µl of buffer containing 10 mM HEPES (pH 7.4), 200 mM 
NaCl, 2 mM CaC1 2 , 2.5 mM MgC1 2 , 1 mM PMSF, 0.1 mM leupeptin 
and 1% (v/v) Triton X-100. Insoluble material was removed 
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by centrifugation at 4°C for 10 minutes at 11000 g. The 
samples were then adjusted to final concentrations of 4 M 
urea, 10% glycerol and i% SOS and subjected to SOS-
polyacrylamide gel electrophoresis (7% acrylamide) in the 
absence of reducing agents. Proteins and molecular weight 
standards were transferred electrophoretically to Hybond-C 
nitrocellulose membranes (Amersham) at 100 mA for 16 hours 
a buffer containing 20 mM Tris base, 150 mM 
glycine and 20% (v/v) methanol. The lane containing 
molecular weight standards was cut off and stained with 
Amide Black (0.1% (w/v) in 45% methanol, 10% acetic acid) 
while the rest of the membrane was incubated as follows: 1 
hour at room temperature in Buffer D (50 mM Tris-HCl (pH 8), 
80 mM NaCl, 2 mM CaCl 2 , 0.05% (v/v) Tween 20) plus 3% bovine 
serum albumin 
membrane); 
(to block non-specific binding sites on the 
1 hour in buffer D plus 5 µg/ml IgG-C7; three 
10-minute washes in buffer D; 1 hour at room temperature in 
buffer D containing 125!-labelled goat anti-mouse IgG (1700 
cpm/ng, 3 x 106 cpm/ml), prepared as described in section 
2 • 1 • 8 • After three 15-minute washes in buffer D, the 
membrane was dried and subjected to autoradiography for 3 
days at -70°C with intensifying screens. 
2.2.14 Preparation of DNA for haplotype analysis 
2.2.14.1 DNA isolation from blood 
DNA was isolated from blood samples by a modification of the 
method of Kunkel (121). Blood (20 ml) from patients was 
collected in tubes containing heparin. Cell disruption was 
achieved by homogenization at 4°C in a glass vessel with a 
Teflon pestle in 60 ml lysis buffer (0.32 M sucrose, 1% 
(v/v) Triton X-100, 5 mM MgC1 2 , 10 mM Tris-HCl (pH 7.6)). 
The nuclear pellets were sedimented by centrifugation for 20 
minutes at 4°C at 2500 g (JAlO rotor, 4800 rpm) in 40 ml 
plastic tubes, and then resuspended in 4 ml 75 mM NaCl, 25mM 
EDTA (pH 8) and 1% SOS. (In some cases, samples were frozen 
at -70°C at this stage, and the DNA isolation continued at a 
later stage). After vortexing, proteinase K was added to a 
final concentration of 0.1 mg/ml, and samples were incubated 
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overnight at 50°C. The samples were then transferred to 
Corex tubes and 0.5 ml 5 M sodium perchlorate and 4 ml TE-
(10 mM Tris-HCl, 1 mM EDTA, pH 8)-saturated phenol were 
added. The mixture was shaken gently until homogeneous and 
then the phases were separated by centrifugation at 10000 g 
for 10 minutes at 10°C. The aqueous phase was removed and 
extracted with an equal volume of chloroform:isoamylalcohol 
(24:1) followed by centrifugation at 10000 g for 10 minutes 
at 10°c. DNA was precipitated from the aqueous phase by 
the addition of 10 volumes of ice-cold 96% ethanol. The 
DNA was sedimented by brief centrifugation in a microfuge 
and washed twice with ice-cold 70% ethanol. Traces of 
ethanol were removed under vacuum and the final pellet was 
dissolved at 4°C in 600 µl TE. The DNA solution was re-
extracted twice with an equal volume of TE-saturated phenol, 
and once with chloroform:isoamylalcohol (24:1). DNA was 
precipitated by the addition of a one-tenth volume of 3M 
sodium acetate (pH 5.5) and 2.5 volumes of ice-cold 96% 
ethanol. The DNA was washed twice with ice-cold 70% 
ethanol, dried under vacuum and dissolved at 4°C in approxi-
mately 0.6 ml TE. 
2.2.14.2 DNA isolation from cultured cells 
DNA was isolated from cultured human skin fibroblasts (ten 
75 cm 2 flasks) or from Epstein-Barr virus-transformed 
lymphoblastoid cells (103)(100 x 10 6 to 200 x 10 6 cells) by a 
modification of the method described by Davis et al. (122). 
Cells were harvested by trypsinization and washed with 
phosphate-buffered saline (PBS) by centrifugation. (In some 
cases, the cells were resuspended in 1 ml PBS and stored 
frozen at -70°C until later use). The cell pellet (after 
removal of PBS) was resuspended in 1% SOS, 1 mM EDTA, lxSSC 
(0.15 M sodium chloride, 0.015 M sodium citrate, pH 7) 
(approximately 1 ml per 150 cm 2 flask of cells or per two 75 
cm2 flasks of cells) and proteinase K was added to a final 
concentration of 0.1 mg/ml. The samples were incubated at 
50°C overnight or longer if the DNA was not yet in solution. 
The DNA solution was then extracted with an equal volume of 
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TE-saturated phenol, while shaking, for 1 hour. DNA was 
then precipitated by the addition of a one-tenth volume of 
3M sodium acetate (pH 5.5) and ten volumes of ice-cold 96% 
ethanol. The DNA was sedimented by brief centrifugation in 
a microfuge and washed twice with ice-cold 70% ethanol. 
Traces of ethanol were removed under vacuum and the DNA was 
dissolved overnight or longer in TE (approximately 0.1 ml 
per 75 cm 2 flask) at 4°C. The DNA solution was re-
extracted, re-precipitated and washed as described above for 
the DNA preparation from blood, and dissolved at 4°C in 
approximately 0.1 ml TE per 75 cm 2 flask of cells. 
The concentration of DNA in samples isolated from blood or 
from cultured cells was determined by the optical density 
measured at 260 nm, and the level of protein contamination 
by the ratio of the absorbances at 260 nm and 280 nm. The 
A26o/A 280 ratio for all samples was between 1.8 and 2.0. 
The DNA samples were subjected to electrophoresis in 1% 
agarose gels, after incubation in the absence or presence of 
EcoRI (Boehringer Mannheim) for 2 hours at 37°C, to ensure 
that the DNA was intact, essentially free of RNA and 
sufficiently free of protein and salts to be digested by 
restriction enzymes. 
2.2.14.3 Haplotype analysis 
Haplotype analysis of DNA from the various FH subjects was 
performed by H.E. Henderson (manuscript in preparation) or 
by E. Leitersdorf, J.L. Goldstein, M.S. Brown and H.H. Hobbs 
(manuscript in preparation). DNA samples were digested 
with each of the restriction enzymes known to result in 
polymorphic patterns (47,55-57) and analyzed by Southern 
blotting with the appropriate probes. 
Haplotype analysi~ of homozygous FH subjects from the Cape 
region (those described in ref. 98 plus RI and TD) was 
carri•d out by Henderson (manuscript in preparation), using 
10 different polymorphic restriction sites in the LDL 
receptor gene (Taq I (57), Stu I (49), Bst EII (55), Ava II 
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(50), Apa LI (5' and 3' sites) (52), Pvu II (42,51), Nee I 
(53), Msp I (56), Pst I (54) 
The assignment of haplotypes in the large group of Afrikaner 
FH homozygotes from the Transvaal region (103) was done by 
Leitersdorf, Hobbs et al. (manuscript in preparation). In 
addition to Stu I, Ava II, Apa LI (5' and 3' sites), Pvu II, 
Nee I and Pst.I (also used by Henderson), Leitersdorf, Hobbs 
et al. made use of DNA polymorphisms for the enzymes Bsm i, 
Sph I and Spe I (47) in the haplotype determinations. 
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The condition of homozygous familial hypercholesterolaemia 
(FH) was originally clinically defined by severe elevation 
of plasma cholesterol, xanthomata and coronary heart disease 
in childhood (74). It was later established that FH is 
caused by mutations in the gene for the low-density 
lipoprotein (LDL) receptor (74). On the basis of LDL-
binding studies in cultured cells, three types of defects 
were defined by Goldstein and Brown: receptor-negative, 
receptor-defective and receptor internalisation-defective 
(75). The LDL receptor was later purified to homogeneity 
(17) and the monoclonal anti-LDL receptor antibody, IgG-C7 
was produced (18). Using this antibody as a probe, at 
least four classes of LDL receptor mutations were 
distinguished (19,20), including defects in synthesis, 
intracellular transport, LDL binding and internalisation of 
the LDL receptor (3). More recently, the isolation of 
complementary DNA (cDNA) clones corresponding to the LDL 
receptor messenger RNA (21) and gene (22) has facilitated 
genetic haplotype assignments, by analysis of polymorphic 
restriction sites in LDL receptor genes (47), and 
elucidation of the molecular defects underlying the 
different classes of mutations (10). These studies have 
revealed the genetic heterogeneity of homozygous FH. 
FH is particularly prevalent in the South African Afrikaner 
population, presumably because of founder-gene effects 
(section 1.7.4). Previous studies of LDL receptor activity 
in 23 clinically homozygous Afrikaner patients (98,103) and 
two FH homozygotes from other South African ethnic groups 
(98) indicated a predominance of a receptor-defective type 
of mutation, while one pair of siblings were apparently 
receptor-negative (103). The wide range of receptor 
activity in the Afrikaner group suggested the presence of 
more than one type of mutant allele. Haplotype analysis of 
2 polymorphic restriction sites (59,104) suggested that FH 
homozygotes in all except one Afrikaner family shared a 
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common haplotype, thus supporting the idea of a founder gene 
mutation. 
studies in 
Preliminary LDL receptor immunoprecipitation 
3 Afrikaner subjects suggested defects in 
intracellular receptor transport (103). 
In the study reported in this chapter, the basis for the 
heterogeneity of receptor activity in South African FH 
homozygotes was investigated by studying receptor synthesis 
and processing, using [ 35s]-methionine pulse-chase studies 
and immunoprecipitation by the monoclonal anti-LDL receptor 
antibody, lgG-C7. The results are interpreted on the basis 
of haplotype assignments through analysis of 10 polymorphic 
restriction sites in the LDL receptor genes of the FH 
subjects. 
3.2 Results 
The results of [35s]-methionine pulse-chase experiments 
(section 2.2.7), assays of surface LDL receptor activity 
(section 2.2.5) and haplotype analysis (section 2.2.14.3) 
are summarized in Table 3.1, p. 86. 
3.2.1 Phenotypic expression of mutant LDL receptors in 
the Afrikaner population 
Post-translational processing of the LDL receptor was 
studied in 10 unrelated Afrikaner kindreds, including 11 
homozygous FH subjects. As shown in Figure 3.1A, the 
precursor form of the normal LDL re~eptor (apparent 
molecular weight 120 kDa) was rapidly and quantitatively 
processed (t~ approximately 15 minutes) to the 160 kDa 
mature form by the addition of carbohydrate residues, (see 
section 1.3). The newly-synthesized precursor in cells 
from all Afrikaner FH subjects studied had an apparentiy 
normal molecular weight (120 kDa), indicating that the 
mutation(s) caused no large deletions or insertions in the 
protein (see Fig. 3.1, B to F). However, the conversion of. 
precursor into mature 160 kDa receptor, which accompanies 
transport from the endoplasmic reticulum to the Golgi 
complex and maturation of core sugars (32) was retarded in 
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TABLE 3.1. LDL RECEPTOR GENE HAPLOTYPES, RECEPTOR ACTIVITY AND POST-TRANSLATIONAL PROCESSING IN SOUTH AFRICAN 
Ethnic 
Group 
' HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLAEMIA 

















Afrikaner JG I,'I 41% ,. ,. processing; defective 
LDL binding ' 
ES I/I 28% 
,r FH la 3/3 25% 12% 
FH7a 3/3 19% N.D. 
FH2a 3/16 18% N.D. 
FH2b 3/16 15% N.D. 
GM I/I 11% 
FH12b 3/3 11% N.D. 
FH12a 3/3 10% N.D. 
Fll6a 3/15 6% 77. 
,r FH3b 15/15 2% n.d. 
~Coloured" CF I/III 8% 
RI V/V 18% 
TD V/V 77. 
Xhosa TT IV/IV 30% (76) 30% 
N.D. not determined 
































































receptor not recognized 
by IgG-C7 
a - haplotypes were assigned by H.E. Henderson or E, Leitersdorf, H.H. Hobbs et al. as described in section 2.2.14.3. 
b - 125I-LDL degradation was determined from the noniodide trichloroacetic acid-soluble radioactivity in the medium 
after 4 hours at 37°C (98,103) 
c - t! for LDL receptor processing is the chase time required to reach an equal distribution of 35s-label between the 
precursor and mature LDL receptor bands, assuming no label in the mature receptor band at zero time. 
* see Figure 3.1 
+ Van der Westhuyzen and Coetzee, unpublished results 
t Van der Westhuyzen, D.R., Stein, M., Henderson, H.E., Coetzee, G.A., manuscrip~ in preparation. 
11 Homozygous siblings FH3a and FHlb described later in Chapters 4 and 5, respectively. 
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Figure 3.1 (legend overleaf) 
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Figure 3.1 Biosynthesis and processing of LDL receptors 
from normal cells and selected homozygous 
Afrikaner FH subjects 
Fibroblasts from normal (A) and homozygous FH subjects were 
pre-incubated for 16 hours in lipoprotein-deficient medium 
to induce LDL receptor synthesis. The cells were then 
pulse-labelled with [ 35s] methionine (50 µCi/ml) at 37°C,for 
1 hour (Normal and FH3b), 2 hours (FH1a, 6a and 12a) or 2.3 
hours (JG). The medium was then changed to DMEM/LPDS 
containing 200 µM unlabelled methionine and the cells were 
incubated at 37°C for various chase times. The cells were 
then washed and solubilized and 35S-labelled LDL receptors 
immunoprecipitated 
containing IgG-C7. 
with a preformed immune complex 
Immunoprecipitates were subjected to 
SDS-polyacrylamide gel electrophoresis (5-20% acrylamide) 
and fluorography. The positions of the 160 kDa (mature) 
and 120kDa (precursor) LDL receptors are indicated. The 
band above the 160 kDa band in some cases is a non-specific 
contaminant. 
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all cases, but to different degrees. Although all these 
mutations can thus be classified as Class 2 defects (3), the 
severity of the delay in transport and maturation of the 
receptor varied considerably, ranging from a half-time for 
processing (defined in footnotes to Table 3.1) of 1.5 hours 
to 6 hours, compared to the normal time of less than 30 
minutes (see Table 3.1). 
All the Afrikaner FH homozygotes analyzed by Henderson were 
ho~ozygous for a haplotype designated "I" (see Table 3.1). 
By analysis of additional polymorphic sites, Leitersdorf, 
Hobbs et al. were able to sub-divide haplotype I into 
haplotypes "3" and lt15", ~nd detected an additional 
haplotype in kindred 2, designated "16". The heterogeneity 
in post-translational processing rates can thus be partly 
explained by the association 
alleles (haplotypes 3 and 




least two different 
and possibly another 
processing phenotype. 
However, variations in receptor transport rates and levels 
of activity were observed even between individuals 
homozygous for the same haplotype, suggesting that genetic 
factors other than the LDL receptor locus may influence 
phenotypic expression of the mutations. Selected examples 
of post-translational processing in FH subjects, defined 
previously as high receptor-defective (FHla, JG), low 
receptor-defective (FH6a, FH12a), and receptor-negative 
(FH3b), are shown in Figure 3.1 (B to F). 
Cells from FH3b synthesized significant amounts of LDL 
receptor precursor and mature forms and are thus not truly 
receptor-negative. The virtual lack of surface receptor 
activity in FH3b may be related to the loss of more than 
half the original incorporation df 35 S-label from the 
receptor bands during the 3 hour chase period, indicating 
accelerated receptor degradation. 
in detail in Chapter 4). · 
(This aspect is discussed 
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Although both haplotypes 3 and 15 are associated with slow 
processing phenotypes, haplotype 3 appears to represent the 
mutation giving rise to the most severe impairment of 
transport, but 
expression. 
significant levels of surface receptor 
In addition, the receptor protein associated 
with haplotype 3 may be defective in LDL binding, as shown 
by the higher proportion of surface antibody binding 
compared to LDL binding in FHla. On the other hand, 
haplotype 15 is associated with a mutant receptor molecule 
processed at a rate only slightly slower than normal, but 
rapidly degraded at some stage, resulting in virtually no 
surface receptor activity (as seen for FH3b). It is 
interesting to note that FH6a, a compound heterozygote of 
haplotypes 3 and 15, expressed surface receptor activity 
intermediate between homozygotes of the two haplotypes 
(Table 3.1), and showed a higher proportion of antibody 
versus LDL binding, and the severely retarded processing 
phenotype associated with haplotype 3~ 
3.2.2 Immunoprecipitation of LDL receptors from homozygous 
FH Xhosa patient, TT 
The LDL receptors in cells from a black (Xhosa) South 
African FH homozygote, TT, were able to bind LDL with high 
affinity, but not IgG-C7 (87, Fig. 2.1B, p. 86). Therefore, 
a polyclonal antibody, 698-7, to the bovine·LDL receptor, 
was used to immunoprecipitate the LDL receptor produced by 
TT and normal cells. In normal fibroblasts (Fig. 3.2), 
essentially the same result was obtained as for normal cells 
using monoclonal IgG-C7 (Fig. 3.1A). However, the rate of 
processing in TT cells of the 120 kDa precursor to the 
mature form was markedly delayed (Fig. 3.2). Even after a 
two-hour chase, approximately half of the receptor protein 
was still in the precursor form. 
Biosynthesis and processing of LDL receptors in cells from 
the heterozygous mother of TT were also analyzed using a 
sequential immunoprecipitation technique (Fig. 
, 
First, IgG-C7 was used to selectively precipitate the 
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Figure 3.2 Biosynthesis and processing of LDL receptors in 
fibroblasts from TT and a normal subject 
After 16 hours incubation in lipoprotein-deficient medium, 
cells were pulse-labelled for 30 minutes with [ 35 s]-
methionine (normal cells - 120 µCi/ml, cells from TT - 60 
µCi/ml) in methionine-free EMEM, followed by a chase for the 
indicated times in medium containing 200 µM unlabelled 
methionine. Cells were washed, solubilized and subjected 
to immunoprecipitation with polyclonal anti-LDL receptor 
antibody 698-7, after which SDS-polyacrylamide gel 
electrophoresis (5-20% acrylamide) of immunoprecipitates and 
fluorography were performed. The positions of the mature 
(160 kDa) and precursor (120 kDa) LDL receptor bands are 
indicated. 
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Figure 3.3 Biosynthesis and processing of LDL receptors in 
fibroblasts from FH homozygote, TT, his 
heterozygous mother and a normal subject 
After 16 hours incubation in lipoprotein-deficient medium, 
cells were pulse-labelled for 30 minutes with 
methionine (70 µCi/ml) in methionine-free EMEM, followed by 
a chase for 30 minutes in medium containing 200 µM 
unlabelled methionine. The cells were washed, solubilized 
and subjected to immunoprecipitation with an immune complex 
containing monoclonal anti-LDL receptor antibody, IgG-C7, 
antibody. and an anti-transferrin receptor monoclonal 
After collection of the immunoprecipitates, the supernatants 
were subjected to a second immunoprecipitation with an 
immune complex containing the polyclonal anti-LDL receptor 
antibody, 698-7. Precipitates from the first and second 
immunoprecipitations were analyzed by SDS-polyacrylamide gel 
electrophoresis (5-20% acrylamide) and fluorography. The 
positions of the mature (160 kDa) and precursor (120 kDa) 
LDL receptors, 
indicated. 
and the 90 kDa transferrin receptor are 
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receptor produced from the normal 
polyclonal antibody 698-7 was used 
receptors produced by the mutant allele. 
allele, and then, 
to precipitate the 
As a control, the 
transferrin receptor was simultaneously immunoprecipitated 
by including 83/25, an antibody to the transferrin receptor, 
in the IgG-C7 containing immune complex. In cells from a 
normal subject and from the mother of TT, the first 
immunoprecipitation yielded 120 kDa, 160 kDa and 90 kDa 
bands, corresponding to the precursor and mature LDL, and 
transferrin receptors, respectively. Only the 90 kDa 
transferrin receptor was immunoprecipitated from TT cells. 
When the polyclonal anti-LDL receptor antibody, 698-7, was 
used to subsequently immunoprecipitate receptor protein not 
recognized by IgG-C7, a large amount of the 120 kDa 
precursor LDL receptor protein was precipitated from TT and 
his mother's cells, but not from normal cells. Some mature 
160 kDa receptor was also seen in normal and TT's mother ' s 
cells, due to incomplete prior immunoprecipitation with 
IgG-C7. Only a very small amount of mature receptor was 
seen in TT cells, consistent with the slow processing of 
this mutant protein. This experiment showed that the 
presence of the abnormal protein produced by the mutant 
allele did not interfere with processing of the normal gene 
product in the heterozygous cells. 
Haplotype analysis by Henderson and by Leitersdorf, Hobbs et 
al. (see section 2.2.14.3) of the LDL receptor gene in the 
Xhosa patient, TT, showed homozygosity for a single, unique 
haplotype. Since the first cysteine-rich binding repeat in 
the LDL receptor, coded for by exon 2, contains the epitope 
for monoclonal antibody IgG-C7 (29), and since the receptor 
from TT cells did not recognize IgG-C7, exon 2 was predicted 
as the site of the mutation (87). Amplification of this 
exon by the polymerase chain reaction technique and 
subsequent sequence analysis revealed a deletion of 6 base 
pairs, resulting in removal of two amino acids, aspartic 
acid and glycine, from the first cysteine-rich repeat (87). 
This mutation is thus also responsible for the slow 
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maturation of the LDL receptor precursor observed in these 
cells (Fig. 3 • 2 ) • The small deletion in the receptor 
shortens the distance between two cysteine residues, and may 
thus interfere with correct disulphide bonding and protein 
folding ( 87), therefore causing slow transport of the 
protein from the endoplasmic reticulum to the Golgi 
apparatus (78-80). Abnormal conformation may also be 
responsible for loss of the epitope for IgG-C7 (87). 
3.2.3 Mutant LDL receptors in FH homozygotes from the so-
called "Coloured" population 
Phenotypic expression of LDL receptors from three 
clinically-defined FH homozygotes from the "Coloured" group 
in South Africa was studied. 
shown to express approximately 
Patient CF was previously 
10% of the normal level of 
LDL receptor activity at 37°C (98) and 4°C (unpublished 
results). Processing of the precursor receptor (120 kDa) 
to the mature form (160 kDa) in cells from subject CF was 
much slower than normal (Fig. 3.4). The half-time for 
conversion to the mature receptor was approximately 4 hours, 
compared to less than half an hour in normal cells (Fig. 
3.1A). The mature surface receptors in CF appeared to be 
defective in LDL binding, as indicated by the higher 
proportion of IgG-C7 versus LDL binding. Haplotype analysis 
by H.E. Henderson (manuscript in preparation) showed that CF 
was a compound heterozygote for haplotype I (also found in 
Afrikaner FH subjects) and another haplotype, "III". 
Although slow processing and defective binding appear to be 
associated with haplotype I, it is not clear what contri-
bution the gene product from the allele represented by 
haplotype III makes to the LDL receptor phenotype in CF. 
Subjects RI and TD appeared to be receptor-negative when LDL 
receptor activity was assessed 
37°C with 125 I-LDL (Van der 
by a 4-hour incubation 
Westhuyzen D.R., Stein 
at 
M., 
Henderson H.E., Coetzee G.A., manuscript in preparation), 
but showed approximately 20% of normal LDL receptor levels 
when assayed at 4°C (Table 3.1). After a 2-hour pulse-
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Figure 3.4 Biosynthesis and processing of LDL receptors in 
fibroblasts from subject, CF 
Fibroblasts from FH homozygous patient, CF, were incubated 
for 16 hours in lipoprotein-deficient medium and then pulse-
labelled with c35s]-methionine (50 µCi/ml) for 2.3 hours at 
37°C, followed by various chase periods in medium containing 
200 µM unlabelled methionine. 35 s-labelled LDL receptors 
were then immunoprecipitated and subjected to SOS-PAGE (5-
20% acrylamide) and fluorography. The positions of the 160 
kDa (mature) and 120 kDa (precursor) LDL receptors are 
indicated. The band above the 160 kDa receptor band at 
zero time is a non-specific contaminant. 
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Figure 3.5 Biosynthesis and processing of LDL receptors in 
normal fibroblasts and in cells from homozygous 
FH subject, RI 
Fibroblasts from a normal subject and FH homozygote, RI, 
were pre-incubated for 16 hours in lipoprotein-deficient 
medium and then pulse-labelled in methionine-free EMEM with 
[35s]-methionine (80 µCi/ml) for 2 hours at 37°C, followed 
by a chase period of 1 hour in DMEM/LPDS containing 200 µM 
unlabelled methionine. 35 S-labelled LDL receptors and 
transferrin receptors were immunoprecipitated and subjected 
to SDS-PAGE (5-20% acrylamide) and fluorography. The 
positions of the normal LDL receptor precursor (120 kDa) and 
mature (160 kDa) forms and transferrin (90 kDa) receptors 
are shown by solid lines. The position of the RI mature 
(145 kDa) LDL receptor is indicated by the dotted line. 
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labelling period, LDL- and transferrin receptors were 
immunoprecipitated from normal cells and RI cells. In the 
normal cells, mainly the 90 kDa transferrin receptor and 160 
kDa mature LDL receptor bands were seen, as well as a small 
amount of 120 kDa LDL receptor precursor (Fig. 3 • 5 ) • In 
contrast, in RI, although a normal 90 kDa transferrin 
receptor band was observed, the mature LDL receptor band had 
a significantly lower apparent molecular weight than normal 
(145 kDa). The correspondingly smaller precursor band (105 
kDa) was presumably of a similar molecular weight to the 
transferrin receptor and thus obscured. After the cells 
were chased for one hour at 37°C, only 160 kDa LDL receptor 
was seen in normal cells, and a smaller mature receptor in 
RI. The transferrin receptor band had the same molecular 
weight in both normal and RI cells. Similar results were 
obtained for TD cells (results not shown). The results 
suggest that the mutations in RI and TD cause similar 
deletions in the LDL receptor protein, but that post-
translational processing of the mutant receptors is not 
retarded. This has been confirmed by Southern blotting 
(123) and by further pulse-chase experiments (Van der 
Westhuyzen, D.R., Stein, M., Henderson, H.E., Coetzee, G.A., 
manuscript in preparation), which also showed that the 
abnormally-small mature receptor was rapidly degraded. In 
addition, the mature LDL receptors in RI and TD were 
defective in LDL binding (see Table 3.1). TD and RI, were 
both true homozygotes for haplotype V, which was shown, by 
more detailed mapping by Southern· blotting (123), to 
represent a 2.5 kb deletion in the LDL receptor gene. This 
deletion appears to result in the removal of exons 7 and 8, 
which code for the first two cysteine-rich repeats in the 
EGF precursor homologous domain, thus giving rise to the 




The biosynthesis and processing of mutant LDL receptors was 
studied in cultured fibroblasts from 15 clinically 
homozygous South African FH subjects, including 11 from the 
Afrikaner population. Previous cellular studies of these 
patients· showed heterogeneity of LDL receptor activities, 
ranging from essentially receptor-negative up to 40% of 
normal receptor activity (98,103). 
Subjects which have been designated FH homozygotes on the 
basis of clinical criteria and/or LDL receptor activity 
levels, may be true genetic homozygotes (j.~· possess two 
identical mutant alleles) or may be genetic compounds, 
having two different defective alleles. Compound hetero-
zygotes can be detected by immunoprecipitation of 35s-
labelled receptors when the proteins produced by the 
defective alleles have different molecular weights (19,20). 
However, compound heterozygosity cannot be detected when the 
two mutant proteins have the same molecular weight, or, if 
one allele is a "null" allele, producing no detectable 
protein (38). In such cases, the assignment of haplotypes, 
based on combinations of the presence or absence of a series 
of polymorphic restriction enzyme sites in the LDL receptor 
gene, can differentiate between true homozygotes and 
The conclusion that genetically compound heterozygotes. 
mutant genes with different haplotypes represent different 
mutations is based on previous studies showing that, in 
general, RFLP haplotypes of chromosomes antedate mutations 
in the genes (124-126). 
On the basis of 10 polymorphic restriction sites in the LDL 




different haplotypes (I,III,IV,V) in the 
subjects examined. All the Afrikaner FH 
ES, GM) were homozygous for the haplotype 
designated "I". The so-called "Coloured" patient, CF, was 
a compound heterozygote for 
haplotype, "III". The Xhosa 
haplotype I and another 
patient, TT, was homozygous 
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for a different haplotype, designated "IV". The other 
"Coloured" patients, TD and RI, were both true homozygotes 
for haplotype V. By analysis of the additional polymorphic 
sites for BsmI, SphI and SpeI, E. Leitersdorf, H.H. Hobbs et 
.e.l_. were able to further differentiate haplotype I 
(Henderson) into two haplotypes, designated "3" and "15". 
All the Afrikaner FH subjects analyzed (those reported in 
Table 3.1 and FH Sa, Sa, 9a, 10a, lla, 14a (103)), except 
those from kindred 2, were homozygous for either haplotype 3 
or 15, or were compound heterozygotes of these two 
haplotypes • The FH "homozygotes" in kindred 2 were 
compounds of haplotype 3 and an additional haplotype, "16". 
This haplotype has also been detected in a large Western 
Cape family of Afrikaner 6escent (Brink P.A., manuscript in 
preparation) and in an English-speaking subject and another 
Afrikaner from the Cape region (Henderson, haplotype "II", 
manuscript in preparation). On the basis of their 
phenotypes (surface LDL receptor activity and rate of post-
translational processing), it can be predicted that JG and 
ES are probably homozygous for haplotype 3 and that GM may 
either also be homozygous for this haplotype or may be a 
compound heterozygote of haplotypes 3 and 15. 
The only FH subjects which showed normal rates of receptor 
processing were RI and TD. They were also the only 
examples where abnormal receptor size was observed, as a 
result of deletion of exons 7 and 8, encoding cysteine-rich 
repeats A and Bin the EGF precursor homology domain of the 
receptor (Van der Westhuyzen manuscript in 
preparation). Defective LDL binding by the receptors in RI 
and TD is consistent with the finding of Esser et al. (28) 
that repeat A plays a permissive role in LDL binding. The 
rapid degradation of these mutant receptors is discussed 
further in section 4.3. A similar mutation has been 
detected in two Dutch FH subjects, FH 359 and 454 (11). In 
these subjects, a 4 kb deletion, also including exons 7 and 
8, similarly gives rise to a receptor protein lacking the 
first .two growth factor-like repeats. 
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All the other mutant alleles produced slowly-processed 
receptors of normal apparent molecular weight, probably 
point resulting from small deletions, insertions or 
mutations. This would be consistent with the findings for 
other mutant LDL receptors. The deletion of 4 amino acids 
from the third cysteine-rich binding repeat in the receptor 
from the WHHL rabbit (23) or the deletion of a single 
glycine residue from repeat 5 in FH563 (10,23), both 
resulted in delayed receptor transport, presumably as a 
result of abnormal 
disulphide bonding 
folding 
( 2 3) • 
(78-80) because of altered 
In contrast, loss of the entire 
sixth binding repeat in FH626 (89) or duplication of binding 
repeats 1 to 7, and growth-factor-like repeats A and B, ih 
FH295 (46) produced receptor proteins of abnormal size, 
which were transported at a normal rate, and thus apparently 
were able to achieve a normal conformation. These results 
support the idea that disulphide bonds form within each 
repeat (90), so that small deletions or insertions interfere 
with the correct bonding pattern, whereas deletions or 
insertions of whole repeats have no effect. The mutation 
in subject TT (87) is a case in point, since deletion of two 
amino acids from the first repeat impaired transport of the 
TT rec_eptor, 
deletion of 
whereas Van Oriel et al. (29) have shown that 
the entire first repeat by site-directed 
,. 
mutagenesis produced a receptor that was transported and 
processed at a normal rate. 
The fact that the LDL receptors in all the Afrikaner 
subjects studied showed slow post-translational processing 
supports the concept of a founder gene mutation. All the 
Afrikaner FH homozygotes analyzed by Henderson were 
homozygous for haplotype I. The "Coloured" subject, CF, 
was a genetic compound of a unique haplotype (II I ) and 
haplotype I, suggesting some Afrikaner ancestry. 
Leitersdorf, Hobbs et al. were able to show that haplotype I 
included two different haplotypes, 3 and 15, and that 
subjects from 12 different, unrelated Afrikaner families 
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were either homozygous for haplotype 3 or 15, or were 
genetic compounds of these two haplotypes. The high 
occurrence of these haplotypes in unrelated subjects 
strongly suggests that they may represent founder gene 
mutations in the Afrikaner population. Haplotype 16 has 
been found in 3 unrelated families and may represent a minor 
founder mutation. Founder gene mutations have also been 
identified in the French-Canadian (84), Lebanese (88) and 
possibly, the Finnish (91,92) populations. These founder 
mutations are readily detected by Southern blotting, 
allowing rapid and accurate diagnosis of FH in these 
populations. The high incidence of specific haplotypes 
associated with FH in the Afrikaner population suggests that 
similar diagnostic Southern blotting may be developed to 
detect FH mutations within this group. 
FHla and 3b have been shown to be respectively homozygous 
for 2 distinct LDL receptor gene haplotypes, 3 and 15. 
Each of these subjects has a sibling homozygous for the same 
haplotype. The LDL receptor mutations represented by 
haplotype 3 (FHla and lb) and haplotype 15 (FH3a and 3b) 
produce contrasting phenotypes in terms of levels of surface 
receptor activity and rates of receptor transport and 
processing (see Table 3.1). These sibling pairs thus 
afford a unique opportunity to study two contrasting LDL 
receptor mutations, probably representing founder mutations 
in the Afrikaner population, in true genetic homozygotes. 
Therefore, the phenotypic expression of the mutant LDL 
receptors in FH3a and 3b, and in FHla and lb, was 
characterized in detail, and the results are presented and 
discussed in Chapters 4 and 5, respectively. 
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4.1 Introduction 
Previous studies of LDL receptor activity in 23 homozygous 
FH subjects from 17 Afrikaner kindreds (98,103) indicated 
receptor-defective mutations in all but two homozygotes, the 
sibling pair, FH3a and 3b, which were apparently receptor-
negative on the basis of 125 I-LDL binding and metabolism. 
Consistent with this finding, the clinical features of the 
disease in FH3a and 3b were more severe than in the 
receptor-defective subjects. None of the receptor-
defective homozygotes under the age of 16 showed signs of 
coronary heart disease (CHD), whereas even the younger (aged 
10 at the time of study) of the receptor-negative siblings 
suffered from CHD (103). 
On the basis of 10 polymorphic restriction sites in the LDL 
receptor gene, FH3a and 3b have been shown to be true 
genetic homozygotes for haplotype 15 (section 3.2.1). The 
phenotypic expression of the mutation represented by 
haplotype 15 could thus be characterized fully in cells from 
FH3a and 3b, without interference from another normal or 
mutant allele. 
Preliminary biosynthetic studies (reported in section 3.2.1) 
showed significant synthesis and processing, albeit slower 
than normal, of 35 s-labelled, immunoprecipitable receptors 
in FH3b. Similar preliminary results had previously been 
obtained for FH3a (103). The mutation in kindred 3 is thus 
not a "null" allele, although it produces a receptor-
negative phenotype. It was therefore of interest to 
elucidate the mechanism(s) responsible for the apparent lack 
of receptor expression, despite significant receptor 
synthesis. This was done mainly on the basis of c35s]-
methionine pulse-chase experiments, carried out to determine 
rates of synthesis, post-translational processing and 
degradation of immunoprecipitable LDL receptors. 
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4.2 Results 
4.2.1 LDL receptor activity 
FH3a and 3b were designated "receptor-negative" on the basis 
of l25I-LDL binding and metabolism at 37°C (103). However, 
as discussed previously, biosynthetic studies using 
immunoprecipitation by the monoclonal anti-LDL receptor 
antibody, IgG-C7, indicated significant synthesis and 
processing of LDL receptor protein to the mature form, which 
in normal cells is expressed on the cell surface. The 
possibility thus existed that FH3a and 3b cells expressed 
abnormal surface receptor protein, recognized by IgG-C7, but 
not LDL. Previous studies of 125 I-LDL and 12 5I-IgG-C7 
surface binding at 4°C (Table 3.1, ref. 103, unpublished 
results) suggested the possibility of a low level (less than 
10% of normal) of surface receptor expression in these 
cells. Therefore, a number 
binding of both 125 I-labelled 
of assays at 4°C for surface 
LDL and 125 1-labelled IgG-C7 
to FH3b cells were performed, to ascertain whether or not 
surface expression of LDL receptor protein could be 
detected. Binding and metabolism of l25r-LDL and 125r-IgG-
C7 at 37°C were also measured. 
As shown in Table 4.1 (a), in 3 separate experiments, 
surface binding at 4°C of 12 51-LDL or -IgG-C7 to FH 3b cells 
ranged from below the detection limits of the assay to a 
small significant percentage of normal receptor activity. 
Similar results were previously obtained for FH3a (see Table 
4.1). In another experiment, shown in Table 4.1 (b), 
binding levels at 4°C for 125 1-LDL, 125 I-IgG-C7 and another 
lipoprotein ligand, 12 51-~-VLDL, to FH3b cells were 
determined. ,-vLDL binds to the LDL receptor via 
apolipoprotein E, rather than apolipoprotein B-100, as for 
LDL (discussed in section 1.2.1.1), and has been shown to 




High-affinity binding values for LDL, IgG-C7 
to FH3b cells were similar or higher than those 
downregulated normal cells, which presumably do 
express some residual receptor activity. Thus, the results 
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in Table 4.1 indicate that FH3a and 3b may express a very 
low level of surface LDL receptors which is sometimes lower 
than the limits of detection of the assay. 
High-affinity cell-association (bound and intracellular) and 
metabolism of 125 !-LDL and 125 I-IgG-C7 at 37°C in FH3b cells 
(shown in Table 4.2) were below detectable limits, except 
the value of 10% of normal for degradation of 12SI-IgG-C7. 
The high value (<14%) for limits of detection of cell-
associated 125 I-IgG-C7 was due to considerable variation in 
the non-specific background. The apparently significant 
level of 125 I-IgG-C7 degradation may reflect a sensitive 
measurement of a low level of receptor activity, since 
degraded products accumulate linearly over the 4-hour 
incubation period. Since no detectable 125 !-LDL degradation 
was observed for FH3b, the results may indicate the presence 
of abnormal receptor protein~ However, no indication for 
disproportionately higher IgG-C7 versus LDL binding at 4°C 
was observed. 
Brown and Goldstein originally defined "receptor-negative" 
cells as those which bound and metabolized less than 2% of 
normal levels of 12 5 !-LDL, as this represented the detection 
limits of the assay (74). 
have recently shown that 
However, Funahashi et~. (128) 
cells which synthesized no 
immunoprecipitable LDL receptors bound 1% to 9% of normal 
125!-LDL levels, and up to 4% of normal 125 I-IgG-C7 levels. 
They propose that these percentages represent background 
binding and that patients whose fibroblasts bound less than 
10% of normal levels be consid~red "receptor-negative". 
This higher minimum detection limit may reflect greater non-
specific background variability, but this aspect was not 
addressed. 
By the criteria of Funahashi et~. (128); the LDL receptor 
status in FH3a and 3b can be designated "receptor-negative", 
although, by the original criteria of Brown and Goldstein 
(74), a low but significant level of surface receptor 
' 
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Table 4.1 Surface binding of 125 !-labelled-LDL and 1251-
labelled IgG-C7 (a) (and 125 !-labelled a-VLDL (b)) 
to fibroblasts from normal subjects and FH3b 
(overleaf). 
After 48 hours in lipoprotein-deficient medium to induce 
maximal LDL receptor expression (or medium containing 2 
µg/ml 25-hydroxycholesterol to down regulate receptor 
expression), fibroblasts from normal subjects and FH3b 
received 1.5 ml of ice-cold medium containing 7 µg/ml (14 
nM) l25r-LDL or 1 µg/ml (6.7 nM) 125 I-IgG-C7. In the 
experiment shown in (b), some cells received medium 
containing 1 µg/ml 12 51-a-VLDL. After 2 hours at 4°C, the 
amount of 125I-LDL or 12 5I-IgG-C7 (or 1251-a-VLDL) bound to 
the cells was determined. The data are means of duplicate 
or triplicate (indicated in parentheses) incubations and 
represent high-affinity binding, calculated by subtracting 
the non-specific values of 12 5I-ligand or -antibody binding 
in the presence of excess unlabelled LDL (300 µg/ml, 600 
nM), IgG-C7 (50 µg/ml, 330 nM) or a-VLDL (90 µg/ml) from 
total binding. The difference between the individual non-
specific background values (in the presence of excess 
unlabelled ligand or antibody) determined the limits of 
detection for each experiment. Specific binding values for 
FH3b cells were considered significant only if the total 
binding levels from which they were calculated exceeded non-
specific binding by a greater percentage (of normal specific 
binding levels) than the difference between the individual 
non-specific values. 
difference between 
For example, in experiment 2, the 
125I-IgG-C7 binding values in the 
presence of unlabelled IgG-C7 was 4% (non-specific= 10-14% 






of <5% of normal (i.e. total binding 
specific binding level) was not 
(Previous results for binding 
levels in FH3a cells are included in (a) for comparison). 
107 
(a) 
Expt. 125!-LDL bound (ng/ml) 125 I-IgG-C7 bound (ng/mg) 
Normal FH3a/b % Normal Normal FH3a/b % Normal 
FH3b 1 377(3) n.d.(3) <2 85(3) 3 4 
2 189 ( 3} 29 ( 3 J 
38 2 7 ( 3) 8 55 1.6(3) <5 
486(3) 81(3 
3 182 n.d. <2 53 n.d. (1 
FH3a 
Ref. 103 4.5 4 28 0.2 (1 
103 
* 187 n.d. <3 39 4.4 11 
*van der Westhuyzen, D.R. and Coetzee, G.A. (unpublished 
results) 
n.d. = not detectable. 
------------------------------------------------------------
( b) 
Cells 125 I-LDL % 125 I-I9G-C7 % 1251-~- % 
bound Normal bound Normal VLDL Normal 
(ng/mg) (ng/mg) bound 
(ng/mg) 
Normal 155 100 39 100 28 100 
(upregu-
lated) 
Normal 14 9 1 3 0.8 3 
(downre-
gulated) 
FH3b 14 9 2 5 1.5 5 
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Table 4.2 Binding and metabolism of 125 I-LDL and 125I-IgG-C7 
at 37°C by normal and FH3b fibroblasts (overleaf). 
LDL receptor activity in fibroblasts was either upregulated 
for 48 hours in lipoprotein-deficient medium (5 mg/ml LPDS) 
or downregulated in medium containing 1 µg/ml 25-hydroxy-
cholesterol plus 12 µg/ml cholesterol. The cells were then 
incubated for 
125 I-LDL (256 
4 hours at 37°C with either 12 nM (6 µg/ml) 
cpm/ng) or 2.4 nM (3.6 µg/ml) 125 I-IgG-C7 
(1925 cpm/ng). High-affinity binding and metabolism of 
125r-LOL were calculated by subtraction of non-specific 
values determined either in the presence of excess 
unlabelled LDL 
cells. In 
(600 nM, 300 µg/ml) or in down-regulated 
the case of 125 I-IgG-C7, high-affinity values 
were calculated by subtraction of the non-regulatable 
binding and metabolism in down-regulated cells. Non-
specific values for 125 I-LDL represented less than 10% of 
the total, and for 125 I-IgG-C7 the non-specific component 
was less than 20% of the total. Each value is the average 
of duplicate determinations from a single experiment and did 
not differ by more than 5% from the mean values. The 
limits of detectable receptor activity were determined as 
described in the legend to Table 4.1. 
detectable). 
















125I-IgG-C7 Regulatable 296 
FH3b 125!-LDL Specific 18 
Regulatable 7 
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activity may be present in these cells. The ability of LDL 
to stimulate the incorporation of 14c-oleate into 
cholesteryl oleate, as an index of cellular acyl-CoA 
cholesterol acyltransferase (ACAT) induction is believed to 
be a sensitive assay for distinguishing between receptor-
negative and receptor-defective cells (103). In previous 
studies (103) FH3a and 3b cells showed no detectable LDL-
induced ACAT activity, thus supporting their classification 
as receptor-negative. Western blotting of solubilized 
extracts from FH3b cells (see section 5.3.6) showed that the 
level of total cellular receptors was 
excluding the possibility of a large 
undetectable, 
proportion of 
intracellular receptors as the explanation for negligible 
surface expression. 
Thus FH3a and 3b cells express virtually no LDL receptors, 
as measured either by LDL- or IgG-C7-binding activity, 
despite the fact that IgG-C7 was able to immunoprecipitate 
newly-synthesized receptors from these cells. The apparent 
lack of receptor expression could be due to severely 
decreased synthesis of receptor precursors, lack of 
processing to mature receptors, or abnormally ~igh rates of 
degradation of precursors and/or mature receptors. The 
respective contributions of receptor synthesis, processing 
and degradation rates to this lack of expression were 
therefore determined. 
4.2.2 LDL receptor synthesis 
To assess how synthetic rates might influence the steady-
state LDL receptor levels in FH3a and 3b, initial rates of 
(3Ss]-methionine incorporation into immunoprecipitable LDL 
receptors were measured, relative to synthesis of total 
trichloroacetic acid-precipitable protein and transferrin 
receptor synthesis, and compared to the rates in normal 
cells. The results of 2 such determinations are summarized 
in Table 4.3. Cells from FH3a and 3b showed reduced, but 
significant rates of LDL receptor synthesis relative to 
normal cells (40-60% of normal) when expressed either in 
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Table 4.3. LDL receptor synthesis rates in normal, FH3a and 
FH3b fibroblasts (overleaf). 
Fibroblasts from normal subjects and from FH3a and FH3b were 
incubated in lipoprotein-deficient medium for the indicated 
time to induce LDL receptor synthesis. The cells were pre-
incubated in methionine-free medium for 30 minutes, and then 
pulse-labelled with c35s]-methionine (64 µCi/ml (Expt. 1) or 
30 µCi/ml (Expt. 2)) for 30 minutes and 60 minutes (Expt. 
1), or 30 minutes and 45 minutes (Expt. 2). At each time 





taken from each 
35s-incorporation 
cell lysate for 
into total 
trichloroacetic acid-precipitable protein. LDL receptors 
and transferrin receptors were co-immunoprecipitated from 
the lysates and subjected to SDS-polyacrylamide gel 
electrophoresis (5-20% acrylamide) and fluorography. The 
initial rates of 3 5s-incorporation into LDL receptor bands 
(120 kDa + 160 kDa) and transferrin receptor bands were 
quantified by densitometric scanning. Rates 
incorporation into total protein were determined 
of 
by 
scintillation counting of trichloroacetic acid-precipitable 
material. Initial synthesis rates were calculated by 
linear regression through zero. The LDL receptor synthesis 
rates (in arbitrary integration units (discussed in section 
2.2.7.5, p. 64) per hour) are expressed relative to rates of 
transferrin receptor synthesis (arbitrary 
units/hour) and total protein synthesis 
methionine incorporated x 10-5 /hour). 
integration 
(dpm c35s1-
1 1 2 
Expt. Upregu- Cell LDL receptor % LDL receptor % 
lation type synthesis/ Normal synthesis/ Normal 
time Transferrin Total 
( h) receptor protein 
synthesis synthesis 
1 30 Normal#l 2.00 3.09 
1.83 100 4.34 100 
Normal#2 1.67 ± ± 3.88 ± ± 
0.17 9% 1.54 35% 
Normal#3 1.83 6.06 
FH3a 0.68 37% 2.70 62% 
FH3b 1.03 56% 2.26 52% 
------------------------------------------- .----------------
2 16 Normal 1.02 100% 3.71 100% 
FH3b 0.89 49% 1.88 51% 
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terms of total protein synthesis or the synthesis of 
transferrin receptors. These results confirmed that the 
"receptor-negative" phenotype in FH3a and 3b was not the 
result of severely decreased synthesis of receptors. 
4.2.3 Biosynthesis and processing of LDL receptors 
Post-translational processing of newly-synthesized receptors 
was studied by c35s]-methionine pulse-chase experiments. 
Fibroblasts from a normal subject, FH3a and FH3b were 
induced for LDL receptor synthesis by incubation for 24 
hours in lipoprotein-deficient medium, and then pulse-
labell~d for 1 hour with c35s]-methionine, followed by 
various chase periods. At the end of the pulse-labelling, 
approximately equal amounts of 35S-label were present in the 
precursor (120 kDa) and mature (160 kDa) LDL receptors in 
normal cells (Figure 4.l(a)). During the chase, the normal 
precursor was rapidly and quantitatively conver~ed (t~ 
approximately 15 minutes) to the mature form by 
oligosaccharide processing reactions (discussed in section 
1.3). 
The precurs~r receptor in FH3a (not shown) and 3b (see 
figure 3.lF) had a normal apparent molecular weight (120 
kDa), indicating that the mutation caused no large deletion 
or insertion in the protein. However, the conversion of 
precursor into mature 160 kDa receptor; which accompanies 
transport to the Golgi complex and maturation of core 
sugars, was slower than in normal cells, with a half-time 
for conversion of about 1.5 hours (Figures 4.l(b) and (c)). 
Further evidence for slow processing was the fact that only 
the precursor form of the receptor in FH3a and 3b was 
labelled after the pulse period, whereas 50% of the 35s-
labelled precursor had already been converted to mature 
receptor in normal cells. Although post-translational 
processing in cells from FH3a and 3b was slower than normal, 
significant processing took place nevertheless, and 
conversion to the mature form was essentially complete 































0 1 2 3 
Time of chase (h) 
Figure 4.1 (legend overleaf) 
1 1 5 
Figure 4.1 Processing of LDL receptors in normal, FH3a and 
FH3b fibroblasts 
Fibroblasts from a normal subject (a), FH3a (b) and 3b(c) 
were induced for LDL receptor synthesis by incubation for 24 
hours in lipoprotein-deficient medium. The cells were pre-
incubated for 30 minutes in methionine-free EMEM/LPDS, and 
then pulse-labelled with [ 35s]-methionine (50 µCi/ml) for 1 
hour, at 37°C. The medium was then changed to DMEM/LPDS 
containing 200 µM unlabelled methionine and the fibroblasts 
were 
were 
incubated at 37°C for various chase times. The cells 
then washed and solubilized and 35s-labelled LDL 
receptors were immunoprecipitated. Immunoprecipitates were 
subjected to SDS-polyacrylamide gel electrophoresis (5-20% 
acrylamide gradient) and fluorography (Normal - overnight, 
FH3a and 3b - 2 day exposure, -70°C). The 35s-radio-
activity in the 120kDa precursor (0) and 160 kDa mature <•) 
receptor bands in the fluorograms was quantitated by 
densitometric scanning and expressed as a percentage of the 
maximum 3 5s-incorporation into total LDL receptors. "100%" 
incorporation into receptors in FH3a and 3b represented 60% 
of the maximum incorporation into normal receptors. The 
data points are averages of duplicates (See Figure 3.1 for 
fluorograms of processing in normal cells (A) and FH3b (F)). 
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The most striking feature of the processing in the kindred 3 
mutants, apart from the retarded conversion to the mature 
receptor, was the rapid loss of 35 S-label from the receptor 
bands. In normal cells only a 20% loss of the total 
incorporated [ 35sJ-methionine (present in the precursor and 
mature bands) was observed during the 3 hour time-course. 
However, cells from FH3a and 3b showed disappearance of 35g_ 
labelled receptors with t~ values of less than 2 hours, 
suggesting accelerated receptor degradation at some stage. 
The possibility that this rapid loss represented mature 
receptor degradation was therefore investigated. 
4.2.4 Half-life of mature LDL receptors in FH3a and 3b 
The degradation rate of a protein is an important factor in 
determining its steady-state level in the cell. In the 
case of certain proteins, such as HMG-CoA reductase (72), 
alterations in the degradation rate have a regulatory 
function. However, Casciola et al. (73) have shown that 
regulation of LDL receptor activity in normal fibroblasts is 
solely the result of changes in the rate of receptor 
synthesis. 
cells was 
The half-life of the LDL receptor in these 
shown, by c35 SJ-methionine pulse-chase 
measurements, to be 11.7 ± 2.2 hours, regardless of the 
level of LDL receptor up-regulation or the presence of 
ligand (73). The same procedures were used to compare the 
half-life of the mature LDL receptor in normal, FH3a and 
FH3b cells. 
A typical example of a determination of the half-life of the 
LDL receptor in normal cells by IgG-C7 immunoprecipitation 
of 35S-labelled receptors is shown in Figure 4.2. The 
half-life of another membrane receptor, the transferrin 
receptor, was determined in the same experiment by a second 
immunoprecipitation from the same cell lysate with an anti-
transferrin receptor antibody. Data from 4 separate 
experiments yielded a half-life for the normal mature LDL 
receptor of 12.6 ± 1.3 hours, which agrees well with the 
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Figure 4.2 Degradation of 35S-labelled LDL- and transferrin 
receptors in normal fibroblasts 
Human skin fibroblasts from a normal subject were incubated 
for 24 hours in lipoprotein-deficient medium and then pulse-
labelled for 9 - hours at 37°C with [ 35 s]-methionine (30 
µCi/ml). The medium was then changed to DMEM/LPDS 
containing 200 µM unlabelled methionine and the cells were 
incubated at 37°C for various chase times ("zero" = 1 hour 
chase). The cells were then washed and solubilized and LDL 
receptors (LDL-R), and then transferrin receptors (Tf-R), 
were isolated by sequential immunoprecipitations, with IgG-
C7 followed by anti-transferrin receptor 83/25, from the 
cell lysates. The immunoprecipitates were subjected to 
SDS-polyacrylamide gel electrophoresis (5-20% polyacrylamide 
gradient) and fluorography. 
of the data (duplicates), 
Non-linear regression analysis 
obtained from densitometric ' 
scanning of the fluorographic bands, yielded t~ values (mean 
± S.E.M.) of 16.6 ± 2.9 hours for the LDL receptor and 55.9 
± 11.9 hours for the transferrin receptor. 
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Figure 4.3 Degradation of 35S-labelled mature LDL receptors 
in normal, FH3a and F~3b fibroblasts 
Cells from a normal subject, FH3a and FH3b were induced for 
LDL receptor synthesis by incubation for 16 hours in 
lipoprotein-deficient medium. The cells were pre-incubated 
for 30 minutes in methionine-free EMEM/LPDS, after which 
they were pulse-labelled with [ 35 s]-methionine (40-80 
µCi/ml) for 2 hours, at 37°C. The medium was then changed 
to DMEM/LPDS, containing 200 µM unlabelled methionine, and 
the fibroblasts were incubated at 37°C until virtually none 
of the 35S-label remained in the precursor (120 kDa) band. 
This was assumed to be the "zero" chase time-point (Normal, 
. 
' After subsequent chase 1 hour 
periods, 
FH3a and 3b, 3 hours). 
immunoprecipitation, SDS-polyacrylamide gel 
electrophoresis (5-20% acrylamide) and fluorography were 
performed. The 35S-label in fluorographic receptor bands 
was quantified by densitometric scanning. The data points 
are averages of duplicates and the bars represent variations 
greater than 10% from the mean values. The "100%" value at 
zero time represents the mean± standard deviation of 4 
values for normal, 4 for FH3a and 2 for FH3b cells. The 
data from 3 separate experiments (0, normal and FH3a; • 
normal and FH3b; 6, FH3a only) yielded t~ values (means± 
S.E.M.) for LDL receptor degradation of 12.0 ± 1.8 hours for 
normal cells, and 1.7 ± 0.2 hours for the combined data from 
FH3a and FH3b. 
120 
values obtained by Casciola et al. (73) and Knight et al 
(129). The t~ of the transferrin receptor (from 
guantitation of results in Figure 4.2) was 55.9 ± 11.9 
hours, thus illustrating the unique turnover rates of two 
different membrane proteins. 
Because of the retarded processing to the mature form of the 
receptor in FH3a and 3b, an initial chase period of at least 
3 hours, following pulse-labelling, was necessary to ensure 
that virtually none of the 35 s-label remained in the 
precursor (120 kDa) band. The half-life of the mature 
receptor could then be determined from the rate of 
disappearance of 35s-label from the mature (160 kDa) 
receptor band. As shown in Figure 4.3, the half life of 
the mature LDL receptors was markedly shorter than in normal 
cells. The receptor in FH3a and 3b was degraded with a 
half-life of approximately 1.7 hours, compared to at~ of 12 
hours for the receptor in normal cells analyzed at the same 
time. This extremely rapid degradation can to a large 
extent account for the very low surface receptor activity 
observed in FH3a and 3b (section 4.2.1) and represents a 
mutant phenotype not previously described in the 
classification of naturally-occurring LDL receptor 
mutations. Thus, the mutations in FH3a and 3b (and 2 other 
mutations discussed later in section 4.3) 
class of LDL receptor defects. 
represent a new 
A possible alternative mechanism for the rapid loss of 
mature receptors from FH3a and 3b cells was secretion of 
receptors from the cells, as seen in the class 4 "variants" 
(35,36). Therefore, after 35S-labelling of receptors, 
immunoprecipitations with monoclonal (IgG-C7) and polyclonal 
(489-1) antibodies were carried out on the medium from FH3b 
cells, to detect possible secreted receptors (see section 
2.2.7.4). 
After FH3b cells were pulse-labelled overnight in the 
presence of 5µM unlabelled methionine, immunoprecipitation 
1 2 1 
with IgG-C7 (and anti-transferrin receptor antibody) from 
the cells showed a very small amount of 35s-labelled LDL 
receptor, particularly compared to the amount of 3 5s-
labelled transferrin receptor in the same cells (Figure 
4.4(a)). However, only non-specific bands were present in 
the immunoprecipitate from the medium, suggesting that no 
significant secretion of LDL receptors had occurred from 
FH3b cells. 
When FH3b cells were labelled for 2 hours with [35s]-
methionine, and chased in the presence of 200 µM unlabelled 
methionine for 4 hours (Figure 4.4(b)), the amount of 35s-
labelled LDL receptor immunoprecipitable from the cells, 
particularly by the polyclonal antibody, 489-1 (Figure 
4.4(b)(ii)) was virtually undetectable. As found after 
labelling overnight, only non-specific bands were present in 
immunoprecipitates from the medium. Since the half-life of 
the immunoprecipitable mutant receptors in these cells is 
1.7 hours (discussed above), after 4 hours of chase, only 
approximately 20% of the original 35s-labelled receptors 
would be expected to remain. Since no 35S-labelled 
receptors were immunoprecipitated from the medium with 
either IgG-C7 or polyclonal antibody, it could be concluded 
that the receptor loss (80%) was due to degradation rather 
than secretion. Similar results (not shown) were obtained 









receptors from FH3b cells after the 4 hour chase period, the 
rapid loss of labelled receptors observed using monoclonal 
IgG-C7 appeared to be due to degradation, and not due to 
loss of the antigenic site for IgG-C7 through receptor 
denaturation. The 35S-labelled bands between the 120 kDa 
and 160 kDa positions, immunoprecipitated by IgG-C7 and 
polyclonal antibody 489-1 from FH3b cells (Figure 4.4(b)(i) 
and (ii)), may represent degradation fragments of the mature 
receptor and are discussed later in section 4.2.7. 
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Figure 4.4 Immunoprecipitation from medium of FH3b cells 
Fibroblasts from FH3b were induced for LDL receptor 
synthesis by incubation in lipoprotein-deficient medium for 
24 hours. 
(a) Cells were pulse-labelled with [ 35 s]-methionine (50 
µCi/ml) in EMEM containing 5 µM unlabelled methionine 
for 18 hours at 37°C. Immunoprecipitation with IgG-C7 
was then performed on half the total pulse medium and 
on the total cell lysate. 
(b) The fibroblasts were pulse-labelled in methionine-free 
medium with [ 35S]-methionine (80 µCi/ml) for 2 hours at 
37°C, and then chased in medium containing 200 µM 
unlabelled methionine for 4 hours. Immunoprecipitation 
was performed on the total chase medium or on the cell 
lysate, using IgG-C7 (i) or polyclonal 489-1 (ii). 
All immunoprecipitates were subjected to SDS-polyacrylamide 
gel electrophoresis ((a) 5-20%. ( b) (i) 5-12%. (ii) 7% 
acrylamide) and fluorography.As references for the positions 
of the 120 kDa and 160 kDa bands, LDL receptors from FH1b 
(2 h pulse, 1 h chase) (a) or normal cells (2 h pulse) (b) 
were immunoprecipitated and electrophoresed with the 
immunoprecipitates from FH3b. The bands just above the 160 
kDa band, and at ±200 kDa (possibly myosin) and ±40 kDa 
(possibly actin) represent non-specific contaminants. 
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4.2.5 Biosynthesis, processing and degradation of LDL 
receptors in the heterozygous subject, 3c 
Since FH3a and 3b have been shown by haplotype analysis to 
be homozygous for a single type of mutant allele, 
represented by haplotype 15, each of their heterozygous 
parents must therefore carry one copy of this mutant allele, 
together with a normal allele. To examine the phenotypic 
expression of the mutant allele, in the presence of a normal 
allele, the synthesis, processing and degradation of 35s-
labelled LDL receptors were studied in the heterozygous 
mother of FH3a and 3b, subject 3c (103). 
Previous studies of LDL receptor activity in 3c (103) showed 
approximately 50% of the normal levels of l25r-LDL binding 
and metabolism, intermediate between that obtained for 
normal cells, 
findings, the 
and for FH3a and 3b. 
phenotypic expression 
Consistent with these 
of cellular LDL 
receptors in 3c showed synthesis, processing and degradation 
rates intermediate between those observed in normal cells 
and FH3b (Figure 4.5). After a 2 hour pulse, the 
distribution of 35S-label between mature and precursor bands 
in 3c resembled that in the normal cell more closely than 
that in FH3b, possibly as a result of the reduced 
translation rate of the mutant allele (section 4.2.2). 
After 1 hour of chase, the conversion to the mature receptor 
was essentially complete in normal cells, whereas 35s-
labelled precursor persisted in 3c, presumably representing 
the slowly-processed 
observed in FH3b cells. 
product of the mutant allele as 
After a 4-hour chase period, the 
product of the 
disappeared, while 
mutant allele in 
35s-labelled mature 
FH3b had virtually 
receptor was still 
observed in 3c, at a level of approximately half that 
produced by two normal alleles in the normal control. 
These results are consistent with the interpretation that, 
in the heterozygous cells, the product of the normal allele 
is synthesized, processed and degraded independently at 
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Figure 4.5 Biosynthesis, processing and degradation of 35 s-
labelled LDL receptors in cells from a normal 
subject, FH heterozygote 3c, and FH homozygote, 
3b 
Fibroblasts from a normal subject, FH heterozygote 3c, and 
FH homozygote 3b were 
medium for 24 hours, 
methionine-free EMEM 
incubated in lipoprotein-deficient 
pre-incubated for 30 minutes in 
and pulse-labelled with 
methionine (80 µCi/ml) for 2 hours, at 37°C. Cells were 
harvested after pulse-labelling, and after 1 hour and 4 hour 
chase periods in DMEM/LPDS containing 200 µM unlabelled 
methionine. 35s-labelled LDL receptors were immune-
precipitated and subjected to SDS-polyacrylamide gel 
electrophoresis (5-12% acrylamide) and fluorography. The 
band above the 160 kDa band is a non-specific contaminant. 
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normal rates, despite the presence of the abnormal receptor 
produced by the mutant allele, and vice versa. This 
strongly suggests that the slow processing and rapid 
degradation of the receptor observed in FH3a and 3b are due 
to a defect in the receptor ~ se, and not in another 
protein(s) responsible for its intracellular transport 
and/or metabolism. 
4.2.6 Sensitivity of mature LDL receptors to Pronase and 
neuraminidase. 
Although rapid 
and 3b was 
degradation of 
shown by 
mature LDL receptors in FH3a 
[ 35s]-methionine pulse-chase 
measurements, this method gives no indication of the site of 
degradation, and it was not known whether the mature 
receptors were degraded before or after reaching the cell 
surface. Pronase is known to degrade surface LDL receptors 
(19), whereas neuraminidase causes a small decrease in 
apparent molecular weight of the receptors on SDS 
polyacrylamide gel electrophoresis through removal of sialic 
acid residues ( 33) • Pronase and neuraminidase sensitivity 
were therefore used to determine whether mature receptors in 
FH3b were degraded intracellularly before reaching the 
plasma membrane, or were transported to the surface and 
degraded thereafter. In normal cells, the mature receptor 
band showed a slight but significant decrease in molecular 
weight after neuraminidase treatment and 
susceptibility to Pronase digestion (Figure 4.6). 




cells, and thus all the mature FH3b receptor observed in the 
control incubations without neuraminidase (lanes 6 and 7) or 
Pronase (lanes 12 and 13) must have reached the cell 
surface. The precursor receptor in FH3b would not be 
expected to be susceptible to neuraminidase treatment as it 
presumably does not contain sialic acid residues. The lack 
of susceptibility of the precursor to Pronase digestion 
confirms that it is intracellular, and that no contaminating 
Pronase activity was present in the cell lysate. 
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Figure 4.6 Sensitivity of LDL receptors in normal and FH3b 
cells to treatment with neuraminidase and 
Pronase 
Lanes 1 and 2: upregulated normal fibroblasts were pulse-
labelled with [ 35s]-methionine (80 µCi/ml) for 30 minutes, 
followed by a 30 minute chase period. 35 s-labelled LDL 
receptors were then immunoprecipitated, and the immune-
precipitates were incubated overnight at 4°C in the absence 
or presence of neuraminidase (0.8 units/ml) (44). Lanes 3 
to 15: upregulated cells from a normal subject or FH3b were 
pulse-labelled with [ 35 s]-methionine (80 µCi/ml) for 60 
minutes, at 37°C, followed by a chase for 60 minutes in 
medium containing 200 µM unlabelled methionine. The chase 
medium was removed and the cells were washed and incubated 
at 37°C in the absence or presence of neuraminidase 
(Calbiochem-Behring, 0.05 
Pronase (20 µg/ml) for 
units/ml) for 
20 minutes ( 19 ) • 
then washed and solubilized, after which 
30 minutes (33) or 
The cells were 
35s-labelled LDL 
receptors were immunoprecipitated and subjected to SDS-
polyacrylamide gel 
fluorography. 
electrophoresis (10-20% acrylamide) and 
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The sensitivity of the mature receptors in FH3b to 
neuraminidase and Pronase treatment of intact cells shows 
that 35S-labelled mature receptors in these cells all 
apparently reach the surface. 
for these receptors (section 
Thus, the short t~ observed 
4.2.4) is the result of 
degradation of mature receptors after they have reached the 
cell-surface. The results also show that there is some, 
albeit very low, expression of LDL receptors on the surface 
of these cells, which may account for periodic detection of 
significant LDL- and IgG-C7-binding activities in these 
cells (section 4.2.1). Although all the 35 s-labelled 
mature receptors in FH3b appear to reach the cell-surface 
before being rapidly degraded, the results do not exclude 
the possibility of another population of mature receptors, 
degraded intracellularly so rapidly that they are not 
detected. 
4.2.7 Effect of lysosomal inhibitors on rapid degradation 
of LDL receptors in FH3b 
The degradation of membrane proteins, and m~re specifically 
cell-surface receptors, is not well understood. Protein 
degradation can be broadly classified into lysosomal and 
non-lysosomal processes. Receptors which do not recycle in 
the presence of ligand are thought to be degraded in 
lysosomes along with their ligands (130). However, the 
role of the lysosome in the breakdown of recycling 
receptors, such as the LDL receptor, remains uncertain. 
Degradation in the lysosome is catalyzed by a number of 
thiol proteases (cathepsins B, Hand L) 
Lysosomal 
and a carboxyl 
involvement in protease, cathepsin D (131). 
degradative processes has traditionally been demonstrated by 
the prevention of proteolysis through inhibition of the 
lysosomal enzymes, either through the use of relatively 
specific inhibitors such as leupeptin for cathepsin B, or 
pepstatin for cathepsin D (132), or by non-specific 
inhibition using lysosomotropic agents such as ammonium 
chloride and chloroquine. The latter compounds are weak 
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bases which accumulate in the lysosomes once they become 
protonated, and thereby increase intralysosomal pH, 
preventing the action of the acidic proteases (133). In 
addition to disrupting lysosomal pH, 
specifically inhibits cathepsin B activity (132). 
chloroquine 
Although 
lysosomal inhibitors, such as ammonium chloride, chloroquine 
and leupeptin, do not inhibit normal LDL receptor turnover 
(Casciola, L.A.F •• et~., manuscript in preparation), the 
possibility that the abnormally rapid receptor degradation 
in FH3a and 3b occurred in lysosomes was investigated by 
examining the effects of various lysosomal inhibitors. 
The effects of ammonium chloride (10 mM), leupeptin (150 
µg/ml) and chloroquine (50 µM) on total receptor 
degradation, and more specifically, mature 160 kDa receptor 
degradation, in FH3b cells _were investigated. After pulse-
labelling for 2 hours with [ 35s]-methionine, the cells were 
chased for 1 hour, at which stage approximately 50% 





The chase medium was then 
either ammonium chloride, 
leupeptin, chloroquine or combinations of these agents, at 
the concentrations given above, and the chase incubation 
continued for 2 hours, after which LDL receptors were 
immunoprecipitated. The results in Figure 4.7 suggest that 
the presence of ammonium chloride in the chase medium 
markedly inhibited the rapid loss of 35 S-label, from both 
precursor (120 kDa) and mature (160 kDa) receptor bands, 
observed in the absence of additions. The combination of 
ammonium chloride, leupeptin and ~hloroquine had an even 
more dramatic inhibitory effect on receptor degradation. 
The decreased loss of 35 S-label in the precursor band in the 
presence of the lysosomal inhibitors may suggest that the 
decrease in intensity of the 120 kDa band in the control, 
attributed to processing to the mature form, is also 
partially due 
Alternatively, 
to degradation of precursor receptors. 
ammonium chloride and/or chloroquine may 
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Figure 4.7 Effect of ammonium chloride, plus or minus 
leupeptin and chloroquine, on total LDL receptor 
degradation in FH3b cells 
Fibroblasts from FH3b were incubated for 18 hours in 
lipoprotein-deficient medium to induce LDL receptor 
synthesis. The cells were pre-incubated for 30 minutes at 
37°C in methionine-free EMEM and then pulse-labelled for 2 
hours with [3 5 s]-methionine (112 µCi/ml). After an initial 
chase incubation for 1 hour in DMEM/LPDS (containing 200 µM 
unlabelled methionine), the medium was changed to DMEM/LPDS 
supplemented with no, additions, ammonium chloride ( 10 mM), 
or ammonium chloride plus leupeptin (150 µg/ml) plus 
chloroquine (50 µM) for a further 2 hour chase period. The 
cells were then solubilized and 35 S-labelled LDL receptors 
immunoprecipitated and subjected to SDS-polyacrylamide gel 
electrophoresis 
fluorography. 
(5-12% acrylamide gradient) and 
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retard processing. However, this possibility seems unlikely 
since an inhibition of processing would cause a concomitant 
decrease in 35S-label transferred to the mature form of the 
receptor and this is not observed. The apparently higher 
level of 35 s-label relative to the control precursor band 
may represent an increased level of a putative degradation 
fragment observed at approximately the same molecular weight 
in a number of experiments (see Figure 4.8 and discussion 
later). Accumulation of such a degradation intermediate 
would imply that ammonium chloride inhibits a degradation 
step subsequent to the formation of this fragment. Ammonium 
chloride, alone or in combination with leupeptin and 
chloroquine, apparently 
on loss of 35s-labelled 
showed a dramatic inhibitory effect 
mature receptor in FH3b cells. 
However, this could possibly have been an effect secondary 
to prevention of precursor degradation, thus making more 
precursor available for conversion to mature receptor. The 
results of another experiment to test the effects of the 
three agents, alone or in different combinations, on LDL 
receptor degradation in FH3b cells are shown in Table 4.4. 
Chloroquine and leupeptin alone each had similar effects to 
ammonium chloride on the levels of precursor and mature 
receptors. Combinations of these agents, particularly 
ammonium chloride plus chloroquine or leupeptin, were 
apparently more effective. The results suggest that at 
least some of the steps in the degradation of the precursors 
and/or mature receptors and/or degradation intermediates may 
take place in lysosomes (or other acidified vesicles, for 
example, endosomes) and may involve cathepsin B activity. 
To examine more specifically the effects of these agents on 
degradation of the mature receptor, the initial chase period 
in the absence of agents was extended to 3 hours, to allow 
more complete conversion of precursor to mature receptors 
(see section 4.2.3). The chase medium was then changed to 
one containing no additions, ammonium chloride, leupeptin, 
or a combination of these two agents for further 2-hour and 
4-hour chase periods. The results are shown in Figure 4.8. 
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Table 4.4 Effect of ammonium chloride, chloroquine and 
leupeptin, alone or in combination, on total LDL 
receptor degradation in FH3b cells 
FH3b cells were incubated for 18 hours in lipoprotein-
deficient medium to induce LDL receptor synthesis. The 
cells were then pulse-labelled with [ 35 s[-methionine (70 
µCi/ml) for 2 hours and chased for one hour in the absence 
of added agents (= "zero" chase). After this initial chase 
period, the medium was changed to one supplemented with no 
additions, ammonium chloride (10 mM), chloroquine (50 µM), 









cells were then 
receptors immune-
SDS-polyacrylamide gel 
electrophoresis (5-12% acrylamide) and 
amount of 35S-label in the precursor 
fluorography. The 
(120 kDa) and mature 
(160 kDa) receptor bands was quantified by densitometric 
scanning and expressed as a percentage of the total 35 s-
radioactivity after the initial one-hour chase period 
("zero"). The values are averages of duplicates. 
Chase Additions 35 S-LDL Receptor ( % ) 
120 kDa 160 kDa Total 
"Zero" 53 47 100 
2 h 14 30 44 
NH 4Cl 29 41 70 
Chloroquine 26 48 74 
Leupeptin 24 49 73 
NH 4Cl + chloroquine 33 68 101 
NH 4Cl + leupeptin 27 64 91 
Chloroquine + leupeptin 29 43 72 
NH 4Cl, chloroquine, 24 54 78 
leupeptin 
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In the absence of agents, a marked loss of 35 S-label from 
i.e. degradation, took place the mature receptor band, 
during the first 2 hours, despite the fact that some 
processing from the precursor still occurred. In addition, 
the appearance of possible degradation fragments, at 
apparent molecular weights slightly (± 20 kDa) lower than 
the mature receptor (Dl) and slightly (± 10 kDa) greater 
than the precursor receptor (D2) was observed. By 4 hours 
of chase, 
disappeared, 
the mature receptor band had essentially 
and an increase in the intensity of the 
putative degradation bands, particularly Dl was observed. 
Both Dl and D2 were observed in at least 3 other experiments 
(see, for example, Figure 4.6(b) (i) and (ii)). The bands 
did not appear to be non-specific contaminants, since they 
were not present at early chase times, but only appeared 
later when significant receptor degradation had taken place, 
thus supporting the possibility that they might be 
degradation fragments. Although similar bands to Dl and D2 
were sometimes observed in immunoprecipitates from normal 
cells, they were always present in very low amounts relative 
to the amount of intact 160 kDa receptor, whereas in FH3a 
and 3b they were often present in amounts equal to or 
greater than the mature receptor band (see section 4.3 for 
further discussion). 
Rapid receptor degradation was observed even in the presence 
of the lysosomal inhibitors. However, ammonium chloride, 
particularly in the presence of leupeptin, appeared to 
inhibit loss of 35s-label from the 160 kDa band, suggesting 
inhibition of receptor degradation. Densitometric scanning 
of the fluorograms of the 4 hour chase point showed clearly 
discernible 160 kDa peaks for incubations with ammonium 
chloride in the absence (8) and presence (D) of leupeptin, 
whereas essentially no peaks above background were observed 
for incubations in the absence of agents (A) or in the 
presence of leupeptin alone (C). The apparent decrease in 
background of the fluorogram in the region below the 160 kDa 
peak position is probably due to the presence of residual 
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Figure 4.8 Effect of ammonium chloride and leupeptin on 
degradation of the mature LDL receptor in FH3b 
cells 
Fibroblasts from FH3b were induced for LDL receptor 
synthesis by incubation for 18 hours in lipoprotein-
deficient medium. The cells were then pre-incubated for 30 
minutes at 37°C in methionine-free EMEM, followed by pulse-
labelling with [ 35s]-methionine (60 µCi/ml) for 2 hours. 
The medium was then changed to DMEM/LPDS (containing 200 µM 
unlabelled methionine) for an initial 3 hour chase period at 
37°C ("zero" time) and then to DMEM/LPDS supplemented with 
ammonium chloride (10 mM), leupeptin (1SO µg/ml), the 
combination of these two agents, or no additions, and the 
chase was continued for a further 2 hours or 4 hours. The 
cells were lysed and subjected to immunoprecipitation with 
IgG-C7. Immunoprecipitates were to sos-
polyacrylamide gel electrophoresis 
subjected 
(S-12% acrylamide 
gradient) and fluorography. Densitometric scans of the 
fluorographic bands after 4 hours of chase are shown. The 




non-reduced IgG (150 kDa), which is not radioactively 
labelled. The 160 kDa peaks in (B) and (D) were comparable 
in size or greater than the degradation fragment (01) peak, 
in contrast to the relatively large 01 peaks in (A) and (C), 
supporting the idea that ammonium chloride, particularly in 
the presence of leupeptiri, inhibited the degradative process 
giving rise to fragment 01. It was not possible to 
accurately guantitate the fluorographic bands corresponding 
to the mature receptor and degradation fragments, as their 
intensities were below the linear response range of the X-
ray film. Although leupeptin and ammonium chloride in 
combination appeared to have additive inhibitory effects on 
the degradation, leupeptin alone did not inhibit the rapid 
loss of 35s-label from the mature receptor. Possibly, 
leupeptin inhibited 
proteolytic cleavage. 
a step subsequent to an initial 
Similar observations were made by 
Ascoli (134) for degradation of receptor-bound human 
choriogonadotropin. It was found that ammonium chloride 
inhibited the formation of all intracellular degradation 
products, while leupeptin allowed the formation of the first· 
product to occur, but blocked any further degradation. 
The half-life of the LDL receptor in FH3b cells is less than 
2 hours in the absence of added inhibitors (section 4.2.4). 
If the combination of ammonium chloride and leupeptin was 
able to significantly increase this half-life by inhibition 
of degradation (without any effect on synthesis rates), an 
"accumulation" of receptor protein levels, relative to those 
in untreated FH3b cells, would be expected after incubation 
with the agents for a period encompassing a number of half-
lives. Therefore, the effects of pre-incubation of FH3b 
cells for 13 hours in the presence of ammonium chloride and 
leupeptin on steady-state receptor levels, as measured by 
125r-LDL and -IgG-C7 binding, were determined. The results 
(Table 4.5) showed no significant increase in receptor 
levels, relative to normal cells, after this treatment. 
This is consistent with the observation that although 
ammonium chloride and leupeptin showed inhibition of mature 
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Table 4.5 Effect of pre-incubation with ammonium chloride 
and leupeptin on LDL receptor activity in FH3b 
cells (overleaf) 
After incubation for 30 hours in lipoprotein-deficient 
medium, normal and FH3b fibroblasts were incubated at 37°C 
for 13 hours in the same medium, in the absence or presence 
of 10 mM ammonium chloride and 150 µg/ml leupeptin. LDL 
receptor activity was then determined by 12 5!-LDL (629 
cpm/ng, 10 µg/ml) binding and uptake during 30 minutes at 
37°C, or by the amount of 125 I-IgG-C7 (1272 cpm/ng, 1 µg/ml) 
bound during 2 hours at 4°C. Cells were then washed as 
described in section 2.2.5 and dissolved in 1 M NaOH for 
determination of the 1251-radioactivity associated with the 
cells. 
and 
The data are averages of duplicate determinations 
represent high-affinity values, calculated by 
subtracting non-specific values obtained in the presence of 
excess unlabelled LDL (350 µg/ml) or IgG-C7 (50 µg/ml). 
LDL receptor 
assay 
l2 5 I-LDL, 30 
minutes at 37°C 
125 I-IgG-C7, 2 






















receptor degradation, turnover of receptors in FH3b cells 
was considerably more rapid than in normal cells, even in 
the presence of these agents (Figure 4.8). 
Although the results are still somewhat preliminary and 
quantitatively 
chloride (and 
variable between experiments, ammopium 
other lysosomal inhibitors) consistently 
showed inhibition of the rapid receptor degradation in the 
kindred 3 mutant cells, in the experiments described above 
and others not shown. Thus, although the results are not 
yet conclusive, a strong indication for the involvement of 
proteolysis in lysosomes or other acidified vesicles (such 
as endosomes) in the abnormal receptor degradation, was 
obtained. Some of the variability in the experimental 
results, and the inability to totally inhibit the rapid 
degradation of the mutant receptors, may be related to the 
problem that lysosomotropic agents and proteolytic 
inhibitors (even in combination) incompletely inhibit 
lysosomal function (135) and therefore may complicate 
interpretation. In addition, since the inhibitors take 
some time to accumulate substantially in the cells, their 
use in experiments on short half-life proteins, such as the 
rapidly-degraded mutant LDL receptors, may be unsatisfactory 
(136). An alternative approach for future studies on the 
site and mechanism of receptor degradation in FH3a and 3b 
cells may be the use of temperatures below 20°C to inhibit 
lysosomal proteolysis, presumably by prevention of endosome-
lysosome fusion and thus of delivery of material to the 
lysosome for degradation (137,138). Since all processes 
will be slowed considerably at this temperature, this 
manipulation may allow a clearer dissection of the cellular 
events involved in the very rapid degradation (at 37°C) of 
the mutant receptors. 
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4.3 Discussion 
LDL receptors in FH3a and 3b were shown to be synthesized at' 
reduced but significant rates, and then processed more 
slowly than normal to mature forms which undergo rapid 
degradation after reaching the cell surface. Although the 
post-translational processing of. these mutant receptors is 
slower than normal, their half-time for processing of 1.5 
hours is much faster than typical Class 2 "variants", where 
conversion to the mature receptor is retarded approximately 
ten-fold (19,77). 
The most striking feature in the phenotype of FH3a and '3b is 
the rapid degradation of the mature LDL receptor (described 
in ref. 139). This type of defect was not previously 
described in the phenotypic classification of L~L receptor 
mutations, which included defects in synthesis, processing,· 
ligand binding, internalisation or receptor secretion 
(section 1.5). Thus, at the time when their mutant 
receptor phenotype was first reported (102), FH3a and 3b 
were the first examples of a new class of naturally-
occurring LDL receptor mutations. Recently, however, two 
other mutations giving rise to rapidly-degraded mature 
receptors have been characterized. One of these has been 
described by Funahashi et~. (128) in three siblings from a 
Japanese kindred. Cells from these homozygous FH subjects 
produce precursor and mature LDL receptors which have 
apparent molecular weights about 5 kDa less than normal. 
The precursors are converted at a normal rate to mature 
forms, which are rapidly degraded with a half-life of 0.5 to 
1 hour. A similar phenotype is produced by the mutation in 
South African FH subjects, RI and TD (section 3.2.3), which 
results in removal of the first two cysteine-rich repeats (A 
and B) from the EGF precursor homologous domain of the LDL 
receptor. The smaller precursor (105 kDa) is processed 
normally to a mature receptor (145 kDa) that is degraded 
with a half-life of 2 hours (van der Westhuyzen et ~-, 
manuscript in preparation). 
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Although the phenotypes of the two mutations discussed above 
are similar to that of FH3a and 3b, they have other 
distinguishing features. Both the Japanese mutants· and RI 
and TD express measurable, immunologically-detectable, 
levels of surface receptors (Table 3.1, ref. 128), whereas 
FH3a and 
4 • 2 • 1 ) • 
3b are essentially receptor-negative (section 
In addition, the receptors synthesized in FH3a and 
3b cells have normal apparent molecular weights and are 
slowly processed, whereas the Japanese subjects, and RI and 
TD, all produce abnormally small receptors which are 
processed at a normal rate. Presumably the Japanese, RI 
and TD mutations do not disrupt protein folding, and thus 
transport and processing, because they involve deletions of 
entire receptor units, such as cysteine-rich repeats, 
whereas FH3a and 3b may have small deletions or 
substitutions within such repeats, causing abnormal folding 
and retarded processing (discussed in section 3.3). 
Accelerated turnover of mature LDL receptors has also been 
observed in site-directed mutations where the whole EGF 
precursor-like domain, or only cysteine-rich repeats A and B 
(as in RI and TD), have been deleted (31). In transfected 
Chinese hamster ovary cells, these mutant receptors are 
rapidly degraded in the presence of the ligand, ~-VLDL, but 
not in its absence, presumably because the receptor is 
unable to undergo the acid-dependent con£ormational changes 
required to allow dissociation of the ligand in the 
endosome. The mutation in FH3a and 3b leads to rapid 
recepto~ degradation, even in the absence of ligand. There 
is no evidence for ligand-induced acceleration of receptor 
turnover in these cells since (i) pulse-chase studies show 
no dramatic increase in receptor degradation in the presence 
of LDL (not shown), and (ii) no significant difference is 
detected between receptor activity measured at 37°C after 
30-minute or 4-hour incubations with LDL (compare results in 
Tables 4.2 and 4.5). It is of interest to note that, 
although the mutations in RI and TD are very similar (if not 
1 4 1 
identical) to the constructed mutation lacking cysteine-rich 
repeats A and 8, the mature receptors in RI and TD cells 
turn over rapidly even in the absence of ligand, as observed 
for FH3a and 3b. However, this rapid degradation is 
further accelerated in the presence of ligand (van der 
Westhuyzen et tl•, manuscript in preparation). 
In their studies of experimentally-induced mutations in the 
LDL receptor in Chinese hamster ovary cells (section 1.5.2), 
Kozarsky et ~. (66) showed that 0-linked sugar-deficient 
receptors reached the cell-surface but were abnormally 
unstable due to proteolytic cleavage and release into the 
medium of most of the N-terminal extracellular domain. The 
proteolytic site was postulated to be within or near the 
domain usually containing clustered 0-linked 
oligosaccharides, which presumably protect the cleavage site 
in the normally-glycosylated receptor. The unstable 
receptors in FH3a and 3b cells appear to undergo retarded 
but normal glycosylation, since the expected 120 kDa to 160 
kDa apparent size increase, associated with maturation of 
oligosaccharide residues, is observed (section 4.2.3) and 
the mature surface receptors contain terminal sialic acid 
residues (section 4.2.6). Thus, a glycosylation-related 
defect in the LDL receptor does not appear to be responsible 
for the rapid degradation· of mature receptors in FH3a apd 
3b. 
However, the appearance of putative proteolytic receptor 
fragments D1 and D2, at apparent molecular weights slightly 
(± 20 kDa) lower than the mature receptor and slightly 
(±10 kDa) greater than the precursor receptor, respectively, 
was observed in immunoprecipitates from FH3a and 3b cells. 
Lehrman et al. (37) and Kozarsky et al. (93) have identified 
degradation products of the normal LDL receptor with 
apparent molecular weights of 125 kDa in fibroblasts and 118 
kDa in Chinese hamster ovary cells, respectively. These 
fragments were detected by antibodies to the C-terminal 
region of the receptor, and were not recognized by IgG-C7 
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(37) or another antibody directed against the N-terminal 
domain of the receptor (93), thus suggesting that these 
degradation products had been formed by proteolytic removal 
of an N-terminal fragment. Casciola et~. (73) identified 
a putative high molecular weight (120 kDa) degradation 
intermediate using a polyclonal antibody to the LDL 
receptor, although this fragment was not detected by IgG-C7. 
Since the degradation products observed in FH3a and 3b were 
detected by IgG-C7, they cannot correspond to the above 
receptor fragments. However, Lehrman et~. (36) identified 
a fragment, slightly larger than the precursor receptor, 
that was specifically immunoprecipitated by IgG-C7, from 
fibroblasts of a normal subject, homozygote FH274, and his 
heterozygous parents. The band obtained in FH3a and 3b 
approximately 10 kDa above the precursor position (D2) may 
represent a similar fragment. A band at this molecular 
weight was also observed periodically in normal cells in 
these studies. 
The only precedents for N-terminal, IgG-C7-recognisable, 
fragments of slightly lower molecular weight than the mature 
form of the receptor, are those which are secreted from 
cells into the medium, as found by Kozarsky and co-workers 
for 0-linked sugar-deficient receptors (66) and Lehrman et 
al. (36) for the secreted form of the truncated receptor in 
FH274. It seems unlikely that the fragments in FH3a and 3b 
which migrate at approximately 20 kDa smaller than the 
mature receptor (Dl) have lost a C-terminal fragment, as 
they would then be expected to lack the membrane-spanning 
region and be secreted as for the abnormal receptors 
described above (36,66). One possible explanation is that 
proteolysis of the mutant receptors may cleave the receptor 
molecules at a site in the N-terminal region, but that 
inter-repeat disulphide bonding, possibly abnormal, 
maintains the receptor "intact", including the first 
cysteine-rich repeat at the N-terminus, containing the 
epitope for IgG-C7 (29). After immunoprecipitation, the 
disulphide bonds of the receptor are reduced prior to 
143 
electrophoresis, and, at this stage, the N-terminal fragment 
could be lost. 
Alternatively, fragment D1 may represent receptors which 
have lost a C-terminal fragment (including the membrane-
spanning region) by proteolysis in intracellular vesicles, 
such as endosomes, which have been shown to contain certain 
proteolytic enzymes (140,141). If such a proteolytic step· 
affected all endocytosed mutant receptors, thus converting a 
large percentage of the receptor population to the 
proteolyzed form trapped in intracellular vesicles, and if 
this form were then degraded rather than "recycled" and 
secreted, this could explain why the N-terminal fragment 
could be detected in cell lysates and was not found as a 
secreted form of the receptor. 
The site(s) and mechanisms(s) for the 
degradation in FH3a and 3b, like that of 
rapid receptor 
the normal LDL 
receptor, remain obscure. Some lines of evidence suggest 
that the LDL receptor in normal cells is degraded by a non-
lysosomal mechanism (Casciola, L.A.F •• et~., manuscript in 
preparation) which may involve a short-lived mediator 
protein (73) since inhibition of protein synthesis by 
cycloheximide dramatically inhibits receptor degradation. 
Lysosomotropic agents, such as ammonium chloride, do not 
inhibit normal LDL receptor turnover. In the presence of 
ligand (LDL), these agents actually lead to a marked 
acceleration of degradation, ·presumably because of receptor 
trapping by inhibition of acid-dependent ligand dissociation 
(see section 2.2.9), similar to that observed when the EGF 
precursor-like region of the receptor is deleted (31). In 
contrast, lysosomal inhibitors which raise intravesicular 
pH, cause partial inhibition of the rapid degradation in 
FH3a and 3b (section 4.2.8). This suggests that 
proteolysis in the lysosome or in the acidic endosome 
(140,141) may play a role in turnover of the mutant 
receptors. 
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It is not known whether degradation of the mutant receptors 
in FH3a and 3b is mediated by . a short-lived mediator 
protein, as for the normal LDL receptor (73). Since the 
receptors in FH3a and 3b are themselves short-lived, 
inhibition of synthesis of another rapidly turned-over 
protein may not have a dramatic effect on their short half-
life. No evidence for any effect of cycloheximide on 
receptor degradation in FH3a was obtained in a preliminary 
experiment (not shown). 
Since the site(s) of rapid degradation and the molecular 
defect in the mutant FH3a and 3b receptors have not yet been 
elucidated, the reason for the short half-life of the 
receptor protein is open to speculation. The mutation may 
create a new site for protease activity or may lead to an 
abnormal protein conformation that renders the protein more 
susceptible to pr-oteolysis. The r-etarded post-
translational tr-ansport and processing of the mutant 
receptor-s suggest that they ar-e abnor-mally folded (78-80). 
Recycling of LDL receptors may require a relatively stable 
str-uctur-e to allow r-epeated passage thr-ough the acidic 
endosome without irreversible denaturation of receptors 
taking place ( 3) • The mutant r-eceptors in FH3a and 3b may 
have a mutation which renders their structure unstable to 
continual recycling and r-esults in rapid degradation (139). 
Although relatively little is known about the turnover of 
membr-ane r-eceptors, it is believed that receptor-s which do 
not recycle in the presence of ligand, such as those for EGF 
and insulin, and the macrophage Fe receptor-, are degr-aded in 
the lysosome along with ligand (130). These receptors 
therefore have half-lives of appr-oximately 1 to 2 hours, 
similar to those of endocytosed ligands. Receptors which 
r-ecycle on the other hand, have relatively long half-lives, 
between 10 and 80 hours (130). It is therefore interesting 
to note that the t~ of less than 2 hours for mature LDL 
r-eceptors in FH3a and 3b would be typical for a receptor 
which did not recycle, in contrast to the half-life of 12 
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hours for the normal, recycling LDL receptor (73,129). 
Similarly, typical "non-recycling" t~ values have been· 
observed for (i) a site-directed mutant LDL receptor 
(lacking the EGF precursor-like region) which is unable to 
undergo acid-dependent dissociation of bound ligand, and is 
therefore rapidly degraded (31) and thus does not recycle 
(ii) mutants RI and TD, which lack part of the EGF-
precursor-like region (discussed earlier), and (iii) the 
normal LDL receptor in the presence of LDL and ammonium 
chloride, which is degraded with a t~ of about 2 hours, 
presumably because of intracellular receptor trapping by 
inhibition of acid-dependent ligand dissociation (section 
2.2.9). The appearance in FH3a and 3b cells of an N-
terminal, IgG-C7 recognisable fragment (Dl) of slightly 
lower molecular weight than the mature LDL receptor may 
represent a prelysosomal, proteolytic product which would 
not be recycled but, having lost its membrane-spanning 
region, be segregated from recycling components, as for 
dissociated ligand, and possibly delivered eventually to the 
lysosome for degradation. This possibility is purely 
speculative, but should be considered in future work. 
Elucidation of the mechanism for the rapid degradation of 
the LDL receptor in FH3a and 3b cells will provide valuable 
information on how a small mutation converts a ·recycling 
receptor, with a relatively long half-life, to one which is 
rapidly degraded, with a much shorter half-life, and thus 
possibly does not recycle. 
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5.1 Introduction 
Analysis of LDL receptor activity in cells 
homozygotes from 17 Afrikaner kindreds 
predominance of a "receptor-defective" type 
(98,103). The receptor-defective subjects 




divided into two groups: "low" receptor-defective (1% to 10% 
of normal receptor activity) and "high" receptor-defective 
(11% to 25% of normal). FH siblings la and lb exhibited 
the highest LDL receptor activity (25% normal) in the latter 
category and clinical symptoms typical of the homozygous 
state of FH i.e. plasma cholesterol concentrations greater 
than 14.3 mmol/1 and the presence of xanthomata in their 
first decade of life (103). No signs of coronary heart 
disease were shown by FHla or lb at ages of 14 and 11 years, 
respectively. 
Haplotype analysis on the basis of 10 
restriction sites (section 3.2.1) showed that 
polymorphic 
FHla and lb 
were true genetic homozygotes for a specific mutant allele 
represented by haplotype 3. This haplotype accounted for 
approximately 65% of the mutant alleles analyzed from 
Afrikaner FH subjects (Leitersdorf E, Hobbs H H, et al., 
manuscript in preparation) thus representing a prevalent, 
possibly founder, mutation in this population. Since FHla 
and lb expressed relatively high levels of the mutant 
receptor encoded by the allele associated with haplotype 3, 
the phenotypic expression of this mutation could be studied 
in these subjects, without interference from another normal 
or mutant allele. 
Preliminary phenotypi.c studies on several homozygous FH 
subjects (including FHla) suggested that haplotype 3 was 
associated with severely impaired post-translational 
receptor transport and processing (Class 2 mutation) and 
defective LDL binding (Table 3.1, section 3.2.1). "Class 
2", or transport-deficient LDL receptor mutants 
these are pbtentially of great cell biological 





receptor protein, such as small deletions or substitutions, 
preserving recognition by antibodies, and, to some extent, 
ligands, but disrupting transport from the endoplasmic 
reticulum to the Golgi apparatus, a complex and poorly-
understood process. In order to gain information on the 
characteristics of, and mechanisms responsible for, the 
delayed transport and reduced receptor level and function, 
the phenotypic expression of the mutation represented by 
hap1otype 3 was studied in fibroblasts from the genetically-
homozygous siblings FHla and lb. 125 1-LDL and 12 5 I-IgG-C7 
binding and metabolism were used to characterize surface 
receptor activity in terms of affinity and maximum levels, 
and how these levels changed during up- and down-regulation. 
LDL receptor synthesis, post-translational processing and 
degradation rates were determined using [35s]-methionine 
pulse-chase studies· and glycosylation of the precursor and 
mature receptors was characterized using glycosidic enzymes 
and glycosylation inhibitors. 
5.2 Results 
5.2.1 LDL receptor activity 
Previous assessments of LDL receptor levels in homozygous 
siblings FHla and lb were based on 125 I-LDL binding and 
metabolism at 37°C at non-saturating LDL concentrations (10 
µg/ml) (103). The possibility thus existed that the 
apparently reduced levels (relative to normal) of LDL 
receptor activity in these subjects could represent somewhat 
higher levels, of binding-deficient receptors. This was 
suggested by the higher proportion of antibody (IgG-C7) 
versus ligand (LDL) binding at 4°C observed for FHla (103). 
Therefore, LDL receptor activity in fibroblasts from FHla 
and lb was characterized on the basis of affinity and 
maximum binding levels for 125I~LDL and 125I-IgG-C7 at 4°C, 
and in terms of the biological activity of these receptors 
at 37°C in binding, and subsequent internalisation and 
degradation, of ligand and antibody. 
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s.2.1.1 Surface binding activity of 125 I-labelled LDL and 
125!-labelled IgG-C7 at 4°C 
Surface LDL receptors in normal, FHla and FHlb cells were 
characterized by 125 r-LDL and 125 I-IgG-C7 binding at 4°C. 
The results of a typical experiment are shown in Figure 5.1. 
125!-LDL binding to cells from FH1a showed a binding 
affinity (mean ± S.D., n=3) for LDL (Kd = 2.2 ± 0.9 µg/ml) 
which was similar to that of normal controls (Kd = 1.5 ± 0.8 
µg/ml), whereas the maximum number of receptors in up-
regulated cells, as assessed by high-affinity LDL binding, 
/ 
was approximately 20% of normal (Figure 5.l(a) and Table 
5.1), in agreement with previous findings (103). 
Surface LDL receptors were also assessed on the basis of 
high-affinity binding of the monoclonal antibody, IgG-C7. 
This antibody recognizes an epitope distinct from the LDL 
·binding site, in the first cysteine-rich repeat of the N-
terminal binding 
125 I-IgG-C7 to 
domain (29). High-affinity binding of 
FH1a cells showed a significantly greater 
number of receptors (approximately 80% of normal) than found 
for l2 5 r-LDL binding, with an affinity for IgG-C7 similar to 
normal (Figure 5.1(b)). As shown in Table 5.1, in 6 
separate experiments, the 125 I-labelled IgG-C7 binding to 
FH1a cells (54 ± 14% [mean ± S.O.] of receptor-normal 
controls) was 3.2 ± 0.4 times higher than the 125 I-labelled 
LDL binding (17 ± 3% of normal). Similarly, in two separate 
experiments, FH1b yielded values for IgG-C7 binding of 3.2-
fold and 3.3-fold higher than LDL binding, respectively. 
Total binding was always corrected for non-specific, low-
affinity values obtained in the presence of excess 
unlabelled ligand or antibody, or calculated by non-linear 
regression of concentration curves. Non-specific values 
were similar for normal and FH1a or FH1b cells and 
represented 10 ± 4% of total 125 I-LDL binding, and 13 ± 4% 
of total l25I-IgG-C7 binding, in normal cells in 10 
different determinations. Specificity of the high-affinity 
component was indicated by the fact that down-regulation of 
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Figure 5.1 Surface binding at 4°C of 125 I-labelled LDL and 
125r-labelled IgG-C7 to normal and FHla 
fibroblasts. 
Cells from a normal subject (I) and FHla (0) were analyzed 
for cell-surface binding at 4°C of 125 I-labelled LDL (a) or 
125!-labelled IgG-C7 (b) as described in section 2.2.5. 
Each value repre~ents the average of duplicate incubations 
from a typical experiment. The Ka values for 125 I-labelled 
LDL in normal and FHla cells were 2.4 and 3.0 µg of LDL 
protein/ml respectively. Maximum high-affinity binding of 
125r-labelled LDL in normal and FHla cells was 237 and 54 
(23% of normal) ng/mg of cell protein respectively. 
Maximum high-affinity binding of 125 I-labelled IgG-C7 was 41 
and 33 (80% of normal) ng/mg of cell protein, respectively. 
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Table 5.1 LDL receptor activity in FHla cells as a 
percentage of normal at 4°C and 37°C, assessed 
using 1 25I-LDL and 125 I-IgG-C7 (Overleaf) 
After incubation for 48 hours (or 24 hours, experiment 5) in 
lipoprotein-deficient medium, each cell monolayer received 2 
ml (37°C) or 1.5 ml (4°C) of medium containing 125 I-LDL (7 
µg/ml at 4°C, 10 µg/ml at 37°C) or 125I-IgG-C7 (1 µg/ml at 
4°C, 5 µg/ml at 37°C). After 2 hours at 4°C or 4 hours at 
37°C the amount of 125 I-LDL and 125 I-IgG-C7 bound (4°C) or 
cell-associated and degraded (37°C) were determined. High-
affinity values were determined by subtraction from total 
values of the values obtained in the presence of excess 
unlabelled LDL or IgG-C7, or, for IgG-C7 at 37°C, by 
subtracting the values obtained for sterol-treated cells 
(down-regulated by incubation with 1 µg/ml 25-
hydroxycholesterol and 12 µg/ml cholesterol for 48 hours) or 
for receptor-negative cells (FH3b, experiment 9). In 
experiment 10, 80 µg/ml 125 I-LDL and 30 µg/ml 125 I-IgG-C7 
were used for the assays at 37°C. *125r-~-VLDL was also 
used to assess LDL receptor activity in experiments 5 (4°C) 
and 9 (37°C). The value for suramin-releasable 125 r-~-VLDL 
binding at 4°C in experiment 5 was 34% of normal, and the 
values for cell-associated and degraded 125 r-~-VLDL at 37°C 
in experiment 9 were 54% and 31% of normal, respectively. 
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receptor by sterols (18) decreased total binding of 
or 12 5 I-IgG-C7 by an amount equal to the high-
affinity binding, i.e. down to 10% and 13% of total binding, 
respectively (data not shown). 
In all experiments with cells from FHla or lb, the maximum 
high-affinity binding of IgG-C7 was several-fold higher than 
that of LDL. The results suggest the presence in FHla and 
lb of one receptor population, comprising about 20% of the 
normal number of fully active receptors possessing normal 
high affinity for LDL, and a second, consisting of inactive 
receptors which fail to bind LDL, but which can nevertheless 
be recognized immunologically by IgG-C7. Th~s would explain 
the disproportionately high IgG-C7 versus LDL binding 
observed previously for FHla and other homozygous FH 
subjects believed to carry the same haplotype (see Table 
3 • 1 ) • 
Further evidence supporting the existence of an abnormal 
population of receptors in FHla cells was obtained from the 
binding, at 4°C, of an additional ligand, 125 r-labelled i-
VLDL. i-VLDL, which binds to the receptor via apoprotein 
E, has been shown to have less stringent requirements of 
receptor structure for binding (28,31). As described in 
the legend to Table 5.1 (Exp. 5), FH1a cells bound a higher 
proportion of 125 r-i-VLDL (similar to 125 I-IgG-C7 binding) 
than 125r-labelled LDL at 4°C, suggesting that the abnormal 
receptors were able to recognize i-VLDL. 
Since FH1a and lb are homozygous for a single type of mutant 
allele, represented by haplotype 3, the results suggest that 
the same receptor protein is present in two forms, an active 
species, which binds LDL, and an inactive form, recognized 
by IgG-C7 (and i-VLDL). This differs from the idea, 
originally proposed by Goldstein, Brown et al. (3), that in 
class 2 variants, the slowly-processed receptors which 
eventually reach the surface constitute a homogeneous 
receptor population which binds LDL "inefficiently". FHla 
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and lb appear to express a functionally heterogeneous 
surface receptor population, consisting of the two for~s 
described above. 
5.2.1.2 Binding and metabolism of 12 5r-labelled LDL and 
125I-labelled IgG-C7 at 37°C 
When LDL receptor activity in FHla was assessed on the basis 
of 12 5 r-LDL binding and metabolism at 37°C, approximately 
20% of normal activity was observed (Table 5.1) with a 
normal affinity for LDL (see Figure 5.2,A and B). Mean 
apparent Kd values (± S.D.) from 3 experiments in normal 
cells were 6.9 ± 0.8 µg/ml for cell-associated (bound plus 
intracellular) 125 I-LDL, and 5.0 ± 1.7 µg/ml for degraded 
125r-LDL. FHla cells yielded apparent Ka values of 7.7 ± 
1.0 µg/ml and 9.0 ± 1.8 µg/ml for cell-associated and 
degraded 125 I-LDL, respectively. Similar results were 
obtained for FHlb (not shown). 
FHla cells bound and metabolized 30 to 40% of.the normal 
level of 125 I-IgG-C7 at 37°C (Table 5.1) with an affinity 
similar to normal (see legend to Figure 5.2). The amount 
of 125 r-IgG-C7 cell-associated (bound and intracellular) by 
FHla cells was 1.8 ± 0.2 (mean± S.D.) times the amount of 
cell-associated 125 r-LDL (relative to normal), while the 
ratio of degraded 125 I-IgG-C7 to 125 r-LDL was 1.5 ± 0.2, 
compared to the ratio for 4°C binding of 3.2 ± 0.4. Thus, 
the same level of active LDL binding receptors as at 4°C was 
observed, but the apparent activity of the IgG-C7-
recognizing receptors was diminished relative to. that 
measured at 4°C. This was well-demonstrated in experiment 
6 (Table 5.1) where assays at 4°C and at 37°C were performed 
in the same experiment. 
One possible explanation for the apparently lower IgG-C7 
binding and metabolism at 37°C versus the binding activity 
at 4°C in experiments 1 to 9 is that, if FHla receptors have 
a lower affinity for IgG-C7 than normal at 37°C, estimation 
of the receptor level versus normal at a non-saturating 
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Figure 5.2 Cell-associated and degraded 125 r-LDL and 125 r-
IgG-C7 at 37°C as a function of concentration in 
normal and FHla fibroblasts. 
After incubation for 48 hours in lipoprotein-deficient 
medium, each cell monolayer received 2 ml of medium 
containing the indicated concentrations of 125 I-LDL (385 
cpm/ng) [A and BJ or l25r-IgG-C7 (854 cpm/ng) [C and DJ. 
After incubation for 5 hours at 37°C, the amounts of cell-
associated (surface-bound plus intracellular) [A and CJ and 
degraded [Band D] 12 5I-LDL and 125 I-IgG-C7 were determined. 
The data are averages of duplicate determinations from a 
typical experiment and represent high-affinity values 
calculated by subtracting non-specific values, determined 
from cells which had been down-regulated by incubation for 
48 hours in the presence of 1 µg/ml 25-hydroxycholesterol 
and 12 µg/ml cholesterol, from total values. The Ka values 
(calculated by non-linear regression) for cell-associated 
and degraded 125 r-LDL were 6.2 and 5.4 µg/ml, respectively, 
for normal cells, and 8.4 and 8.9 µg/ml, respectively, for 
FHla cells. The Kd values for cell-associated 125 I-IgG-C7 
were 14.4 and 14.3 for normal and FHla fibroblasts, 
respectively, and were 15.6 and 12.5 for 125 I-IgG-C7 
degradation in normal and FHla cells, respectively. The 
maximum levels of cell-associated and degraded 125 I-LDL for 
FHla cells were 21% and 31% of normal values, respectively, 
while those for cell-associated and degraded 125 I-IgG-C7 
were 37% and 35% of normal, respectively. 
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concentration (5 µg/ml) could be falsely low. However, LDL 
receptors in FHla cells showed a similar IgG-C7 affinity to 
normal at 37°C (Figure 5.2, C and D), and when saturating 
concentrations of 125 I-LDL and 125 I-IgG-C7 were used at 37°C 
(Experiment 10, Table 5.1), the amount of l2 5 I-IgG-C7 cell-
\ 
associated in FHla cells (as a percentage of normal) was 2.1 
times the amount of cell-associated 125 !-LDL, while the 
ratio of degraded 125 I-IgG-C7 to 125 !-LDL was 1.6. (In the 
same experiment, the ratio of 125 I-IgG-C7 to 125!-LDL 
binding at 4°C was 2.6). The ratios at 37°C agree well 
with those obtained at non-saturating IgG-C7 concentrations 
in experiments 6 to 9. 
Since the amount of ligand or antibody that is cell-
associated (bound and intracellular) or degraded at 37°C 
depends both on the number of receptors and their functional 
ability to internalise and recycle, the difference in the 
results at 4°C and 37°C suggests that, although the abnormal 
receptors bound IgG-C7 (but not LDL), their subsequent 
internalisation and, as a result, degradation of IgG-C7 was 
inefficient. The LDL internalisation index 
(intracellular+degraded / bound[heparin-releasable]) for the 
LDL binding receptor population in FHla was previously shown 
to be normal (103). A similar internalisation index for 
IgG-C7 (i.e. for normal plus abnormal FHla receptors) cannot 
be determined, as there is no satisfactory method for 
distinguishing surface-bound from intracellular IgG-C7. 
The abnormal receptor population in FHla cells was also able 
to bind and metabolize l2 5 r-labelled 8-VLDL at 37°C, as 
shown by the higher level of cell-associated and degraded 
12 5 r-8-VLDL (similar to 125 I-IgG-C7) relative to that for· 
1251-LDL (see legend to Table 5.1, experiment 9). 
5.2.2 LDL receptor synthesis rates 
Studies of LDL receptor activity in FHla and lb (section 
5.2.1) showed that although functional LDL receptor levels 
were 20% of normal values, the actual amount of 
160 
Table 5.2 LDL receptor synthesis rates in normal, FHla and 
FHlb fibroblasts 
[ 35s]-methionine incorporation rates into immunoprecipitable 
LDL receptors and transferrin receptors and into total 
trichloroacetic acid-precipitable protein were determined in 
experiments 1 and 2 as described in the legend to Table 4.3. 
See Figure 5.13A for results of another experiment comparing 
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immunologically-detectable receptor protein in these cells 




LDL receptor synthesis rates to this 
receptor level was 
of [ 35s]-methionine 
assessed by measuring 
incorporation into 
immunoprecipitable LDL receptors (120 kDa precursor + 160 
kDa mature), relative to synthesis of total trichloroacetic 
acid-precipitable protein and immunoprecipitable transferrin 
receptor synthesis. The results in Table 5.2 show that LDL 
receptor synthesis rates in FHla or lb were always within 
10% of the normal range (shown in experiment 1 ) • 
Furthermore, LDL receptor synthesis rates were similar to 
normal at all levels of upregulation (see Figure 5.13A). 
Thus, the synthesis rates in FHla and lb cells were not 
sufficiently reduced relative to normal rates to account for 
the 50% lower surface LDL receptor levels. 
5.2.3 Biosynthesis and processing of LDL receptors 
The LDL receptor is synthesized in the endoplasmic reticulum 
as a precursor, with an apparent molecular weight of 120 
kDa, that is transported to the Golgi apparatus, where 
carbohydrate processing reactions convert the receptor to 
the mature form, with an apparent molecular weight of 160 
kDa (section 1.3). In normal cells, this conversion takes 
place with a half-time of approximately 15 minutes (see 
Figure 3.1A). However, preliminary biosynthetic studies on 
FHla cells showed a marked delay (t~ greater than 5 hours) 
in processing, and hence in transport to the Golgi, of the 
LDL receptor precursor (Figure 3.1C and Table 3.1). 
Post-translational processing of newly-synthesized receptors 
in normal, FHla and FHlb cells was compared. Fibroblasts 
were induced for LDL receptor synthesis by incubation for 18 
hours in lipoprotein-deficient medium, and then pulse-
labelled for 2·hours with c35s]-methionine, followed by 
chase periods of one to nine hours. 35S-labelled LDL 
receptors were then immunoprecipitated and analyzed by SDS-
polyacrylamide gel electrophoresis (5-20% acrylamide) and 
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fluorography. The results obtained by densitometric , 
scanning of the fluorograms are shown in Figure 5.3. In 
normal cells, complete conversion of the precursor (120 kDa) 
to mature (160 kDa) LDL receptors had taken place by the end 
of the one-hour chase period (Figure 5.3(a)). However, this 
maturation process, indicating rate of transport to the 
Golgi complex, was severely retarded in FHla and lb (Figures 
S.3(b) and ( C ) ) • The half-time for processing in these 
cells was approximately S hours, and complete conversion to 
the mature forms required longer than 9 hours. FHla and 
lb therefore have LDL receptor mutations typical of Class 2 
variants, 
(19,77). 
i.e. ten-fold slower processing than normal 
Pronase digestion of intact FHla cells was carried out after 
a 4-hour chase period (approximately equal amounts of 35s-
label in precursor and mature. bands) to differentiate 
surface, Pronase-sensitive, LDL receptors from intracellular 
Pronase-resistant receptors. As was shown in Figure 4.6, 
p.127,for normal and FH3b cells, all the 35s~labelled mature 
receptor in FHla cells was susceptible to Pronase digestion 
and thus on the cell surface, whereas the long-lived 
precursor was Pronase-resistant and therefore remained 
intracellular (results not shown). This result suggests 
that although conversion to the mature form, and thus 
transport of receptors from the endoplasmic reticulum to the 
Golgi complex, 
was complete, 
was severely retarded, once the maturation 
subsequent transport to the cell-surface was 
rapid, since no intracellular (!-~· pronase-resistant) pool 
of mature receptors was detected. 
The initial amounts of 35 s-label in the total LDL receptors 
after one hour of chase was the same in normal, FHla and 
FHlb cells in the experiment shown in Figure 5.3, consistent 
with the essentially normal synthesis rates observed in 
these mutants (section 5.2.2). However, after~ hours of 
chase, the total receptors in FHla and lb contained only 
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Figure 5.3 Processing of LDL receptors in fibroblasts from a 
normal subject (a), and from FHla (b) and FHlb 
l£1· 
Upregulated fibroblasts from a normal subject (a) and from 
FHla (b) and lb (c) were pre-incubated for 30 minutes at 
37°C in methionine-free EMEM/LPDS and then pulse-labelled 
with ( 35SJ-methionine (30-40 µCi/ml) for 2 hours at 37°C. 
The medium was then changed to DMEM/LPDS containing 200 µM 
unlabelled met~ionine and the fibroblasts were incubated at 
37°C for various chase times. 
and solubilized, and 
The cells were then washed 
35s-labelled receptors 
immunoprecipitated and subjected to SDS-polyacrylamide gel 
electrophoresis (5-20% acrylamide) and fluorography. The 
35 s-radioactivity in the 120 kDa precursor (0) and 160 kDa 
mature (.) fluorographic bands was quantified by 
densitometric scanning and is expressed as a percentage of 
the maximum 35S-incorporation into total LDL receptors. 
The data points are averages of duplicates. In normal 
cells, complete conversion of precursor to mature receptors 
had occurred by the first chase point (1 h). (See Figure 
3.18 for fluorogram of processing in FHla, and Figures 3.1A 
(fluorogram) and 4.1 (a) 
normal cells). 
(quantitation) for processing in 
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receptors, suggesting abnormal receptor degradation. This 
is discussed later in the light of the measured half-life of 
the mature receptors in FH1a and lb (section 5.2.4.1). 
The electrophoretic analysis of post-translational 
processing of precursor receptors shown in Figure 5.3 (see 
also fluorogram of FH1a, Fig. 3.lC) was performed in 5-20% 
acrylamide gradients. To achieve better separation in the 
region of migration of the LDL receptor, 5-12% gradients and 
7% acrylamide gels were used. Although 7% acrylamide 
achieved better separation, 5-12% gradients yielded sharper 
bands. 
Analysis of post-translational processing of LDL receptors 
on 7% acrylamide gels (Figure 5.4A)_showed that after a 30 
minute pulse-labelling period for FHla cells and a one-hour 
pulse for normal cells, the apparent molecular weights of 
the normal and mutant precursors were essentially identical. 
The normal cells also showed labelled mature receptor (160 
kDa) due to rapid processing, and both cell types exhibited 
a non-specific contaminant band above 160 kDa found 
frequently in immunoprecipitations in this laboratory and 
others (36,93). Closer examination revealed that in FH1a 
cells, the slowly-processed precursor receptor showed a 
progressive increase in apparent molecular weight with time 
of chase, reaching a maximum apparent increase of 3 to 4 kDa 
after 6 hours of chase, at which stage approximately 80% 
conversion to the mature form had taken place. The 
precursor band also appeared to become more diffuse, and, by 
implication, more heterogeneous, with time. 
A similar 
Figure 5.48 
result was obtained for 
(5-12% acrylamide). 
the experiment shown in 
Comparison of the normal 
precursor band after a one-hour pulse-labelling period, with 
that in FH1a cells after a 2-hour pulse, showed hetero-
geneity in the mutant precursor band, suggesting a number of 
species with molecular weights ranging upwards from 120 kDa. 
When the 2-hour pulse was followed by a 4-hour chase period, 
Figure 5.4 (legend overleaf) 
a, 
a, 
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Figure 5.4 Post-translational processing of LDL receptor 
precursors to mature forms in FHla cells. 
After 16 hours incubation 
fibroblasts from a normal 
incubated for 30 minutes 
then: 
in lipoprotein-deficient medium, 
subject and from FHla were pre-
in methionine-free EMEM/LPDS and 
(A) pulse-labelled at 37°C for 30 minutes (FHla) or 1 hour 
(normal) with [ 35 sJ-methionine (60 µCi/ml ). For FHla 
cells, the medium was then changed to DMEM/LPDS (containing 
200 µM unlabelled methionine) and the cells were incubated 
at 37°C for various chase times. The cells were then 
washed and solubilized. 35 S-labelled LDL receptors were 
immuno-precipitated and subjected to SDS-polyacrylamide gel 
electrophoresis (7% acrylamide) and fluorography. 
(B) pulse-labelled at 37°C with [ 35 sJ-methionine (30 µCi/ml) 
for 1 hour (normal) or 2 hours (FHla) or 2 hours, followed 
by a 4-hour chase period (FHla). 35 s-labelled receptors 
were immunoprecipitated and subjected to SDS-polyacrylamide 
gel electrophoresis (5-12% acrylamide) and fluorography. 
In lane 5, a combination of immunoprecipitates from normal 
cells pulse-labelled for 1 hour, and FHla cells, pulsed for 
2 hours and chased for 4 hours, was run in the same lane to 
illustrate the difference in the size of the respective 
precursor forms. 
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a sharper precursor band was obtained, corresponding to the 
highest apparent molecular weight of the range, thus 
illustrating again the time-dependent increase in apparent 
molecular weight. The difference in apparent molecular 
weight between the precursor in normal cells and the slowly-
processed FHla precursor receptor was evident from the 
combination of immunoprecipitates from normal and FHla 
cells, giving rise to a doublet precursor band (Figure 5.48, 
lane 5). 
In the experiments shown in Figure 5.4, it was not possible 
to clearly distinguish whether or not the small increase in 
apparent precursor molecular weight gave rise to a 
concomitant increase in the molecular weight of the mature 
receptor, since the resolving power of the gel at higher 
molecular weights was not as good as in the region of the 
precursor. 
The normal increase in apparent molecular weight of the LDL 
receptor from 120 kDa to 160 kDa is due to the addition of 
carbohydrate residues to the receptor, and occurs largely 
because of conformational changes induced by the 
glycosylation (see section 1.3). Thus, the small increase 
in apparent molecular weight observed for the mutant 
precursor in FHla may be due to abnormal glycosylation 
and/or conformational changes in the receptor. 
5.2.3.1 N-linked glycosylation of the LDL receptor 
The LDL receptor contains 5 potential sites for asparagine-
or N-linked glycosylation, of which only 2 sites (in the 
EGF-precursor-homologous region see Figure 1.1) are 
glycosylated in the normal receptor (3). Since the other 3 
sites are in the highly-repeated binding domain, where other 
transport-deficient receptors have been shown to have 
mutations (10,23,87), the possibility existed that abnormal 
conformation or unfolding of this region in the slowly-
processed precursor in FHla could lead to abnormal 
glycosylation of these sites, giving rise to the observed 
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increase in molecular weight. Alternatively, N-linked 
oligosaccharides with different, larger structures could be 
attached to the normal glycosylation sites. The role of N-
linked glycosylation in the increase in precursor apparent 
molecular weight in FHla cells was therefore investigated by 
(i) removal of "high mannose" N-linked oligosaccharides from 
the precursor by Endoglycosidase H (section 2.2.12.4) and 
(ii) inhibition of N-linked glycosylation by tunicamycin 
(section 2.2.12.3). Endoglycosidase H treatment of immune-
precipitated LDL receptors from normal and FHla cells (shown 
in Figure 5.5) caused a decrease of approximately 4 kDa in 
apparent molecular weights of the normal and slightly larger 
mutant precursor receptors, by removal of high mannose N-
linked oligosaccharides. However, no discernible effect on 
the difference in apparent molecular weight between normal 
and FHla precursors was observed, since the Endoglycosidase 
H-treated mutant precursor still appeared to be about 3 kDa 
larger than the normal precursor which had been similarly 
treated. Thus, removal of N-linked oligosaccharides did 
not appear to abolish the 
weight of the FHla precursor. 
increased apparent molecular 
Figure 5.6 shows the effects of inhibition of N-linked 
glycosylation by pre-incubation with tunicamycin, on LDL 
receptors in normal and FHla cells. During a 2-hour pulse 
in the absence of tunicamycin, the normal cells synthesized 
both precursor (120 kDa) 
As observed before (Figure 
and mature (160 kDa) 
5.48), after 2 hours 
receptors. 
of 35s-
labelling, a diffuse precursor band was produced in FHla 
cells, apparently containing both newly-synthesized 
receptors of normal molecular weight, and slowly-processed 
precursors of slightly larger apparent molecular weight. 
After a 4-hour chase period, approximately 50% conversion to 
mature receptors had occurred, and only the slowly-processed 
precursors of slightly increased molecular weight remained 
in the precursor band. In the presence of tunicamycin, 
normal and FHla cells both synthesized precursor receptors 
which were approximately 7 kDa smaller than normal. 
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Figure 5.5 Effect of Endoglycosidase H treatment on 35 s-
labelled LDL receptor precursors in normal and 
FHla cells. 
After 16 hours incubation in lipoprotein-deficient medium, 
fibroblasts from a normal subject and from FHla were pre-
incubated for 30 minutes in methionine-free medium, and then 
pulse-labelled at 37°C with 35s-methionine (60 µCi/ml) for 1 






unlabelled methionine (FHla). 
were immunoprecipitated from 
treated in the absence or presence of 
Endoglycosidase Has described in section 2.2.12.4, and then 
subjected to SDS-polyacrylamide gel electrophoresis (5-12% 
acrylamide gradient) and fluorography. Molecular weights 
of receptor bands were determined relative to molecular 
weight standards. The results are from one of two 
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Figure 5.6 Effect of tunicamycin on the post-translational 
processing of the LDL receptor in FH1a and 
normal fibroblasts. 
After incubation for 20 hours in lipoprotein-deficient 
medium, cells from a normal subject (N) and from FH1a were 
pre-incubated in the absence or presence of 10 µg/ml 
tunicamycin for 3 hours at 37°C. The cells were then pre-
incubated for 30 minutes in methionine-free EMEM/LPDS, and 
pulse-labelled with [ 35 sJ-methionine for 2 hours at 37°C, i n 
the absence 
tunicamycin. 
( 40 µCi/ml) or presence (60 µCi/ml) of 10 µg/ml 
After the pulse, some FH1a cells were 
incubated for a chase period of 4 hours in medium containing 
200 µM unlabelled methionine, in the absence or presence of 
tunicamycin. The cells were solubilized and LDL receptors 
were immunoprecipitated and subjected to SDS-polyacrylamide 
gel electrophoresis (5-12% acrylamide gradient) and 
fluorography. Molecular weights of LDL receptor bands were 
determined relative to molecular weight standards. The 
band above the 160 kDa band is a ?on-specific contaminant. 
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Although the precursor band after the pulse-labelling in 
FHla appeared to be less diffuse than in the absence of 
tunicamycin, an increase in molecular weight (± 4 kDa) still 
occurred during the chase period (see faint band in lane 5). 
Processing appeared to be inhibited since there was clearly 
less than 50% conversion to the mature form in FHla cells. 
The N-linked sugar-deficient mature receptors in both cell 
types were 13 to 16 kDa smaller than normal. Since 
inhibition of N-linked glycosylation decreased the apparent 
molecular weight of the mature receptor more significantly 
than that of the precursor, it would appear that maturation 
of N-linked sugars contributes to the anomalously low 
mobility of the mature receptor on SDS-polyacrylamide gels, 
possibly as a result of terminal sialylation of N-linked 
oligosaccharides (see Figure 1.3). Kozarsky et al. (93) 
found that tunicamycin treatment of human fibroblasts 
decreased the apparent molecular weight of the precursor by 
approximately 8 kDa and that of the mature receptor by 10 
kDa. Similar results were obtained by Cummings et al. (32) 
for fibroblasts and A431 cells, and by Davis et~- (33) for 
transfected Chinese hamster ovary cells. 
Thus, removal of N-linked oligosaccharides from the 
precursor receptor in FHla cells, or prevention of N-linked 
glycosylation of the receptor did not abolish the increase 
in apparent molecular weight of the slowly-processed 
precursor. The results suggest that the observed increase 
was not due to abnormal N-linked glycosylation. Therefore, 
the role of 0-linked glycosylation was investigated. 
5.2.3.2 0-linked glycosylation of the LDL receptor 
In other transport-deficient mutant LDL receptors, the 
stalled precursor has been shown to contain N-linked sugars, 
which are added co-translationally, in addition to core 0-
linked sugars, which are added post-translationally, either 
in the endoplasmic reticulum (ER) or in a transitional zone 
between the ER and Golgi apparatus (63,64). Since these 
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are the sites where the blockage of transport of the mutant 
receptors takes place (64), 
linked glycosylation is more 
glycosylation. 
abnormal post-translational 0-
likely than abnormal N-linked 
As shown in Figure 5.7 (last 2 lanes) when normal and FHla 
cells were pulsed for 30 minutes with ( 35 sJ-methionine, the 
newly-synthesized precursors had the same apparent molecular 
weight. However, comparison of a one-hour pulse in normal 
cells with a 2-hour pulse, followed a 4-hour chase period, 
in FHla cells showed an increase in the apparent molecular 
weight of the slowly-processed precursor. No obvious 
increase in molecular weight of the mature FHla receptor 
could be detected, but as previously discussed, this may 
have been due to the lower resolving power of the 
polyacrylamide gel in that particular range of molecular 
weights. Removal of sialic acid residues by neuraminidase 
treatment decreased the apparent molecular weight of the 
mature LDL receptors in both normal and FHla fibroblasts by 
approximately 24 kDa (Figure 5.7), without affecting the 
precursor receptors which do not contain sialic acid. This 
who is similar to the results of Cummings et ~. ( 32), 
showed decreases of 20 kDa in normal human fibroblasts and 
25 kDa in A431 cells, while Kozarsky et E-l• (93) showed a 
decrease of greater than 17 kDa in fibroblasts. 
Subsequent treatment of the desialylated, immuno-
precipitated receptors with 0-glycanase, which liberates the 
disaccharide Gal(~1~3) GalNAc from 0-linked oligo-
saccharides, decreased the apparent molecular weight of the 
normal receptor by 8 kDa and that of the FHla receptor by 14 
kDa, in the experiment shown in Figure 5.7. However, in a 
subsequent experiment, 
weights of both the 
approximately 11 kDa. 
0-glycanase decreased the molecular 
normal 
Thus, 
and FHla receptors by 
it was not clear whether or 
not 0-glycanase caused a greater decrease in the molecular 
weight of the mutant receptor, which would have implied 
abnormal 0-linked glyco~ylation. However, whereas the 
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Figure 5.7 Effect of neuraminidase and 0-glycanase 
treatment on 35 S-labelled LDL receptors in 
normal (N) and FHla fibroblasts. 
After incubation for 16 hours in lipoprotein-deficient 
medium, cells from a normal subject and FHla were pre-
incubated at 37°C for 30 minutes in methionine-free 
EMEM/LPDS, followed by pulse-labelling with [ 35 s]-methionine 
(30 µCi/ml) for 1 hour (normal) or 2 hours followed by a 
chase for 4 hours in medium containing 200 µM unlabelled 
methionine (FHla). Normal and FHla cells were also pulse-
labelled for 30 minutes at 110 µCi/ml. 35 S-labelled LDL 
receptors were immunoprecipitated from solubilized cells and 
then treated in the absence or presence of neuraminidase, or 
neuraminidase followed by 0-glycanase, as described in 
section 2.2.12.2. The immunoprecipitates were then 
subjected to SDS-polyacrylamide gel electrophoresis (5-12% 
acrylamide gradient) and fluorography. Molecular weights 
of receptor bands were determined relative to molecular 
weight standards. The band above the 160 kDa band is a 
non-specific contaminant. 
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precursors from normal and FH1a cells showed a clear 
difference in molecular weight, their corresponding 0-linked 
sugar-deficient mature receptors migrated, in the same 
region of the gel as the precursors, with apparently 
identical molecular weights. This suggests that if the 
fully-glycosylated normal and mutant mature receptors had 
different molecular weights (which could not be 
distinguished because of insufficient resolution), then 
0-linked oligosaccharides from the mature removal of 
receptors had abolished their size difference. 
Unfortunately, a specific inhibitor of 0-linked glycosyl-
ation (such as tunicamycin for N-linked glycosylation) or -an 
enzyme for removal of core 0-linked sugars from the 
precursor is not available to directly test the role of 0-
linked glycosylation in the increase in apparent molecular 
weight of the FH1a precursor. 
It was interesting to note that 0-glycanase treatment of the 
desialylated receptors in both cell types apparently did not 
remove all the 0-linked oligosaccharides, since the 
receptors still migrated with slightly lower mobility than 
the precursors. If all the 0-linked sugars were removed, 
the receptor should contain only two desialylated N-linked 
sugars, and should thus migrate at an apparent molecular 
weight of approximately 100 kDa, as found by Davis et~· 
(33) for the human LDL receptor transfected into receptor-
deficient Chinese hamster ovary cells, or 110 kDa, as found 
by Yoshimura ~t ~· (155) for the endogenous Chinese hamster 
ovary ce·11 receptor. Cummings et al. (32) found that the 
0-linked sugars on the LDL receptor from fibroblasts, but 
not A431 cells, contained an additional monosaccharide 
postulated to be N-acetylglucosamine. Since 0-glycanase is 
unable to remove the· disaccharide of N-acetylgalactosamine 
and galactose if an N-acetylglucosamine substituent is 
present, this could explain why removal of the 0-linked 
sugars from the fibroblast receptor was incomplete. 
0-linked However, the results suggest that the 
oligosaccharides are heterogeneous, since, as shown in 
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Figure 4.7, some remqval occurred and thus some of the 
disaccharides must have been free of substituents. 
The effects of N- and 0-linked glycosylation of the LDL 
receptor on LDL- and IgG-C7 binding activity in normal and' 
FHla cells, are discussed in section 5.2.8. 
5.2.4 Degradation rate of mature LDL receptors 
Although the degradation rate of certain proteins has a 
regulatory function in determining the steady-state level in 
the cell, regulation of LDL receptor expression in normal 
fibroblasts is solely the result of changes in the rate of 
receptor synthesis (73). The steady-state level of surface 
LDL receptors in FHla and lb cells, determined by 125 I-IgG-
C7 binding (section 5.2.1) was approximately 50% of normal, 
although the receptor synthesis rates in these cells were 
not significantly reduced (section 5.2.2). In post-
translational processing studies (section 5.2.3), a more 
rapid loss than normal of 35s-label from LDL receptors in 
FHla cells was observed, suggesting abnormal receptor 
degradation, albeit far less dramatic than in the case of 
the receptor-negative mutants, FH3a and 3b (sections 4.2.3 
and 4.2.4). To further investigate the possibility of 
abnormal receptor degradation rates in FHla and lb, the 
half-life of the mature LDL receptor was determined by 
[ 35SJ-methionine pulse-chase experiments, and from down-
regulation kinetics of surface receptor activity measured by 
125I-LDL and 125 I-IgG-C7 binding. 
5.2.4.1 Half-life of 35 S-labelled mature receptors 
After induction of LDL receptor synthesis by incubation for 
24 hours in lipoprotein-deficient medium, fibroblasts from a 
normal subject, FHla, and FHlb were pulse-labelled with 
c35sJ-methionine and then chased until virtually none of the 
35S-label remained in the slowly-processed mutant 
precursors. This was assumed to be the "zero" chase time-
point, and the rate of disappearance of 35s-label from the 
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Figure S.8 Degradation of 35S-labelled mature receptors in 
cells from a normal subject, FHla and FHlb. 
Fibroblasts from a normal subject, FHla, and FHlb were 
incubated in lipoprotein-deficient medium for 24 hours to 
induce LDL receptor synthesis. The cells were pre-
incubated for 30 minut~s at 37°C in methionine-free EMEM, 
and then pulse-labelled with [ 35 S]- methionine (20 µCi/ml) 
for 4 hours. The medium was then changed to DMEM/LPDS 
(containing 200 µM methionine) and the fibroblasts were 
incubated at 37°C for 11.S hours to ensure that virtually 
none of the 35S-label remained in the precursor band. This 
was assumed to be the "zero" chase time point. After 
sos-subsequent chase periods, immunoprecipitation, 
polyacrylamide gel electrophoresis (5-20% acrylamide) and 
fluorography of 35S-labelled receptors were performed. The· 
35s-label in fluorographic receptor bands was quantified by 
densitometric scanning. The data points are averages of 
duplicates from a single experiment and did not differ by 
more than 10% from the means, except where indicated by the 
error bar. The t~ values (means± S.E.M.) for LDL receptor 
degradation (determined by non-linear regression) were: 
normal' 12.7 ± 1.6 hours, FHla 10.3 ± 2.0 hours, FH1b 10.3 ± 
1.1 hours. 
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its rate of degradation. Non-linear regression (section 
2.2.8) of the data (Figure 5.8) from densitometric scanning 
of the fluorograms yielded t~ values (mean± S.E.M.) of 12.7 
± 1.6 hours for the normal receptor, and 10.3 ± 2.0 hours 
and 10.3 ± 1.1 hours, for FH1a and lb, respectively. 
(These values were confirmed by down-regulation kinetics 
reported in section 5.2.4.2). Thus, the mature LDL 
receptors in FH1a and lb, including both the LDL-binding 
population and the abnormal population which recognized only 
IgG-C7 (discussed in section 5.2.1) were turned over with 
apparently normal half-lives. To confirm 
attempted to measure the degradation rates 
binding and IgG-C7-binding populations 
discussed below (section 5.2.4.2). 
this result, we 
of the LDL-
separately, as 
The fact that the 35S-labelled mature receptors in FH1a and 
lb were apparently 
that the greater 
degraded at normal 
than normal loss of 
rates, suggested 
35 s-label from 
total receptors (120 kDa + 160 kDa) observed during post-
translational processing (Figures 5.38 and C) could be 
due to precursor degradation, as observed for other 
transport-deficient mutant 
computer simulation of the 
FH1a, assuming a half-life 
receptor, showed that the 
receptors (23,82,88). A 
time-course of processing in 
precursors was more rapid 
of 10.3 hours for 
disappearance of 
than c'ould be 





correlation (solid line) with the experimental data points 
(from Fig. 5.3(b)) was generated by assuming that processing 
of precursor to mature receptors took place with a half-time 
of 5.1 hours, while precursor degradation occurred with at~ 
of 7.6 hours. The latter value is approximately 60% of the 
t~ value for the normal LDL receptor, and th~ mature (160 
kDa) receptor population in FH1a cells appeared to reach 
about 60% of the level that it should have, if no precursor 
degradation had occurred (dotted line). Thus, turnover of 
precursor receptors during slow processing may account for 
the lower than normal steady-state level of surface 
·,receptors in FH1a (54 ± 14% of normal) despite normal rates 
I 
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Figure 5.9 Computer simulation of LDL receptor processing 
in FHla cells. 
The data points ·from Figure 5.3(8) (mature 160 kDa (0) and 
precursor 120 kDa (0) LDL receptors) were used for a 
computer simulation of LDL receptor processing. Assuming a 
t~ of 10.3 hours for the degradation of the mature (160 kDa) 
receptor (from results in Figure 5.8), the amounts of mature 
receptor that would be generated if the precursor were 
quantitatively processed to the mature form (dotted line), 
or if processing and degradation of the precursor took place 
(solid line), were determined by fitting a single 
(t~(processing) = 3.3 h) or a double exponential decay curve 
(t~(processing) = 5 .lh, t~(degradation) 
tively, to the precursor data points (0). 
= 7.6 h), respec-
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of receptor synthesis (section 5.2.2) and mature receptor 
degradation. 
5.2.4.2 Degradation rates of the LDL-binding and IgG-C7-
binding receptor populations in FH1a. 
LDL receptor activity in normal and FH1a fibroblasts was 
maximally upregulated by incubation for 48 hours in 
lipoprotein-deficient medium. The cells were then incubated 
in the presence of 40 µg/ml LDL to suppress receptor 
synthesis, and the decline in surface binding activity for 
125 I-labelled-LDL and -IgG-C7, in the absence of synthesis, 
was then determined as a measure of degradation rates of the 
"normal" and "abnormal" receptor populations, respectively. 
As shown in Figure 5.10, the downregulation kinetics of the 
1 2 5r-LDL and 125r-IgG-C7 binding activities, in both normal 
and FH1a cells, were virtually identical. Surface binding 
activity for both LDL and IgG-C7 decreased with a half-life 
of approximately 11 hours, which was consistent with the 
results from [3 5s]-methionine pulse-chase .experiments 
(section 5.2.4.1). At all stages of downregulation, FH1a 
cells bound 3 times more 12 5I-IgG-C7 (60-70% normal) than 
125I-LDL (20-25% normal). [See Table 5.3]. 
Table 5.3 125I-LDL and 12 5I-IgG-C7 binding at 4°C to 
fibroblasts from a normal subject and FH1a 
during downregulation shown in Fig. 5.10 
-----------------------------------------------------------
Normal FH1a 
Down- 125 I-LDL 1251 _ 125 I-LDL % of l25I-IgG-C7 % of 
regu- Binding IgG-C7 Binding: Normal Binding Normal 
lation (ng/mg) Binding (ng/mg) (ng/mg) 
( h) (ng/mg) 
0 215 35 40 19 25 62 
\ 
(100%) (100%) ("100%") ("100%") 
8.7 131 23 22 17 15 65 
(61%) (66%) ( "56%") ("65%") 
20.7 38 7 10 26 5 71 
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Figure 5.10 Do-nregulation kinetics of IgG-C7 and LDL-
binding populations in normal and FHla 
fibroblasts. 
After incubation for 48 hours in lipoprotein-deficient 
medium, each monolayer received 2 ml of medium containing 40 
µg/ml LDL. At zero time and after 8.7 hours and 20.7 hours 
incubation at 37°C, the cells were analyzed at 4°C for cell-
surface binding of 125 r-LDL (407 cpm/ng, 5.5 µg/ml) and 
125 I-IgG-C7 (2812 cpm/ng, 0.8 µg/ml). The data shown from 
a single experiment represent high-affinity values 
calculated by subtracting non-specific values (means of 
duplicates), obtained in the presence of excess unlabelled 
LDL (300 µg/ml) or IgG-C7 (50 µg/ml)? from total values 
(means of triplicates), and are expressed as percentages of 
the values at zero time. The line joins the mean 
percentage values at each time point. 
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Thus, despite their functional differences, the LDL- and 
IgG-C7-binding receptor populations were degraded at the 
same rate, similar to the rate for normal LDL receptors. 
In addition, the results of the downregulation showed that, 
at a receptor level where 125 I-LDL binding in normal cells 
was 20% of the usual upregulated level {as in FHla), 125 r-
IgG-C7 binding to the same cells was also down to 20% of the 
normal level. Thus the higher 125 I-IgG-C7 binding relative 
to 125 I-LDL binding in FHla was not an artifact of low 
receptor levels. 
Whereas the same kinetics for LDL receptor downregulation 
were observed in normal and FHla cells in the presence of 40 
µg/ml LDL, at a level of 10 µg/ml LDL, FHla cells still 
exhibited 60% ~f the upregulated receptor activity even 
after 20 hours of incubation, while normal cells showed a 
similar time-course of downregulation to that observed for 
40 µg/ml LDL (results not shown). LDL receptor activity is 
suppressed in response to cellular cholesterol levels (6-9). 
Goldstein et al. (142) have shown that in cells from an FH 
heterozygote, a 2.5-fold higher LDL concentration than for 
normal cells was required for 50% suppression of the LDL 
receptor level within three days. This was presumably 
because of the diminished rate of delivery of LDL-
cholesterol to the cells via the lower receptor number 
(approximately 50% of normal) in the FH heterozygote cells. 
Consistent with these results, FHla cells required a 4-fold 
higher concentration of LDL (40 µg/ml) to achieve the same 
level of suppression within 20 hours as normal cells at 10 
µg/ ml LDL, because they express only approximately 25% of 
the normal level of LDL-binding receptors. 
5.2.S Phenotypic expression of LDL receptors in cells from 
FH heterozygous subject, ld. 
On the basis of 125 I-LDL binding and metabolism at 37°C, 
cells from heterozygous FH subject, ld (the father of FHla 
185 
and lb) were previously shown to express 60 to 80% of normal 
LDL receptor activities (103), consistent with expression of 
one normal allele, and one mutant allele giving rise to a 
"high-defective" receptor level. Biosynthetic studies, 
using [ 35S]-methionine labelling and immunoprecipitation of 
receptors, showed that subject ld expressed a LDL receptor 
phenotype intermediate between normal and FHla cells (Figure 
5.11). After a 2-hour pulse, approximately 90% of the 35 s-
label was in the mature receptor band in normal cells, and 
after a 1-hour chase period, no label remained in the 
precursor form. In contrast, in FHla cells, the vast 
majority of the label 
band, even after the 
remained in the precursor receptor 
1 hour chase period, only reaching an 
equal distribution between precursor and mature receptors 
after 4 hours of 
the 35S-label was 
chase. In cells from subject 1d, 70% of 
in the precursor after pulse-labelling, 
but within one hour of chase, the mature receptor band 
contained 65% of the label, presumably mainly due to rapid 
processing of the normal gene product. At the end of the 
4-hour chase period, the proportion of 35s-label in the 
mature receptors had increased to 85%, consistent with 
additional slow processing of the abnormal receptors. The 
results suggest that the receptor proteins, produced by the 
normal and mutant alleles in the heterozygous cells, are 
synthesized and processed independently, so that the 
phenotypic expression of the normal allele is unaffected by 
the abnormal allele in the same cell, and vice versa. 
5.2.6 Immunoblotting of solubilized LDL receptors from 
normal, FHlb and FH3b cells. 
The WHHL rabbit produces transport-deficient LDL receptor 
precursors which undergo essentially no processing to mature 
receptors ( 2 3) • Ligand-blotting of solubilized LDL 
receptors from these cells visualized a significant cellular 
precursor pool and no detectable mature receptor pool, in 
contrast to normal cells where at least 90% of the cellular 
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Figure 5.11 Biosynthesis and processing of 35 S-labelled LDL 
receptors in cells from a normal subject, FH 
heterozygote. ld and FH homozygote. la. 
Fibroblasts from a normal subject, FH heterozygote, ld and 
FH homozygote, la, were incubated in lipoprotein-deficient 
medium for 24 hours, pre-incubated for 30 minutes in 
methionine-free EMEM, and pulse-labelled with 
methionine (80 µCi/ml) for 2 hours, at 37°C. Cells were 
harvested after pulse-labelling, or after 1-hour and 4-hour 
chase periods in DMEM/LPDS containing 200 µM unlabelled 
methionine. 35S-labelled LDL receptors were immuno-
precipitated and 
electro-phoresis 
subjected to SDS-polyacrylamide 
(5-12% acrylamide gradient) 
gel 
and 
fluorography. The band above the 160 kDa band is a non-
specific contaminant. 
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receptors were visualized in the mature form (23). Since 
FHla cells exhibited retarded precursor processing and 
approximately 50% of normal mature surface receptor levels, 
the possibility existed of a precursor pool, comparable in 
size to the mature receptor pool, in these cells. The 
precursor receptors in FHla fibroblasts were known to bind 
IgG-C7 (from immunoprecipitation studies) and immunoblotting 
with IgG-C7, followed by detection with 125 I-labelled goat-
anti-mouse IgG, was therefore carried out on normal, FHla 
and FH3b (receptor-negative) cells, to determine whether or 
not FHla cells had a large, 
precursor pool. 
intracellular LDL receptor 
Immunoblotting of receptors from the three cell types, in 
which LDL receptor activity had either been upregulated or 
downregulated for 48 hours, was performed as described in 
section 2.2.13. In normal cells, a distinct band, at a 
molecular weight of 130 kDa, was immunologically detected in 
upregulated, but not downregulated cells (Figure 5.12, lanes 
1 and 2). This corresponds to the molecular weight of the 
LDL receptor under non-reducing conditions ( 161). In 
contrast, in FH3b cells, no receptor band could be detected 
and no difference between up- and down-regulated cells could 
be seen (lanes 5 and 6), consistent with the "receptor-
negative" phenotype of these cells (section 4.2.1). An 
intermediate amount of 130 kDa receptor was observed in FHla 
cells, in addition to a faint band at approximately 92 kDa 
(lane 3), 
(lane 4), 
which was not present in down-regulated cells 
and presumably represented a small, intracellular 
precursor pool, not detected in normal cells. The fact 
that very low levels of precursor receptor, relative to the 
amount of mature receptor, were visualized by immunoblotting 
in FHla cells, lends further support to the idea of 
degradation of the transport-deficient precursors retained 
in the endoplasmic reticulum in these cells (section 
5 • 2 • 4 • 1 ) • 
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Figure 5.12 Immunoblotting of solubilized LDL receptors 
from normal, FHla and FH3b fibroblasts 
After incubation in lipoprotein-deficient medium for 48 
hours in the absence (upregulation) or presence 
(downregulation) of 2 µg/ml 25-hydroxycholesterol, the 
monolayers were washed, scraped from the dishes, collected 
by centrifugation, s:olubilized, and subjected to SDS-
polyacrylamide gel electrophoresis in a 7% acrylamide gel 
under non-reducing· conditions. Proteins and molecular 
weight standards were transferred electrophoretically to a 
Hybond-C nitrocellulose membrane at 100 mA for 16 hat 4°C. 
The membrane was then incubated, as described in section 
2.2.13, with IgG-C7 and 125 I-labelled goat-anti-mouse IgG, 
washed, dried, 
at -70°C. 
and subjected to autoradiography for 3 days 
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If the blotting technique is performed quantitatively, 
particularly in terms of the amount of solubilized cell 
protein electrophoresed, it may be possible, by using both 
immunoblotting with IgG-C7, and ligand blotting with LDL, to 
comparatively demonstrate the small "normal", LDL-binding, 
and much larger "abnormal" IgG-C7 binding, receptor pools in 
FHla (and lb) cells. 
5.2.7 Appearance at the cell-surface of newly-synthesized 
LDL- and IgG-C7-binding receptor populations in FHla 
cells 
It has been shown (section 5.2.4.2) that the LDL- and IgG-
C7-binding receptor populations in FHla cells were degraded 
at the same rates. Although initial receptor synthesis 
rates in FHla and lb cells were shown to be normal (section 
5 • 2 • 2 ) , no information was available on the formation of 
the functionally distinct forms which originate from the 
same newly-synthesized protein. To address this aspect, 
normal and FHla cells, which were growing in medium 
containing 10% foetal calf serum, were incubated for 72 
hours in lipoprotein-deficient medium to upregulate LDL 
receptor activity. During upregulation, initial LDL' 
receptor synthesis rates and 125 r-LDL and -IgG-C7 binding 
were measured to monitor induction of receptor synthesis and 
the appearance of newly-synthesized receptors at the cell 
surface. Upregulation of synthesis rates (Figure 5.13A) 
and receptor levels (Figure S.13B) in FH!a cells followed a 
similar time-course to that in normal cells, reaching 
maximum levels after 48 hours in lipoprotein-deficient 
medium. Throughout the incubation, FHla cells exhibited 
approximately 3-fold higher IgG-C7- than LDL-binding 
activity, suggesting that the abnormal form of the mutant 
receptors predominated even in newly-synthesized surface 
receptors. 
The results of the computer simulation in Figure 5.9 (p. 180) 
suggested degradation of slowly-processed precursor 
receptors with a half-life of approximately 60% of the 
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Figure 5.13 LDL receptor synthesis rates (A) and surface 
expression (8) in normal and FHla cells during 
a 72-hour period of incubation in lipoprotein-
deficient medium. 
Fibroblasts from a normal subject and FHla were seeded (Day 
0) at 1x10 5 cells per 60 mm Petri dish in medium containing 
10% foetal calf serum. Medium was changed on the 3rd day 
and on day 4 was replaced with lipoprotein-deficient medium 
(DMEM supplemented with LPDS at 2.5 mg protein/ml). Medium 
was changed every 24 hours thereafter. LDL receptor 
synthesis rates (A) (arbitrary integration units per mg cell 
protein) were determined (in duplicate) from the amount of 
[ 35sJ-methionine incorporated into IgG-C7-immunoprecipitable 
LDL receptors during a 30 minute pulse-labelling period, and 
are expressed relative to [ 35 s]-methionine incorporation 
into total trichloroacetic acid-precipitable protein (dpm 
35s-label incorporated x 10- 5 ) during the same incubation. 
LDL receptor activity was a~sayed by measuring 125 !-LD~ (260 
cpm/ng) and 125 I-IgG-C7 (460 cpm/ng) binding levels (B) 
after 2 hours at 4°C. The data are averages of duplicates 
from a single experiment~ and did not differ by more than 
12% from the means, and represent high-affinity values 
calculated by subtraction of non-s_pecific binding qbtained 
in the presence of excess unlabelled LDL (300 µg/ml) or IgG-
C7 (50 µg/ml). Non-specific binding was approximately 10% 
of the total bind~ng in normal cells after 47 hours in 
lipoprotein-deficient medium. High-affinity binding values 
(ng/mg cell protein) were normalized to the rate of protein 
synthesis at each time point, taking the rate for normal 
cells at 47 hours to be unity, in order to express binding 
in terms of viable cell protein rather than total protein 
content. Although a decrease in protein synthesis was 
observed after changing from full medium to lipoprotein-
deficient medium, protein synthesis per mg protein between 
12 and 72 hours incubation in the latter medium did not vary 
by more than 10% in normal cells, or by more than 22% in 
FHla cells. 
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normal receptor half-life. Consistent with these results, 
surface receptor levels in FH1a cells at maximum 
upregulation after 48 hours, as assessed by 12 5I-IgG-C7 
binding, were only 70% of normal (Figuri S.13B), although 
initial receptor synthesis rates in FH1a fibroblasts were 
slightly higher than normal (Figure 5.13A). 
S.2.8 Effect of pre-incubation of FHla cells with ammonium 
chloride and LDL on the LDL- and IgG-C7-binding 
receptor populations 
As discussed in section 2.2.9, normal LDL receptors are 
trapped intracellularly in the presence of ammonium chloride 
and LDL, and rapidly degraded. Since this process is LDL-
dependent, it is believed that disruption of endosomal pH by 
ammonium chloride inhibits the acid-dependent dissociation 
of bound LDL, and therefore receptor-LDL complexes are 
trapped and degraded. Because the trapping and degradation 
appear to depend on LDL binding, it was of interest to 
determine the effects of ammonium chloride plus LDL on the 
LDL-binding receptors, and the abnormal receptors that do 
not recognize LDL, in FH1a cells. 
S.2.8.1 Effect of ammonium chloride and LDL on surface 
receptor activity in FH1a cells 
Upregulated fibroblasts from a normal subject and FH1a were 
pre-incubated for 30 minutes at 37°C with 40 µg/ml LDL, 
followed by a one-hour inqubation in the presence of both 40 
µg/ml LDL and 10 mM ammonium chloride. After releasing 
bound unlabelled LDL with heparin, surface receptor activity 
was determined from 125r-LDL or -IgG-C7 binding at 4°C. 
As shown in Table S.4, 125r-LDL-binding in normal and FHla 
cells decreased to approximately 30% of the control value 
after incubation for 1 hour with ammonium chloride (10 mM) 
and LDL (40 µg/ml) presumably because of intracellular 
trapping of undissociated receptor-ligand complexes. 
However, although 125r-IgG-C7 binding decreased by the same 
amount in· normal cells, 60% of the original IgG-C7 binding 
receptors in FHla were detectable at the surface, implying 
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Table 5.4 Effect of ammonium chloride and LDL on 125 I-IgG-C7 
and 125 I-LDL surface binding in normal and FHla 
fibroblasts 
After incubation for 48 hours in lipoprotein-deficient 
medium, fibroblast monolayers from a normal subject and FHla 
were either incubated for 30 minutes at 37°C in the presence 
of 40 µg/ml LDL, or for 30 minutes with 40 µg/ml LDL 
followed by one hour at 37°C in the presence of 40 µg/ml LDL 
plus 10 mM ammonium chloride. After releasing bound 
unlabelled LDL for 40 minutes at 4°C with 0.3% heparin in 
PBS, the cells were analyzed at 4°C for cell-surface binding 
of 125 r-LDL (406 cpm/ng, 6 µg/ml) and 125 I-IgG-C7 (420 
cpm/ng, 0.9 µg/ml). The data shown represent high-affinity 
values calculated by subtraction of non-specific values 
obtaihed in the presence of excess unlabelled LDL (300 
µg/ml) or IgG-C7 (50 µg/ml) from total values. Values are 
means of duplicates from a single experiment. In 3 
separate experiments 125 I-IgG-C7 binding was reduced after 1 
hour with ammonium chloride and LDL to 32±4% (mean± S.D.) 
in normal cells and to 61±4% in FHla cells. 
Cells 125 I-LDL binding {n9Lm9) 125 I-IgG-C7 bindin.2.....JE.2.Lmg) 
30 min 1 h + NH 4 Cl 30 min 1 h + NH 4 Cl 
+ LDL + LDL + LDL + LDL 
Normal 202 74 (37%) 71 24 (34%) 
FHla 50 15 (30%) 31.5 18.5 (59%) 
(25% (20% (44% (77% 
normal) normal) normal) normal) 
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that the majority of these receptors did not bind LDL, and 
were therefore 
chloride. In 
not trapped in the presence of ammonium 
3 separate experiments, 125 I-IgG-C7 binding 
activity in FHla cells showed a significantly smaller 
decrease than in normal cells, after incubation with 
ammonium chloride and LDL (see legend to Table 5.4). These 
results therefore supported the postulate of populations of 
both normal and abnormal receptors in FHla (and lb) cells, 
previously proposed on the basis of 125 I-LDL and 125 I-IgG-C7 
binding curves (section 5.2.1). In addition, the results 
suggested that the LDL-binding population of receptors in 
FHla could 
population. 
function independently of the abnormal 
5.2.8.2 Effect of ammonium chloride and LDL on 35 s-
labelled, IgG-C7 immunoprecipitable receptors in 
FHla cells 
After incubation in lipoprotein-deficient medium to induce 
LDL receptor synthesis, fibroblasts from a normal subject 
and FHla were pulse-labelled with [ 35 s]-methionine, and then 
chased until virtually none of the 35 S-label remained in the 
slowly-processed mutant precursors. This was assumed to be 
the "zero" chase-point. The cells were then pre-incubated 
with 10 mM ammonium ~hloride in the absence or presence of 
40 µg/ml LDL for 3 hours at 37°C (Figure 5.14A). In a 
second experiment (Figure 5.14B), cells were pre-incubated 
for 3 hours in the presence of either no additions, ammonium 
chloride, LDL, or ammonium chloride plus LDL, and, in 
additibn, for 6 hours in the presence of LDL and ammonium 
chloride. 
As shown in Figure 5.14A, incubation of normal cells with 
ammonium chloride and LDL caused a dramatic decrease in the 
amount of 3 5s-labelled mature LDL receptors which could be 
immunoprecipitated, whereas 
chloride alone had no effect. 
the presence of ammonium 
As discusses previously 
(section 2.2.9), this wa• interpreted to indicate that 




ammonium chloride, and therefore rapidly 
However, in FHla cells, only a small decrease in 
the level of IgG-C7 immunoprecipitable mature receptors in 
the presence of ammonium chloride and LDL was observed, once 
again consistent with the idea of a large proportion of 
receptors that do not bind LDL, and are therefore not 
trapped and degraded intracellularly in the presence of 
ammonium chloride. The fact that a small decrease in the 
amount of 35S-labelled receptors was observed (relative to 
incubation with ammonium chloride alone) confirms the 
existence of a small sub-population of receptors which bind 
and internalize LDL normally, and are therefore trapped and 
degraded, as for normal receptors. 
In Figure S.14B, guantitation of the results from a similar 
experiment are shown. Whereas ammonium chloride or LDL 
alone had no significant effect on 35S-labelled LDL receptor 
levels in normal or FHla cells, the combination of these two 
agents caused a dramatic decrease after 3 hours in normal 
35S-labelled receptors, which decreased even further after 6 
hours of incubation. However, even prolonged incubation 
(up to 6 hours) in the presence of LDL and ammonium chloride 
did not cause any dramatic decrease in 35S-labelled 
immunoprecipitable receptors from FHla 
of 35s-label in the receptor band in 
cells. The amount 
FHla cells at "zero" 
time <i·~· "100%") was equal to 51% of that in the normal 
receptor band. After 6 hours in the presence of ammonium 
chloride and LDL, the 35s-label in the FH1a receptor band 
was 2-fold higher than that in the normal receptor band, and 
represented approximately 60% of the original amount at 
"zero" time. Since the t~ for degradation of normal 
receptors trapped in the presence of ammonium chloride and 
LDL is approximately 2 hours, this result suggests that a 
very small proportion of the FH1a receptors was able to bind 
LDL, and subsequently to be trapped and degraded. 
The selective trapping and degradation of only the LDL-
binding receptor population in FH1a cells, demonstrated by 
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Figure S.14 Effect of ammonium chloride and LDL on c35 sJ-
labelled IaG-C7-immunoprecipitable LDL 
receptors in normal and FHla fibroblasts. 
A. After 24 hours incubation in lipoprotein-deficient 
medium, cells from a normal s~bject and FHla were pulse-
labelled for 2.5 hours at 37°C with [ 35 sJ-methionine (30 
µCi/ml) in methionine-free EMEM, followed by a 13-hour chase 
period in medium containing 200 µM unlabelled methionine, to 
ensure that all the labelled receptors in FHla had been 
processed to the mature form. The medium was then changed 
to one containing 10 mM ammonium chloride plus or minus 40 
µg/ml LDL and the cells were incubated for a further 3 hours 
at 37°C. The cells were then washed, solubilized and LDL-
receptors were immunoprecipitated, and subjected to SDS-
polyacrylamide gel electrophoresis (7% acrylamide). 
8. After upregulation in lipoprotein-deficient medium for 
30 hours, normal and FHla cells were pulse-labelled for 3 
hours at 37°C with [ 35sJ-methionine (50 µCi/ml) in 
methionine-free medium, followed by a 13.S hour chase 
period. Duplicate dishes from each cell type were 
harvested and taken to represent the "zero" chase time 
point. The medium was then changed to one containing no 
additions, 10 mM NH 4 Cl, 40 µg/ml LDL, or both 10 mM NH 4 Cl 
and 40 µg/ml LDL, and chased for a further 3 hours at 37°C. 
One set of dishes was chased for 6 hours in the presence of 





the indicated time-points, cells were 
and 35 S-labelled LbL · receptors 
subjected to SDS-PAGE (5-12% 
acrylamide) and fluorography. The amount of 35 S-labelled 
LDL receptor in each sample was quantified by densitometric 
scanning and expressed as a percentage of the amount at 
' 
"zero" time. The results are averages of duplicates except 
those for normal cells at "zero" time, and for FHla cells 
after 3 hours in the presence of NH 4Cl, which are results of 
single determinations. 
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the effects described above of ammonium chloride and LDL on 
35 s-labelled immunoprecipitable receptors, thus provided 
more definitive proof for the existence of 2 surface 
receptor populations~ originally distinguished on the basis 
of ligand and antibody binding (139). 
In the pulse-chase experiments described above, long initial 
chase incubations (> 10 hours) were employed to ensure that 
all the 35S-label was chased from the slowly-processed 
precursor into the mature receptor, before the effects of 
ammonium chloride plus LDL were examined. The effect of 
these agents on newly-synthesized surface receptors was 
investigated by chasing in the presence of ammonium chloride 
and LDL for short periods (3 hours) after pulse-labelling. 
No dramatic selective loss of mature receptors was observed 
(results not 
detectable, 
shown), indicating that the 
processed 
"earliest" 
mature newly-synthesized and 
receptors, which reached the cell-surface in FHla cells, 
were predominantly in the abnormal form which does not bind 
LDL, consistent with the results obtained for newly-
synthesized receptors during up-regulation (section 5.2.7). 
5.2.9 Effect of glycosylation on the LDL- and IgG-C7 
binding populations in FHla 
During the retarded post-translational processing of the LDL 
receptor in FHla cells, an apparent increase in the 
molecular weight of the transport-deficient precursor 
receptor was observed (section 5.2.3), possibly as a result 
of abnormal glycosylation. To establish whether or not 
abnormal glycosylation played a role in the formation of the 
normal and abnormal receptor populations in FHla, the 
effects of N-linked and 0-linked glycosylation on 125 r~LDL 
and 12 5I-IgG-C7 binding activity in normal and FH1a cells 
were determined. 
5.2.9.1 N-linked glycosylation 
The effect of inhibition of N-linked glycosylation by 
tunicamycin on the LDL- and IgG-C7 binding activity in 
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normal and FHla cells was determined after pre-incubation in 
the absence or presence of 1 µg/ml tunicamycin in 
lipoprotein-deficient medium for a 24-hour upregulation 
period. The results in Table 5.5 show that tunicamycin 
treatment decreased LDL-binding activity in normal and FHla 
cells to approximately 40% of control values, and IgG-C7 
binding activity to 60% of control. 
antibddy binding may reflect a decrease 
The decrease in 
in the amount of 
receptor protein, because of inhibition of glycoprotein 
synthesis by tunicamycin (67). The greater relative 
decrease in ligand binding may indicate that N-linked sugar-
deficient receptors had a lower affinity for LDL, so that 
the concentration of 125 I-LDL used in the assay was no 
longer saturating, and thus an apparent decrease relative to 
maximum normal binding levels was observed. Alternatively, 
if the decreased level reflected LDL binding with normal 
affinity, the results would imply the existence of abnormal 
receptors which did not bind LDL, but were recognized by the 
antibody. Since Chatterjee et al. (67) have shown that 
receptors synthesized in the presence of tunicamycin had a 
normal affinity for LDL, the latter explanation seems more 
likely, suggesting that inhibition of N-linked glycosylation 
created a population of abnormal receptors, unable to bind 
LDL, in normal cells. Tunicamycin treatment did not change 
the ratio of the abnormal to "normal" LDL receptors in FHla, 
suggesting that abnormal N-linked glycosylation was not 
responsible for creating the two populations observed under 
normal (fully-glycosylated) conditions. Similarly, it was 
shown that N-linked oligosaccharide~ did not play a role in 
the apparent increase in molecular weight of transport-
deficient precursor receptors in FHla (section 5.2.3.1). 
5.2.9.2 Sialic acid and 0-linked glycosylation 
Since there is no specific inhibitor available to prevent 
the addition of 0-linked oligosaccharides, the approach used 
to examine the role of 0-linked glycosylation in the 
formation of the heterogeneous receptor population in FHla 
cells was to remove 0-linked oligosaccharides from 
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Table 5.5 Effect of tunicamycin treatment on 125 I-LDL and 
I 
125r-IgG-C7 binding at 4°C to normal and FHla 
cells 
On day 4 of cell growth, the medium was changed and the 
cells were incubated for 24 hours at 37°C in the absence, or 
presence of 1 µg/ml tunicamycin • The cells were then 
chilled to 4°C and 125 r-LDL (402 cpm/ng, 5.5 µg/ml) and 
125I-IgG-C7 (809 cpm/ng, 0.8 µg/ml) binding levels were 
determined. The data are means of duplicates from a single 
experiment and represent high affinity values, calculated by 
subtracting the values from dishes that had 1 µg/ml 25-
hydroxycholesterol and 12 µg/ml cholesterol present in the 
medium during the 24 hour incubation, from total binding 
values. The non-specific values for normal cells in the 
absence of tunicamycin represented 11% of total LDL binding 
and 24% of total IgG-C7 binding. 
Cell 125 I-LDL binding 125 I-IgG-C7 binding 
type (ng/mg protein) (ng/mg protein) 
-Tunica- +Tunica- % -Tunica- +Tunica-
mycin mycin mycin mycin 
Normal 341 126 37 34 21 62 
FHla 46 19 41 15 9 60 
(13 % (15% (44% (43% 
normal) normal) normal) normal) 
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"normally"-glycosylated receptors at the cell surface using 
the enzyme, 0-glycanase, after neuraminidase treatment to 
first remove terminal sialic acid residues which interfere 
with the action of 0-glycanase. Neuraminidase treatment 
alone, or followed by 0-glycanase treatment, decreased LDL-
binding and IgG-C7 binding by different relative amounts 
(29-45% and 4-18%, respectively), but to the same extent in 
normal and FHla cells (Table 5.6). Thus, the ratio of 
abnormal to LDL-binding receptors (relative to normal cells) 
was not changed in FHla cells. However, neuraminidase and 
0-glycanase treatment of immunoprecipitated, 35S-labelled 
LDL receptors (section 5.2.3.2) suggested possible 
involvement of abnormal 0-linked glycosylation in the 
increased molecular weight of the slowly-processed receptor 
precursor. The results of the binding assays cannot 
exclude a role for abnormal 0-linked glycosylation in the 
creation of the 2 receptor populations in FHla cells for 2 
reasons: (i) To allow restoration of fibroblast morphology 
after incubation in the acidic medium required for 
neuraminidase and 0-glycanase activity, .measurement of LDL-
and IgG-C7 binding activity were performed after a one-hour 
recovery period during which newly-synthesized, fully-
glycosylated receptors could have masked effects of the 
deglycosylation, and (ii.) studies on 35 s-labelled receptors 
(section 5.2.3.2) showed that, possibly due to heterogeneity 
of substituents, incomplete removal of 0-linked 
oligosaccharides by 0-glycanase occurred. In addition, as 
for tunicamycin treatment, neuraminidase treatment alone, or 
in combination with 0-glycanase, caused a significant 
decrease in LDL-binding activity in normal and FHla cells, 
but virtually no difference in IgG-C7 binding levels. This 
suggests that (as discussed above for N-linked 
glycosylation) unless a difference in receptor affinity for 
LDL is created, defective 0-glycosylation (or defective 
sialylation of both 0- and N-linked oligosaccharides) can 
result in populations of normal and abnormal receptors, as 
observed in FHla cells. 
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Table 5.6 Effect of neuraminidase and 0-glycanase treatment 
on 125I-LDL and 125 I-IgG-C7 binding at 4°C to 
cells from a normal subject and FHla. 
After incubation for 48 hours in lipoprotein-deficient 
medium, cells from a normal subject and FHla were washed 
once with PBS and then incubated for 40 minutes at 37°C in 
the presence of (i) no additions, (ii) 0.1 units of 
neuraminidase (Sigma), (iii) 0.1 units of neuraminidase for 
20 minutes, followed by the addition of 2.5 milliunits of 0-
glycanase for the last 20 minutes. The medium was then 
removed and the cells were incubated in DMEM/LPDS for 1 hour 
at 37°C. The cells were then chilled to 4°C and 125 I-LDL. 
(406 cpm/ng, 6 µg/ml) and l2 5 I-IgG-C7 (420 cpm/ng, 0.9 
µg/ml) binding were determined. The data are means of 
duplicates from a single experiment and represent high 
affinity values calculated by subtracting values obtained in 
the presence of excess unlabelled LDL (300 µg/ml) or lgG-C7 
(50 µg/ml) from total binding values. The non-specific 
values for normal cells represented 12% of total LDL binding 
and 7% of total lgG-C7 binding. (Abbreviations: N'ase = 
neuraminidase; 0-G'ase = 0-glycanase) 
Normal FHla 
Preincu- 125 1-LDL 1251- 125 1-LDL % 1251- % 
bation bound lgG-C7 bound Normal lgG-C7 Normal 
(ng/mg) bound bound 
(ng/mg) (ng/mg) (ng/mg) 
Control · 190 42 55 29 22 52 
(100%) (100%) (100%) (100%) 
+N'ase 105 39 33 31 18 46 
(55%) (94%) (60%) (82%) 
+N'ase 135 41 34 25 20 49 





The mu~ant LDL receptor allele present in the homozygous 
form in FHla and lb, produces a gene product that is 
evidently slowly processed to one of two mature forms, which 
constitute a functionally heterogeneous surface receptor 
population. On the basis of ligand and antibody binding at 
4°C, one population, comprising 20% of the normal number of 
receptors, which bound LDL with normal affinity, was 
distingtiished from a second population (40% of the nor~al 
receptor number) which recognized only IgG-C7, but not LDL. 
Since these two populations are products of a single mutant 
allele, conformational differences may account for their 
functional heterogeneity. Abnormal folding or denaturation 
of receptor precursors may also be responsible for the delay 
in transport and processing. More definitive proof for two 
populations of surface receptors was provided by selective 
trapping and degradation of the LDL-binding population in 
the presence of ammonium chloride and LDL. Studies of 
receptor activity at 37°C suggested that the receptor 
population which recognizes only IgG-C7 does not efficiently 
internalize and degrade surface-bound IgG-C7. This 
functionally abnormal form of the receptor predominates even 
in newly-synthesized receptors, suggesting that an early 
post-translational event inv~lving protein folding and/or 
glycosylation, leads to receptors with the same primary 
sequence appearing on the surface in either the "normal", 
LDL-binding, or abnormal form. Despite their functional 
and, presumably, conformational differences, both surface 
forms of the mutant receptor are degraded at equal rates, 
similar to.degradation rates for normal LDL receptors. 
5.3.2 Synthesis and degradation of mutant LDL receptors 
The regulation of receptor levels in FHla is apparently 
normal. Induction of LDL receptor synthesis by incubation 
in lipoprotein-deficient medium follows a similar time-
course in normal and FHla cells. The kinetics of up-
regulation, and down-regulation in the absence of synthesis, 
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of steady-state receptor levels for both surface populations 
in FHla correspond to those in normal cells. 
Although the initial rates of receptor synthesis in FHla, at 
all stages of up-regulation in lipoprotein-deficient medium, 
and the rates of degradation of both the LDL-binding and 
abnormal receptor p·opulations, are normal, the steady-state 
level of surface receptors in FHla cells is approximately 
55% of normal. The Pronase sensitivity of mature 35s-
labelled receptors in intact cells from FHla implies that 
there is no unusually large intracellular pool of mature 
receptors. Although the newly-synthesized precursor 
receptors in FHla are slowly processed to mature forms, 
Western blotting showed no evidence for a large steady-state 
precursor pool relative to the mature receptor pool. Thus, 
in contrast to normal cells ( 7 3) , it appears that the 
synthesis rate in FHla is not the only factor determining 
the cellular LDL receptor content. One possible explanation 
for the apparent loss of receptors is degradation of 
precursors retained in the endoplasmic reticulum. Support 
for this idea is the more rapid disappearance of 35 s-
labelled precursors, than could be accounted for by 
processing to mature forms with normal degradation rates. 
Degradation of transport-deficient precursors has also been 
proposed for the mutant LDL receptors in the WHHL rabbit 
(23), Lebanese FH subjects ( 88) and FH429 ( 82) • In 
transfected Chinese hamster ovary cells the mutation in 
FH429 produced a protein that was not transported to the 
cell-surface, but degraded intracellularly with a half-life 
of 5 hours, compared to one of 8.5 hours for the normal LDL 
receptor protein. Lippincott-Schwartz et al. (76) have 
recently shown that newly-synthesized proteins which failed 
to meet the structural criteria for transport to the Golgi 
could be rapidly and efficiently degraded by the cell at a 
non-lysosomal 
reticulum. 
site closely related to the endoplasmic 
A similar mechanism may lead to degradation of 
precursor receptors trapped in the endoplasmic reticulum in 
FHla and other transport deficient mutants. 
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5.3.3 The role of protein folding in transport from the ER 
Rothman (79), Lodish (80) and Gething et sl_. (81) propose 
that any mutation that affects protein folding will cause 
retardation in the endoplasmic reticulum, since the 
criterion for transport to the Golgi complex appears to be a 
correct, native protein conformation. The most important 
rate-determining steps in protein folding are disulphide 
bond formation, catalyzed by protein disulphide isomerase 
(60,61) and cis-trans isomerism of prolyl peptide bonds, 
which can give rise to the co-existence of alternative, 
slowly interconverting states of the protein (60). The 
fact that the receptors in FH!a cells are retarded in the 
endoplasmic reticulum and eventually processed to two 
different forms of the receptor is thus strong evidence for 
conformational abnormality of the mutant receptors. The 
mutations in the WHHL rabbit (23), FH563 (10) and subject TT 
(87), which produce receptors exhibiting delayed transport 
to the cell surface, all result from small deletions in the 
cysteine-rich binding domain, and could thus lead to 
incorrect disulphide bonding and protein folding. The 
Lebanese allele produces a 
protein that terminates in 
transport-deficient truncated 
the middle of a cysteine-rich 
"growth-factor" repeat, leaving unpaired cysteines and the 
potential for abnormal disulphide bonding and conformation. 
The mutation in FH429 substitutes a valine for a glycine 
residue in a cysteine-poor region of the receptor· (82). 
The deletions in the WHHL rabbit, FH563 and TT also all 
include glycine residues. Since glycine residues are often 
found in space-restricted regions in proteins, their 
deletion or substitution by larger amino acids could 
potentially disrupt protein conformation, and thus impair 
intracellular receptor transport. Since the mutant 
receptors in FH!a have a normal apparent molecular weight, 
and since the same mutation leads to impaired transport and 
defective LDL binding, the FHla (and. lb) mutation can be 
expected to be a small deletion, insertion or substitution 
in the cysteine-rich binding domain which disrupts the 
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normal conformation required for transport and ligand 
recognition. 
Kreis and Lodish (143) and Machamer and Rose (144) have 
demo~strated temperature-dependence of intracellular trans-
port of vesicular stomatitis virus-G protein mutan~s from 
the endoplasmic reticulum to the Golgi. At temperatures of 
37-39°C, transport was blocked, but lowering the temperature 
to 30-32°C allowed transport to the Golgi, processing, and 
transport to the cell-surface, implying a temperature-
dependent polypeptide folding step. However, pre-incubation 
of FH1a cells for 24 hours at 30°C did not significantly 
change the ratio of abnormal to normal (LDL binding) 
receptors on the surface compared to that seen at 37°C 
(results not shown). There do not seem to be gross 
disulphide-bonding abnormalities in the FH1a receptor since 
the non-reduced receptor, on Western blots (section 5.2.6) 
and electrophoresis of immunoprecipitated receptors (not 
shown), migrates with apparently normal mobility. However, 
subtle alterations in disulphide bonding cannot be excluded. 
Attempts by Esser and Russell (82) to directly demonstrate 
conformational abnormality in the receptor from FH429 by 
means of altered protease sensitivity (81,145,146)' or 
aggregation state (81,145) were unsuccessful. Thus, the 
mutations in FHla and FH429 which lead to impaired transport 
of receptors must cause minor or highly localized 
conformational changes. The mechanism by which denatured 
proteins are retained in the endoplasmic reticulum is 
unknown, but a family of proteins, including immunoglobulin 
heavy-chain binding protein (BiP) (81), have recently been 
shown to interact with conformationally abnormal proteins, 
possibly facilitating correct folding and/or preventing 
export of abnormally folded proteins. No evidence was found 
for BiP association with immunoprecipitated mutant receptors 
in FHla. Esser and Russell (82) have detected variable 
amounts of a protein, migrating with the molecular weight of 
B1P, in immunoprecipitation experiments with various 
transport-deficient LDL receptors. 
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5.3.4 The role of protein glycosylation in receptor 
function and intracellular transport 
Another factor which can affect protein conformation and 
function is glycosylation. In a number of in vitro studies 
(147-150), it has been shown that denatured or unfolded 
proteins can be post-translationally glycosylated at sites 
not normally glycosylated in the native protein. In this 
regard, it is of interest that the stalled precursor in FHla 
showed a progressive, increase in apparent molecular weight, 
suggesting abnormal glycosylation. Similarly, Kozarsky et 
al. (93) have shown that in the experimentally-induced class 
2 mutant, ldlA-7, the slowly-processed precursor is 
continually converted to slightly larger, novel, unstable 
intracellular intermediates. They suggest that the apparent 
increase in molecular weight may be the result of additional 
but incomplete processing of 0-linked oligosaccharides or 
other post-translational modifications. The accelerated 
degradation of the slowly-processed receptors (t~ 4-6 hours) 
in ldlA-7 is similar to that observed in FH429 (82) and 
proposed for FHla (section 5.2.4.1) and other transport-
deficient mutants (23,88). Nairn et al. (151) showed that a 
mutation in the sucrase-isomaltase gene in patients with a 
congenital deficiency in this enzyme, led to the production 
of a transport-deficient precursor protein approximately 2 
kDa larger than normal. The increased molecular weight 
could be ascribed to excess N-linked carbohydrate since 
Endoglycosidase H treatment reduced normal and mutant 
proteins to the same molecular weight. They favour an 
interpretation of incomplete carbohydrate trimming in the 
ER, rather than an additional oligosaccharide chain, since 
the mature form of the protein showed no increase in 
apparent molecular weight. The increase in molecular weight 
in FHla could not be abolished by prevention or removal of 
N-linked glycosylation of the precursor. Neuraminidase and 
0-glycanase treatment reduced the mature receptors from FHla 
and normal 
suggesting 
cells to the same apparent molecular 




involved, particularly since recent studies by Pathak et~. 
(64) have shown accumulation of transport-deficient 
receptors in cellular compartments where 0-linked sugar 
addition is proposed to take place. 
Protein glycosylation has been proposed to have various 
functions including induction and maintenance of correct 
polypeptide folding, prevention of intracellular 
aggregation, protection from proteolysis, and signals for 
intracellular targeting and cellular recognition (152). 
Inhibition of N-linked glycosylation· of various proteins 
with tunicamycin has suggested that there is no universal 
role for N-linked oligosaccharides (152). Chatterjee et 
·al. (67) suggest that tunicamycin affects the level of 
surface expression 
functional capacity. 
of LDL receptors, but not their 
However, treatment of normal 
fibroblasts with tunicamycin in the present study (section 
5.2.9.1) appeared to result in abnormal surface receptors, 
as judged by the lower proportion of LDL versus antibody 
binding. Gallagher et al. (153) recently showed by site-
directed mutagenesis that abnormal N-linked glycosylation of 
influenza virus hemagglutinin caused defects in folding, 
transport and activity of the molecule. From their studies 
on glycosylation mutants of vesicular stomatitis virus-G 
protein, Machamer and Rose have concluded that N-linked 
carbohydrate plays a role in the intracellular transport of 
this protein by promoting the correct polypeptide folding 
and protecting molecules from aberrant disulphide bonding 
(144,154). 
the protein 
Thus, the oligosaccharides promote transport of 
indirectly through facilitating correct 
conformation rather than acting as direct "signals" for 
intracellular transport • 
. 
Davis et ..!_!. (33) have shown that deletion of the clustered 
0-linked sugar domain of the LDL receptor has no significant 
effect on intracellular transport, LDL binding and 
internalisation, recycling or receptor half-life in cultured 
hamster fibroblasts. However, Kozarsky et..!_!. (66) showed 
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that experimentally-induced 0-linked sugar-deficient 
receptors were abnormally unstable due to proteolytic 
cleavage within or near the. domain usually containing 
clustered. 0-linked oligosaccharides, which 
site 
presumably 
inaccessible. normally render the proteolytic 
Yoshimura et al. ( 155) have suggested that the low binding 
capacity of the smaller LDL receptor in a monensin-resistant 
mutant of Chinese hamster ovary cells is due to altered 0-
linked glycosylation, since treatment of normal and mutant 
receptors with neuraminidase and 0-glycanase almost 
completely eliminated the difference in their molecular 
weights. They suggest that the mutant receptors lack some 
0-linked chains because a mutation in the cells prevents the 
correct folding of the binding domain necessary for both 0-
linked glycosylation and normal LDL binding affinity. 
Thus, if altered 0-linked glycosylation of the LDL receptor 
in FHla were present, 
receptor conformation, 
it could have an effect on the 
intracellular transport and LDL 
binding, 
functional 
and could conceivably lead to the observed 
heterogeneity of the surface receptors. 
However, treatment of surface receptors with neuraminidase 
and 0-glycanase did not significantly alter the ratio of 
abnormal to normal (LDL-binding) receptors in FHla. This 
observation may not exclude the involvement of abnormal C-
linked glycosylation since neuraminidase and 0-glycanase 
were unable to completely remove all the 0-linked 
oligosaccharides (shown by treatment of immunoprecipitated 
35s-labelled receptors, section 5.2.3.2) and during the one-
hour recovery period after the treatment of the cells in 
acid medium, newly-synthesized, fully-glycosylated receptors 
could mask the effects of the deglycosylation. In 
addition, Lane and co-workers have shown that, although the 
EGF (156,157) and insulin (158) receptors display 
glycosylation-dependent acquisition of ligand-binding 
capacity, subsequent removal of the carbohydrate does not 
affect the functional activity of the receptor. Thus, 
oligosaccharides may contribute to tertiary structure to 
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facilitate further modification such as disulphide bonding, 
' which would not be affected by subsequent removal of the 
sugar residues. 
Tunicamycin, neuraminidase and 0-glycanase treatment of 
normal (and FHla) cells decreased LDL binding relative to 
IgG-C7 binding, suggesting that altered glycosylation of LDL 
receptors can lead to functional heterogeneity. An example 
functional where oligosaccharides play a role in 
heterogeneity is the ~2 -adrenergic receptors of A431 cells 
(159). These proteins are present in 2 distinct 
populations: 55-52 kDa molecules containing complex N-linked 
chains, and exhibiting a high affinity for the agonist,-~(-)-
isoproterenol, and 65-63 kDa 
high-mannose oligosaccharides. 
present in preconfluent cells, 
low-affinity receptors, with 
Both types of receptors are 
but only the high-mannose-
containing molecules are found in postconfluent cells. The 
degree of confluence of FHla cells did not influence the 
expression of the two surface receptor populations, since 
similar ratios of abnormal to LDL-binding receptors were 
obtained over a 4-fold range of protein content (90 to 330 
µg per dish). 
5.3.5 Model for creation of "normal" and "abnormal" mutant 
receptors 
A putative model for the creation of functionally distinct 
surface populations of the same mutant receptor in FHla 
would be that, due to a mutation in the amino acid sequence, 
both .. no·rma l n and abnormal conformations are_ formed, 
presumably in equilibrium with each other (160). Inability 
to achieve.· a "normal" conformation would lead to delayed 
transport from the ER to the Golgi, and thus create the 
possibility for abnormal or excessive glycosylation, and 
possibly degradation. Abnormal. glycosylation could play a 
role in shifting the folding equilibrium to an abnormal 
conformation, which could be rendered irreversible by 
incorrect disulphide bonding, thus leading to non-functional 
protein molecules; 
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6.1 Introduction 
The aim of this study was to characterize fully the 
phenotypic expression of LDL receptor mutations in South 
African FH 
interest, and 
homozygotes, both for medical and genetic 
in order to understand cell-biological 
change~, as a result of these mutations, in the complex 
itinerary of the LDL receptor. 
A number of novel findings have emerged from detailed 
studies of selected cells, shown to be homozygous for each 
of 2 mutant LDL receptor alleles prevalent in Afrikaner FH 
subjects. In cells from FH3a and 3b, the mature mutant LDL 
receptors are subject to abnormally rapid degradation, 
representing a mutant receptor phenotype not previously 
, 
described in the classification of LDL receptor defects. 
Although the mutation in Kindred 3 was thus the first 
example of a new class of naturally-occurring LDL receptor 
mutations, producing rapidly-degraded receptors (102,139), 
further examples of this class have subsequently been 
detected in South African subjects, TD and RI 
3.2.3) and in three Japanese subjects (128). 
(section 
A novel aspect of the LDL receptor phenotype in Afrikaner 
Kindred 1, is that cells homozygous for a single mutant 
allele apparently display a functionally heterogeneous 
receptor population on their surfaces (139). One-third of 
the receptors bind LDL with normal aff_inity, while two-
thirds recognize only IgG-C7. This functional 
heterogeneity may be caused by conformational differences, 
--, 
which could be the cause or the result of the delayed 
transport and processing of the mutant precursors. The 
interesting observation was made that the slowly-processed 
precursor exhibited a time-dependent increase in apparent 
molecular weight, possibly suggesting the involvement of 
abnormal glycosylation in the creation of both "normal" and 
abnormal forms of the same mutant receptor molecule. The 
·possible role of glyco~ilatlon in protein function and 
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intracellular transport has been discussed (section 5.3.4) 
and is highlighted by recent work of Gallagher et al. (153), 
who showed that oligosaccharides at abnormal sites in the 
influenza virus hemagglutinin (HA) could disrupt folding, 
transport and activity of the molecule, for example, 
glycosylation in some regions disrupted functional epitopes 
on the surface of the protein. The authors postulated that 
certain regions of the HA molecule must remain devoid of 
carbohydrate because these areas may be recognition sites 
for cellular proteins involved in initial folding and 
mobilization of HA into the secretory pathway, such as BiP 
(81), or for structural reasons, since attachment of 
oligosaccharides at some positions might interfere with 
correct folding or oligomerization of the molecule. 
Similarly, abnormal glycosylation of the LDL receptor in 
FHla and lb cells could have detrimental effects on folding, 
transport and activity of the protein. 
6.2 Cellular "signals" for transport and degradation of 
proteins 
Major questions in cell biology today are ( i ) why are 
cellular proteins degraded at very different rates? and (ii) 
how are secretory and membrane proteins targeted to the 
cell-surface and why are they transported from the 
endoplasmic reticulum (ER) to the Golgi apparatus at 
different rates? Presumably, some form of biological 
"signal" targets a protein for degradation, or dictates its 
rate and destination of intracellular transport. The two 
LDL receptor mutations examined in detail in the present 
study alter the protein in such a way that it exhibits 
either an. enhanced degradation rate (FH3a and 3b) or 
severely retarded intracellular transport and processing to 
heterogeneous surface receptors (FHla and lb). These 
mutant receptors thus have the potential to elucidate some 
of the answers to the questions asked above. 
Biological "signals" within proteins 
sequences or may consist of "signal 
may comprise specific 
patches" (78) of non-
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contiguous regions on the surface of the protein, brought 
together by protein folding. Sequences which function as 
signals are easily identified because their function is 
usually preserved when they are transferred to different 
proteins, but signal patches are more difficult to identify 
because they cannot easily be transferred between proteins, 
and any mutation which directly or indirectly affects 
protein conformation may .eliminate signal patch function. 
Various sequences which act as signals for degradation have 
been identified (reviewed in ref. 162). For example, 
"PEST" regions, rich in praline, glutamic acid, serine and 
threonine, have been identified in 23 rapidly-degraded 
proteins (163). All PEST-sequence-containing proteins 
appear to be regulatory molecules, which may have fast 
turnover rates in order to rapidly change their 
concentrations. A 20-amino acid peptide (S-peptide) of 
RNase-A, containing the sequence Lys-Phe-Glu-Arg-Gln (KFERQ) 
has been shown to target various proteins for enhanced 
lysosomal degradation during nutrient deprivation (164,165). 
Ubiquitin-mediated proteolysis is enhanced by an unblocked 
amino-terminus and by the presence of oxidized methionine 
residues (166,167). The "N-end" rule, proposed by Bachmair 
et~. (168), proposes that the specific amino acid at the 
amino terminus determines which proteins are targeted for 
degradation. However, this rule may apply mainly to 
unfolded proteins during translation (162). There is no 
consistent experimental evidence for conformational 
properties (!·~· ~ignal "patches") which target proteins for 
degradation, although there are indications that proteins 
with altered conformation due to mutation are sometimes more 
rapidly degraded, and individual subunits are degraded 
faster than oligomeric proteins. The latter process may 
have the function of destroying excess subunits when unequal 
amounts of the different component proteins are produced by 
the cell. For example, five of the chains of the 
heptameric T-cell receptor are synthesized in vast excess 
over ~he others, and are selectively degraded if they are 
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not assembled into receptor complexes of the correct 
stoichiometry (76). 
Although some sequences (discussed above) appear to target 
proteins for degradation, these findings apply mostly to 
cytoplasmic proteins and very little information on 
conformational signals for degradation is available. The 
reasons for differences in degradation rates of membrane 
proteins, including receptors, are essentially unknown, as 
are the structural "signals" for a receptor either to 
recycle or to be degraded along with ligand. Elucidation 
of the structural details of the LDL receptor mutation in 
subjects FH3a and 3b, which change the receptor from a 
relatively long-lived, recycling receptor, to one which is 
rapidly degraded, probably without recycling, should provide 
valuable information on the "signals" controlling these 
processes. 
The "signals" that specify the destination and rate of 
transport of each newly-synthesized protein must be found 
within its sequence or structure. The ER and Golgi 
apparatus appear to be involved in recognizing these 
"signals" and distributing proteins to the cell-surface, 
secretory storage vesicles and lysosomes. For example, the 
generation in the Golgi apparatus of mannose-6-phosphate 
residues on newly-synthesized lysosomal enzymes targets them 
for delivery to the lysosome via binding to mannose-6-
phosphate receptors (78). The rate-limiting step in the 
transport of most proteins to the cell-surface is their exit 
from the ER (78). At any given time, the ER contains a 
great variety of newly-synthesized proteins, only some of 
which are retained in the ER, while the exported proteins 
have been shown to be transported at very different rates. 
Therefore, either (i) exported proteins possess positive 
signals which control their transport rates from the ER or 
(ii) proteins are transported constitutively with the "bulk 
flow", unless they possess signals for retention in, or 
recycling back to, the ER. 
2 1 6 
The only evidence to support signal-dependent transport from 
the ER to the Golgi is the observation that proteins are 
transported at different rates (169,170). Evidence for 
signal-dependent retention of resident ER proteins has been 
obtained from the observation that several luminal ER 
proteins contain a specific C-terminal sequence, Lys-Asp-
(171,172). Gl u-Leu . ( KDEL), which prevents their secretion 
Attachment of this ER retention signal to a lysosomal 
protein, cathepsin D, causes its accumulation in the ER via 
sorting from secretory proteins and retrieval from a post-ER 
compartment (172). The constitutive "bulk flow" rate 
out of the ER, measured using synthetic glycopeptides, has 
been shown by Wieland et al. (173) to have a half-time 
between 5 and 20 minutes. Since no membrane or secretory 
proteins are transported faster than the glycopeptides, 
which are too small to contain- a transport signal, it 
appears that differences in protein transport rates reflect 
differences in retention in the ER. Elucidation of the LDL 
receptor mutation in the South African Xhosa subject, TT 





as opposed to signal-
2 amino acids from the 
first binding repeat of the LDL receptor in TT cells 
impaired its transport from the ER to the Golgi apparatus. 
In contrast, deletion of the entire first repeat by site-
directed mu.tagenesis (29) produced a receptor that was 
transported and processed at a normal rate. Thus, the 
small deletion in the TT receptor could not have caused loss 
of a transport signal, since deletion of the whole repeat 
did not impair transport. The most likely explanation is 
that the 2-amino acid deletion within the repeat caused a 
conformational change in the TT receptor, which was 
recognized as an ER retention signal or signal "patch". 
In general, 
constitute a 
incorrect tertiary or quaternary structure may 
retention "signal", since a variety. of 
mutations in different regions of proteins, which presumably 
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all lead to alterations in conformation or assembly of 
subunits, lead to retention of the mutant proteins in the ER 
(143,146,174-177). Although protein glycosylation is often 
crucial in promoting export of membrane proteins from the 
ER, it apparently does not act as a direct "signal", but is 
required indirectly to promote correct folding of the 
protein chain (144,154,156-158). Recent studies suggest 
that although they are pre-requisites for transport, normal 
folding and assembly of subunits alone may not be 
sufficient, since mutations of VSV-G protein, which had 
little effect on folding and trimerization, disrupted 
transport to the cell-surface (174). 
The normal LDL receptor appears to traverse the transport 
pathway at close to the proposed "bulk flow" rate (173), 
since the half-time for processing to the mature, surface 
form of the receptor is only approximately 15 to 30 minutes. 
Thus, it would appear that the mutation in FHla and lb, 
which causes retardation of receptor transport from the ER, 
may create a conformation-dependent retention "signal" in 
the mutant protein. Elucidation of this mutation at the 
molecular level would thus be of great interest, since 
correlation of protein folding and conformation with 
transport may elucidate the factors responsible for 
directing proteins from the ER, and specifically retaining 
proteins in the ER, respectively. Future work on the 
mutant LDL receptor proteins in FHla and lb should therefore 
aim to detect conformational abnormality through loss of 
recognition by conformation-specific antibodies or ligands, 
abnormal disulphide bond formation, changes in proteolytic 
susceptibility, or altered physical properties, such as 
solubility in detergents, sedimentation pattern, gel 
mobility or ability to be cross-linked (178). However, 
attempts to demonstrate conformational abnormality in 
transport-deficient LDL receptors from FH429 {82), were 
unsuccessful, suggesting that minor, or highly localized, 
changes in conformation may be responsible for retention in 
the ER. 
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Although the major interest to date has been in 
understanding the "signals" that control exit -of proteins 
from the ER, another important aspect is the identification 
of the "receptors" that recognize and bind these putative 
signals, and of the mechanism(s) for retention of proteins 
in the ER. Differential transport rates from the ER may 
simply be due to non-specific "adsorption" by electrostatic 
and/or hydrophobic interactions of exported proteins with 
immobile permanent ER resident proteins (78). 
Alternatively, retention of incorrectly-folded proteins in 
the ER may be due to their tendency to aggregate, as 
observed for mutant forms of vesicular stomatitis virus 
(VSV)-G protein, which were not transported from the ER but 
formed large aggregates (144,174) that were disulphide-
bonded in some cases (144). Incorrectly-folded or 
unassembled protein subunits may be specifically recognized 
and retained by resident ER proteins. Certain unfolded 
proteins associate with a 77 kDa protein, first identified 
as immunoglobulin heavy-chain binding protein (BiP) (81). 
BiP may play a role in retention of proteins in the ER, but 
does not appear to be associated with all misfolded 
proteins. For example, no consistent indication was found 
for BiP association with immunoprecipitated transport-
deficient mutant LDL receptors (82),' and Doms found no 
evidence for BiP in aggregates of a mutant (ts045) VSV-G 
protein exhibiting temperature-sensitive transport (178). 
An example of retention in the ER of a normally-folded 
protein is that of mouse liver ~-glucuronidase, which is 
' 
retained only when it is complexed with a 64 kDa ER protein 
called egasyn (78,178). Since only 10% of egasyn was found 
complexed with ~-glucuronidase, it is possible that most 
egasyn may be complexed with other proteins in the ER (78). 
No evidence was found for association of either BiP or 
egasyn with the immunoprecipitated mutant LDL receptors from 
FHla and lb cells. The defective transport of these mutant 
proteins from the ER to the Golgi may thus be caused by some 
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of the less specific aggregation/adsorption processes 
described above. 
6.3 Self-association of the LDL receptor 
An alternative possible mechanism for delayed transport of 
the mutant receptors in FHla and lb is disruption of correct 
assembly of oligomeric structures, since correct quaternary 
structure also appears to be a requirement for transport. 
In their studies on the role of assembly of hemagglutinin 
(HA) trimers in intracellular transport, Copeland et al. 
(145), showed that trimerization occurred post-
translationally in the ER, followed immediately by transport 
to the Golgi complex. However, approximately 10% of the 
newly-synthesized HA molecules were conformationally altered 
and formed aberrant trimers that were not transported from 
the ER. In another study, it was shown that HA monomer 
folding, trimerization and transport occurred sequentially, 
and that only fully-assembled trimers, and not monomers, 
were transported to the Golgi complex (179). 
It is not known whether the normal LDL receptor is 
transported as a monomer or multimer. Van Oriel et al. 
(40) have recently demonstrated self-association of the 
receptor in noncovalent dimers, and higher order structures, 
mediated by the cytoplasmic domain. Although the 
cytoplasmic domain is also required for clustering in coated 
pits, no causal link between the two processes was 
established. The functional role, if any, of 
oligomerization is not to promote ligand binding. One 
possibility is that it promotes transport of the receptor. 
Schneider et al. (77) have considered this possibility as an 
explanation for variability of receptor expression in 
heterozygous FH. If normal transport requires dimer 
formation, then in heterodimers of mutant and normal 
proteins, the transport signal, or lack of a retention 
signal, in the normal protein may promote transport of the 
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abnormal one. Alternatively, a retention signal in the 
mutant protein may prevent transport of the heterodimer. 
An hypothesis for the expression of "normal" and abnormal 
receptor proteins at levels of approximately 20% and 60% of 
normal, respectively, in FHla and lb cells can be proposed 
based on the above possibilities. If, at any given time, 
approximately 50% of the mutant precursors in the ER achieve 
a "normal" conformation, and thus lack a retention signal, 
those proteins with the normal conformation may promote 
transport of abnormal proteins in heterodimers. This would 
lead to expression of approximately 75% of the normal number 
of receptors on the cell-surface (25% as homodimers between 
2 "normally"-folded proteins, and 50% due to heterodimers). 
Presumably dimers or unassembled monomers of proteins with 
abnormal conformations would be retained in the ER, and 
possibly degraded (76). If the assumption is made that the 
homodimers between 2 mutant proteins which have achieved 
normal conformation are able to bind LDL, whereas the 
heterodimers recognize only IgG-C7, then the 3 to 1 ratio of 
abnormal to normal surface receptors found in FHla and lb 
cells could be explained. 
No clear indication for an effect of the normal allele in 
heterozygote, ld, on processing of the mutant allele was 
observed (section 5.2.5) but the extent of conversion to the 
mature receptor during the 4-hour chase period was 
approximately 10% higher than that expected if processing of 
the products of the normal and mutant alleles proceeded 
independently. In addition, 125 I-LDL degradation in 
subject ld (84% of normal) suggested surface receptor 
expression somewhat higher than that expected for an FH 
heterozygote. However, the possibility of a role for self-
association of receptors in the phenotypic expression of the 
mutation in these mutants remains purely speculative. 
Receptor cross-linking studies (40) in normal and FHla 
(and/or lb) cells may yield more information on this aspect, 
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although interpretations should be made with caution due to 
the inherent inefficiency of cross-linking reactions. 
6.4 Future prospects for studies of mutant LDL receptors 
The discovery of the LDL receptor was made during studies 
which began from a purely medical point of view, in order to 
understand the disease, FH ( 1 ) • However, because of the 
complex intracellular 
study of normal and 
addition, elucidated 
itinerary of the LDL receptor, the 
mutant forms of the receptor has, in 
fundamental processes in cell biology, 
such as receptor-mediated endocytosis. 
In the South African context, the high incidence of FH in 
the Afrikaner population can now clearly be ascribed to 
founder gene effects, particularly on the basis of the high 
incidence of mutations associated with particular haplotypes 
in many unrelated individuals with FH. Therefore, genetic 
counselling to heterozygous FH subjects (1 in 100 
Afrikaners) is important to prevent the incidence of the 
more severe homozygous form of the disease. Future work 
should involve detailed haplotype analysis of all potential 
FH subjects, in addition to normal subjects to establish the 
incidence of specific haplotypes in both normal and FH 
subjects. Identification of a haplotype associated with 
FH, or of a common mutation detectable by Southern blotting, 
possibly after amplification of a specific region of the LDL 
receptor gene by the polymerase chain reaction technique 
(87), may allow direct diagnostic testing for certain 
prevalent mutations in the Afrikaner population, as for the 
French-Canadian (84), Lebanese (88) and Finnish (91,92) 
mutations. In the same way, since the mutation in the gene 
from the South African Xhosa FH subject, TT, creates a new 
PstI restriction site, this can be used to detect the 
deletion, and will enable determination of the prevalence of 
this mutation in the Xhosa community (87). 
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Although therapeutic approaches to 





plasmapheresis, the observation that the "high defective" 
level of mutant LDL receptors in homozygous Afrikaner 
subject, FHla (and presumably in other subjects carrying the 
same mutant allele) is able to be "upregulated" and 
"downregulated" similarly to that in normal cells (discussed 
in section 5.3.2), suggests that therapy usually employed 
for heterozygous subjects, (i.e. upregulation of LDL 
receptor activity from the normal allele by inhibition of 
HMG-CoA reductase combined with the use of bile-acid binding 







contribute to a 
hepatic receptor 
decreased plasma 
From a cell biological point of view, LDL receptor mutants 
have the potential to be very informative. Biochemical 
analysis of mutations in subjects with FH has revealed much 
about the structure-function relationships in the LDL 
receptor protein, and elucidated many steps in its complex 
intracellular pathways. The combination of the study of 
naturally-occurring mutations at the phenotypic and 
molecular level, combined with the ability to create site-
directed mutations should enable extensive analysis of the 
functions of the various protein domains of the receptor, 
and may shed light on the role of glycosylation in these 
functions. The findings may yield general concepts whic~ 
can be applied to understanding structural and functional 
aspects of other membrane 
the two Afrikaner mutations 
proteins. As discussed above, 
described in this thesis can 






of the primary, 
secondary, tertiary, and possibly quaternary, structural 
changes responsible for the phenotypic expression of these 
LDL receptor mutations may lead to an understanding of 
conformational properties constituting either an ER 
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retention signal, or a degradation signal for membrane 
proteins, and, in addition, how these "signals" are 
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